PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
8770789-4	1995	SF1 F, duodenal nutrient and GRP and urecholine resulted in the stimulation of pancreatic secretion reaching, respectively, 50%, 50%, 40%, 85% and 20% of maximal response to caerulein (200 pmol/kg-h i.v.).	Ceruletide	174-183	splicing factor 1	Canis lupus familiaris	0-3
8770789-4	1995	SF1 F, duodenal nutrient and GRP and urecholine resulted in the stimulation of pancreatic secretion reaching, respectively, 50%, 50%, 40%, 85% and 20% of maximal response to caerulein (200 pmol/kg-h i.v.).	Ceruletide	174-183	gastrin releasing peptide	Canis lupus familiaris	29-32
8751086-5	1995	), resulted in elevations in the activities of amylase and lipase in the pancreatic tissue and in the blood serum lasting for at least 4 h after the end of the caerulein infusion.	Ceruletide	160-169	lipase G, endothelial type	Rattus norvegicus	59-65
7648171-6	1995	myeloperoxidase activity 6.79(0.5) units/g in caerulein-treated animals versus 2.08(0.5) units/g in controls (P < 0.001).	Ceruletide	46-55	myeloperoxidase	Rattus norvegicus	0-15
7594767-9	1995	Cerulein infusion led to a marked redistribution of cathepsin B activity from the lysosomal to the zymogen-granule-enriched fractions.For animals killed in the fed state, a redistribution of cathepsin B activity toward the zymogen-granule-enriched fraction was also demonstrated in alcohol-fed animals compared to their pair-fed controls.	Ceruletide	0-8	cathepsin B	Rattus norvegicus	52-63
7594767-9	1995	Cerulein infusion led to a marked redistribution of cathepsin B activity from the lysosomal to the zymogen-granule-enriched fractions.For animals killed in the fed state, a redistribution of cathepsin B activity toward the zymogen-granule-enriched fraction was also demonstrated in alcohol-fed animals compared to their pair-fed controls.	Ceruletide	0-8	cathepsin B	Rattus norvegicus	191-202
7640325-0	1995	Improved event-related potential signs of selective attention after the administration of the cholecystokinin analog ceruletide in healthy persons.	Ceruletide	117-127	cholecystokinin	Homo sapiens	94-109
7590625-2	1995	TRH inhibited carbachol (10(-5) M)-stimulated amylase secretion by a maximum of 24% at a concentration of 10(-11) M (p < 0.05), but did not affect basal amylase release in concentrations from 10(-13) M to 10(-8) M. Ceruletide (3 x 10(-10) M)-stimulated amylase secretion was maximally reduced by 23% at a TRH concentration of 10(-10) M (p < 0.05).	Ceruletide	218-228	thyrotropin releasing hormone	Rattus norvegicus	0-3
7791078-6	1995	In rats, caerulein infusion (4 nmol/kg/hr) induced hypotension, massive pancreatic edema, hypovolemia due to plasma leakage and an increase in serum lipase and amylase activity.	Ceruletide	9-18	lipase G, endothelial type	Rattus norvegicus	149-155
8830200-0	1995	Ca2+ antagonists reveal a novel inhibitory effect of caerulein on guinea pig ileum.	Ceruletide	53-62	LOW QUALITY PROTEIN: carbonic anhydrase 2	Cavia porcellus	0-3
7488737-4	1995	Pretreatment of rats with L-NAME (1-10 mg kg-1) also tended to attenuate the anti-exploratory action of CCK agonist caerulein (5 micrograms kg-1), but this action was not significant.	Ceruletide	116-125	cholecystokinin	Rattus norvegicus	104-107
7746348-2	1995	The subcutaneous (s.c.) administration of caerulein and CCK-8s suppressed dose-dependently TSH and GH levels.	Ceruletide	42-51	gonadotropin releasing hormone receptor	Rattus norvegicus	99-101
7529994-1	1995	Desensitization of rat pancreatic acinar cells with 0.1 mM carbamoylcholine (Cch) or 0.5 nM caerulein (CAE), a cholecystokinin (CCK) agonist, altered the subsequent secretory responses to these two agonists.	Ceruletide	92-101	cholecystokinin	Rattus norvegicus	111-126
7529994-1	1995	Desensitization of rat pancreatic acinar cells with 0.1 mM carbamoylcholine (Cch) or 0.5 nM caerulein (CAE), a cholecystokinin (CCK) agonist, altered the subsequent secretory responses to these two agonists.	Ceruletide	103-106	cholecystokinin	Rattus norvegicus	111-126
7746348-4	1995	caerulein dose-dependently elevated the GH levels.	Ceruletide	0-9	gonadotropin releasing hormone receptor	Rattus norvegicus	40-42
7961057-1	1994	Animal and human studies have suggested a satieting effect of ceruletide, an analog of cholecystokinin.	Ceruletide	62-72	cholecystokinin	Homo sapiens	87-102
7851468-8	1994	In summary, expression of TGF beta 1 in acinar and stromal cells of the rat pancreas is enhanced during regeneration from caerulein-induced pancreatitis, which may indicate an involvement of TGF beta 1 in the regulation of extracellular matrix regeneration in the rat pancreas after caerulein-induced pancreatitis.	Ceruletide	122-131	transforming growth factor, beta 1	Rattus norvegicus	26-36
7851468-8	1994	In summary, expression of TGF beta 1 in acinar and stromal cells of the rat pancreas is enhanced during regeneration from caerulein-induced pancreatitis, which may indicate an involvement of TGF beta 1 in the regulation of extracellular matrix regeneration in the rat pancreas after caerulein-induced pancreatitis.	Ceruletide	283-292	transforming growth factor, beta 1	Rattus norvegicus	26-36
8182534-5	1994	The order of potency of the CCK-peptides administered systemically was: ceruletide > CCK-8S > CCK-8NS >> CCK-4.	Ceruletide	72-82	cholecystokinin	Mus musculus	28-31
8020637-2	1994	Hyperamylasaemia, pancreatic oedema and activation of trypsinogen in the pancreatic tissue, as well as subcellular redistribution of the lysosomal enzyme, cathepsin B, from the lysosomal fraction to the zymogen fraction, were prevented by infusion of 20 mg/kg.h cetraxate for 2 h before caerulein infusion and throughout the 3.5 h of caerulein infusion (5 micrograms/kg.h).	Ceruletide	287-296	cathepsin B	Rattus norvegicus	155-166
8020637-2	1994	Hyperamylasaemia, pancreatic oedema and activation of trypsinogen in the pancreatic tissue, as well as subcellular redistribution of the lysosomal enzyme, cathepsin B, from the lysosomal fraction to the zymogen fraction, were prevented by infusion of 20 mg/kg.h cetraxate for 2 h before caerulein infusion and throughout the 3.5 h of caerulein infusion (5 micrograms/kg.h).	Ceruletide	334-343	cathepsin B	Rattus norvegicus	155-166
8190727-10	1994	These results suggest that chemical mediators, such as free radicals and platelet-activating factor (PAF), which are produced by vascular damage and thrombosis, may accelerate the activation of zymogen proteases in acinar cells in caerulein-induced pancreatitis, leading to hemorrhagic pancreatitis.	Ceruletide	231-240	PCNA clamp associated factor	Rattus norvegicus	73-99
8190727-10	1994	These results suggest that chemical mediators, such as free radicals and platelet-activating factor (PAF), which are produced by vascular damage and thrombosis, may accelerate the activation of zymogen proteases in acinar cells in caerulein-induced pancreatitis, leading to hemorrhagic pancreatitis.	Ceruletide	231-240	PCNA clamp associated factor	Rattus norvegicus	101-104
8199877-14	1994	injection of CCK-8 and ceruletide is the most likely central thermoregulatory change mediated by CCK type B receptors, while the well-known hypothermic response observed after peripheral injection of these peptides might also be explained by their direct effect on variables influencing some of the thermoregulatory effector mechanisms at the periphery.	Ceruletide	23-33	cholecystokinin	Rattus norvegicus	97-100
7528917-2	1994	Continuous infusion of caerulein at doses of 5 and 20 micrograms/kg/h caused a significant increase in PBF in the early phase of caerulein infusion.	Ceruletide	23-32	PTTG1 interacting protein	Rattus norvegicus	103-106
7528917-2	1994	Continuous infusion of caerulein at doses of 5 and 20 micrograms/kg/h caused a significant increase in PBF in the early phase of caerulein infusion.	Ceruletide	129-138	PTTG1 interacting protein	Rattus norvegicus	103-106
7528917-3	1994	The caerulein-induced increase in PBF was not affected significantly by atropine sulfate (100 micrograms/kg), nor by phenoxybenzamine (5 mg/kg) plus propranolol (50 micrograms/kg).	Ceruletide	4-13	PTTG1 interacting protein	Rattus norvegicus	34-37
7528917-4	1994	Administration of L-NNA (0.5, 5, or 30 mg/kg) did not affect the basal PBF, but at 5 mg/kg it inhibited completely the caerulein-induced increase in PBF.	Ceruletide	119-128	PTTG1 interacting protein	Rattus norvegicus	149-152
8090278-0	1994	In man the mu-opiate agonist loperamide specifically inhibits ACTH secretion induced by the cholecystokinin-like peptide ceruletide.	Ceruletide	121-131	proopiomelanocortin	Homo sapiens	62-66
8090278-1	1994	Ceruletide, a cholecystokinin-8-like peptide, was recently reported to stimulate ACTH secretion in man.	Ceruletide	0-10	proopiomelanocortin	Homo sapiens	81-85
8090278-2	1994	The aim of this study was to investigate the effect of the mu-opiate agonist, loperamide, and the opiate antagonist, naloxone, on ceruletide-induced ACTH secretion in man.	Ceruletide	130-140	proopiomelanocortin	Homo sapiens	149-153
8090278-4	1994	After stimulation with 8 ng ceruletide/kg body weight/min over a period of 5 min, the maximum ACTH levels (at 7.5 min) were significantly reduced by loperamide from 26 +/- 7 to 6 +/- 1 pmol/l and the maximum cortisol levels (at 30 min) were significantly reduced from 676 +/- 47 to 392 +/- 58 nmol/l.	Ceruletide	28-38	proopiomelanocortin	Homo sapiens	94-98
8090278-7	1994	The suppressive effect of loperamide on basal and ceruletide-induced ACTH and cortisol secretion was completely reversed by the administration of 0.8 mg naloxone, 20 min before and during infusion of ceruletide.	Ceruletide	50-60	proopiomelanocortin	Homo sapiens	69-73
8090278-9	1994	In conclusion, ACTH is released by peripherally administered ceruletide within a short period.	Ceruletide	61-71	proopiomelanocortin	Homo sapiens	15-19
7517544-5	1994	Prophylactically or therapeutically administered, L-364,718 exerts a beneficial effect on caerulein-induced acute pancreatitis, indicating that CCK (exogenous or endogenous) plays an important role in the development of this pathology.	Ceruletide	90-99	cholecystokinin	Rattus norvegicus	144-147
7529987-4	1994	Caerulein stimulated the secretion of cathepsin B into the pancreatic juice in a dose-dependent manner, as in amylase secretion, and caerulein in higher doses (1.0 and 1.5 microgram/kg.hr) inhibited cathepsin B output as it did amylase output.	Ceruletide	0-9	cathepsin B	Rattus norvegicus	38-49
7529987-5	1994	There was a significantly high positive correlation between cathepsin B output and amylase output after stimulation with caerulein.	Ceruletide	121-130	cathepsin B	Rattus norvegicus	60-71
7529987-8	1994	Redistribution of cathepsin B activity in the pancreatic subcellular fractions was noted with an increase in the amount of cathepsin B recovered from zymogen-rich pellets after 15 min of centrifugation at 1300 x g. These changes after temporary pancreatic duct obstruction are very similar to those previously noted during the early stage of diet-and caerulein-induced experimental pancreatitis and suggest colocalization of lysosomal enzymes and digestive enzymes.	Ceruletide	351-360	cathepsin B	Rattus norvegicus	18-29
7529987-8	1994	Redistribution of cathepsin B activity in the pancreatic subcellular fractions was noted with an increase in the amount of cathepsin B recovered from zymogen-rich pellets after 15 min of centrifugation at 1300 x g. These changes after temporary pancreatic duct obstruction are very similar to those previously noted during the early stage of diet-and caerulein-induced experimental pancreatitis and suggest colocalization of lysosomal enzymes and digestive enzymes.	Ceruletide	351-360	cathepsin B	Rattus norvegicus	123-134
8118705-1	1993	The inhibitory effects of ceruletide (CLT), a cholecystokinin-8 (CCK)-like peptide, were investigated in the epileptogenesis in the amygdaloid kindled rats.	Ceruletide	26-36	cholecystokinin	Rattus norvegicus	46-63
8405076-1	1993	The effects and pharmacological mechanisms underlying the inhibiting effect of ceruletide, a cholecystokinin (CCK)-related peptide, on apomorphine-induced turning behavior in 6-hydroxydopamine lesioned rats were investigated.	Ceruletide	79-89	cholecystokinin	Rattus norvegicus	110-113
8159285-1	1994	We compared the action of subdiaphragmatic vagotomy upon the anti-exploratory and motor depressant effects of caerulein, an agonist of cholecystokinin (CCK) receptors, in male rats.	Ceruletide	110-119	cholecystokinin	Rattus norvegicus	135-150
7508112-7	1993	CCK-JMV-180 had no effect on the ultrastructure of the apical region of the acinar cell and it prevented the ablation of apical cytoskeleton induced by a supramaximal concentration of caerulein (10 nM).	Ceruletide	184-193	cholecystokinin	Rattus norvegicus	0-3
7508112-8	1993	CCK-JMV-180 inhibited the increase in 1,2-diacylglycerol formation and the inhibition of amylase release caused by 10 nM caerulein.	Ceruletide	121-130	cholecystokinin	Rattus norvegicus	0-3
8405076-4	1993	The antiapomorphine effect of ceruletide was reversed by the selective CCKA receptor antagonist, devazepide, but not by the selective CCKB receptor antagonist, L-365,260.	Ceruletide	30-40	cholecystokinin A receptor	Rattus norvegicus	71-84
8448591-19	1993	In rats with caerulein-induced pancreatitis, there was a time-dependent increase in the activities of amylase and lipase in blood serum as well as in the pancreas.	Ceruletide	13-22	lipase G, endothelial type	Rattus norvegicus	114-120
8494049-6	1993	Whereas amylase release was induced by low concentrations of cerulein (10(-11) mol/L), relatively high concentrations of cerulein (10(-9) mol/L) were required for the observed increases in PAF synthesis and the [Ca2+]i, indicating that these two responses may not occur under physiological conditions.	Ceruletide	121-129	PCNA clamp associated factor	Rattus norvegicus	189-192
8397343-3	1993	Caerulein (0.1-5 micrograms/kg s.c.), an agonist at CCK receptors, only at the highest dose (5 micrograms/kg) significantly decreased the exploratory behaviour of rats housed in groups, but not in the isolated rats.	Ceruletide	0-9	cholecystokinin	Rattus norvegicus	52-55
7685311-1	1993	The redistribution of cathepsin B, a representative lysosomal enzyme, from the lysosomal pellet to the zymogen pellet in subcellular fractions and the colocalization of cathepsin B with digestive enzymes within acinar cells have been found during the early stage of caerulein-induced acute pancreatitis in the rat.	Ceruletide	266-275	cathepsin B	Rattus norvegicus	169-180
7679894-8	1993	Gastrin(2-17 ds) at 100 nM enhanced chymotrypsinogen biosynthesis by 26% and its mRNA level by 35%; these responses were lower than those evoked by 0.1 nM caerulein.	Ceruletide	155-164	gastrin	Homo sapiens	0-7
8103993-3	1993	Caerulein (1-100 nM), a CCK receptor agonist, caused a rightward shift of the glutamate dose-response curve.	Ceruletide	0-9	cholecystokinin	Rattus norvegicus	24-27
7678215-7	1993	PYY, 400 pmol/kg.h, infused simultaneously with caerulein significantly reduced by 39%, 35%, and 45% increases in pancreatic weight, RNA and DNA contents stimulated by caerulein, respectively.	Ceruletide	48-57	peptide YY	Rattus norvegicus	0-3
8440305-1	1993	This study concerned the effects of ceruletide, a cholecystokinin (CCK)-related peptide, on amphetamine-stimulated behaviors (hyperlocomotion and stereotypy) and amphetamine-induced dopamine (DA) release from the striatum and the nucleus accumbens of the rat.	Ceruletide	36-46	cholecystokinin	Rattus norvegicus	67-70
7686520-0	1993	Protective effect of lactoferrin on caerulein-induced acute pancreatitis in rats.	Ceruletide	36-45	lactotransferrin	Rattus norvegicus	21-32
8103993-4	1993	The effect of caerulein was abolished by adding L365,260 (1 microM), a selective CCKB receptor antagonist.	Ceruletide	14-23	cholecystokinin B receptor	Rattus norvegicus	81-94
8352636-4	1993	Moreover, 4-hour pre-infusion of ethanol caused a significant increase in pancreatic cathepsin B output stimulated by caerulein (0.2 microgram/kg.hr) and secretin (0.2 CU/kg.hr) compared with the control rats.	Ceruletide	118-127	cathepsin B	Rattus norvegicus	85-96
7870888-0	1993	Ondansetron, an antagonist of 5-HT3 receptors, antagonizes the anti-exploratory effect of caerulein, an agonist of CCK receptors, in the elevated plus-maze.	Ceruletide	90-99	cholecystokinin	Rattus norvegicus	115-118
7870888-1	1993	Systemic treatment with caerulein (0.25-5 micrograms/kg SC), non-selective agonist of cholecystokinin (CCK) receptors, dose-dependently suppressed the exploratory behaviour of rats in an elevated plus-maze without producing remarkable changes in the locomotor activity of animals in an open field test.	Ceruletide	24-33	cholecystokinin	Rattus norvegicus	103-106
7870888-6	1993	Consequently, we propose that 5-HT-ergic mechanisms are involved not only in the regulation of CCK release in the cerebral cortex and nucleus accumbens, but also in the modulation of the anti-exploratory effect of caerulein, a CCK agonist, in the elevated plus-maze.	Ceruletide	214-223	cholecystokinin	Rattus norvegicus	227-230
1465218-1	1992	The effect of caerulein, an analog of cholecystokinin-8, on expression of the immediate-early genes c-fos and zif/268 was studied in the rat brain using Northern blot analysis and an in situ hybridization technique.	Ceruletide	14-23	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	100-105
1294265-4	1992	PAF release and serum amylase) changes developed 5 hours after caerulein administration.	Ceruletide	63-72	PCNA clamp associated factor	Rattus norvegicus	0-3
1475033-7	1992	The effect of caerulein (5 micrograms/kg) was antagonized by devazepide, a CCK-A antagonist, at 100 micrograms/kg, but not by a CCK-B antagonist L-365,260 tested at a wide dose range.	Ceruletide	14-23	cholecystokinin	Rattus norvegicus	75-78
1465218-1	1992	The effect of caerulein, an analog of cholecystokinin-8, on expression of the immediate-early genes c-fos and zif/268 was studied in the rat brain using Northern blot analysis and an in situ hybridization technique.	Ceruletide	14-23	early growth response 1	Rattus norvegicus	110-117
1465218-4	1992	Pretreatment with caerulein suppressed the PTZ-induced c-fos and zif/268 expression.	Ceruletide	18-27	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	55-60
1465218-4	1992	Pretreatment with caerulein suppressed the PTZ-induced c-fos and zif/268 expression.	Ceruletide	18-27	early growth response 1	Rattus norvegicus	65-72
1282294-1	1992	The redistribution of cathepsin B, a lysosomal enzyme, from the lysosomal pellet to the zymogen pellet in the subcellular fractionation, the colocalization of cathepsin B with digestive enzyme, and increased cellular, lysosomal, and mitochondrial fragility within acinar cells have been found during the early stages of caerulein-induced acute pancreatitis in rats.	Ceruletide	320-329	cathepsin B	Rattus norvegicus	22-33
1375937-2	1992	It is generally believed that the caerulein-induced release of Ca2+ is mediated by phospholipase C-catalyzed production of 1,4,5-inositol triphosphate (IP3).	Ceruletide	34-43	carbonic anhydrase 2	Rattus norvegicus	63-66
1527448-3	1992	CR-induced AP in control rats (no alcohol) was characterized by a significant elevation in serum lipase content, pancreatic interstitial edema, infrequent occurrences of karyorrhexis, and the appearance of vacuoles in acinar cells.	Ceruletide	0-2	lipase G, endothelial type	Rattus norvegicus	97-103
1527448-4	1992	Chronic feeding of the ethanol diet followed by treatment with CR resulted in increases in serum lipase content, interstitial edema, karyorrhexis, and acinar vacuolization that were significantly greater than that seen in rats fed the control diet and treated with CR.	Ceruletide	63-65	lipase G, endothelial type	Rattus norvegicus	97-103
1281974-2	1992	Caerulein stimulated the secretion of amylase and cathepsin B into pancreatic juice in controls.	Ceruletide	0-9	cathepsin B	Oryctolagus cuniculus	50-61
1375937-4	1992	Caerulein-stimulated release of Ca2+ was completely blocked by either neomycin, an inhibitor of phospholipase C, or by heparin, an IP3 receptor antagonist.	Ceruletide	0-9	carbonic anhydrase 2	Rattus norvegicus	32-35
1375937-4	1992	Caerulein-stimulated release of Ca2+ was completely blocked by either neomycin, an inhibitor of phospholipase C, or by heparin, an IP3 receptor antagonist.	Ceruletide	0-9	inositol 1,4,5-trisphosphate receptor, type 3	Rattus norvegicus	131-143
1407694-0	1992	Effect of the 5-HT3 receptor antagonist ondansetron on hypothalamic self-stimulation in rats and its interaction with the CCK analogue caerulein.	Ceruletide	135-144	cholecystokinin	Rattus norvegicus	122-125
1608534-1	1992	C-fos mRNA expression by stimulation with subcutaneous (s.c.) administration of saline or cycloheximide (CHX) was examined in the rat striatum with or without pretreatment with ceruletide, an analogue of cholecystokinin.	Ceruletide	177-187	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	0-5
1575758-5	1992	Stimulation by caerulein, carbachol, or their combination caused an immediate and significant burst in both protein and GP2 outputs.	Ceruletide	15-24	glycoprotein 2	Rattus norvegicus	120-123
1608534-0	1992	Late onset and long-lasting suppressive effects of ceruletide, an analogue of cholecystokinin, on c-fos mRNA expression in the rat striatum.	Ceruletide	51-61	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	98-103
1608534-2	1992	The c-fos mRNA induction 1 h after CHX stimulation (25 mg/kg, s.c.) was significantly suppressed by ceruletide pretreatment (80 micrograms/kg, s.c.) 2 h before CHX stimulation in the striatum, and tended to be suppressed by ceruletide pretreatment 4 h before saline or CHX stimulation.	Ceruletide	100-110	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	4-9
1608534-2	1992	The c-fos mRNA induction 1 h after CHX stimulation (25 mg/kg, s.c.) was significantly suppressed by ceruletide pretreatment (80 micrograms/kg, s.c.) 2 h before CHX stimulation in the striatum, and tended to be suppressed by ceruletide pretreatment 4 h before saline or CHX stimulation.	Ceruletide	224-234	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	4-9
1608534-4	1992	The present findings together with previous reports suggest that ceruletide might have late onset and long-lasting suppressive effects on the expression of c-fos mRNA in the striatum and that these effects might be related to its effects on DAergic neuronal transmission.	Ceruletide	65-75	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	156-161
1372484-2	1992	The basal as well as caerulein-stimulated in vivo rate of cathepsin B was further increased by infusion of either chloroquine or methylamine while neither the basal nor the secretagogue-stimulated rates of amylase secretion were altered by the lysosomotropic agents.	Ceruletide	21-30	cathepsin B	Rattus norvegicus	58-69
1372484-5	1992	That in vitro rate of cathepsin B secretion stimulated by caerulein was not increased in acini prepared from animals infused with caerulein, chloroquine, or methylamine, but the in vitro rate of cathepsin B secretion stimulated by caerulein was increased in acini prepared from animals infused with caerulein plus either chloroquine or methylamine.	Ceruletide	58-67	cathepsin B	Rattus norvegicus	22-33
1943086-0	1991	Anti-tumor necrosis factor antibody augments edema formation in caerulein-induced acute pancreatitis.	Ceruletide	64-73	tumor necrosis factor-like	Rattus norvegicus	5-26
1539670-3	1992	TGF-beta 1 inhibition of growth stimulated by a maximal dose of caerulein (1 nM) was dose dependent with one-half maximal effects occurring at approximately 5 pM and maximal inhibition seen with 30 pM.	Ceruletide	64-73	transforming growth factor, beta 1	Mus musculus	0-10
1382403-6	1992	Caerulein stimulated the secretion of cathepsin B into pancreatic juice in a dose-dependent manner, as it did that of amylase, and at higher concentrations of caerulein (1.0 and 2.0 micrograms/kg.	Ceruletide	0-9	cathepsin B	Oryctolagus cuniculus	38-49
1382403-8	1992	There was a significant positive correlation between cathepsin B output and amylase output into pancreatic juice during stimulation with caerulein.	Ceruletide	137-146	cathepsin B	Oryctolagus cuniculus	53-64
1370663-3	1992	After 3 days of rest, the cerulein-treated rats were divided into four groups: rats with acute pancreatitis fed 20% casein, who received no treatment; rats fed 50% casein; rats fed 20% casein supplemented with 1% soybean trypsin inhibitor (SBTI); and rats fed 20% casein who received 1 microgram.kg-1 of subcutaneous cerulein, three times a day.	Ceruletide	26-34	kunitz trypsin protease inhibitor	Glycine max	221-238
1726453-2	1991	Serum amylase levels, pancreatic water content, and lysosomal fragility in duct obstructed with caerulein infused animals were significantly increased compared with the control groups, and remarkable shift of cathepsin B from lysosomal fraction to zymogen fraction was observed in this group.	Ceruletide	96-105	cathepsin B	Rattus norvegicus	209-220
1795164-0	1991	Palatal myoclonus following Behcet"s disease ameliorated by ceruletide, a potent analogue of CCK octapeptide.	Ceruletide	60-70	cholecystokinin	Homo sapiens	93-96
1802707-10	1991	Finally, Northern blots with a cDNA of rat cathepsin B showed that the concentration of cathepsin B mRNA in total pancreatic RNA increased following in vivo stimulation of the exocrine pancreatic cells with optimal doses of cerulein, a cholecystokinin analogue.	Ceruletide	224-232	cathepsin B	Rattus norvegicus	43-54
1802707-10	1991	Finally, Northern blots with a cDNA of rat cathepsin B showed that the concentration of cathepsin B mRNA in total pancreatic RNA increased following in vivo stimulation of the exocrine pancreatic cells with optimal doses of cerulein, a cholecystokinin analogue.	Ceruletide	224-232	cathepsin B	Rattus norvegicus	88-99
2008656-7	1991	Pretreatment of cerulein preparations with the free radical scavengers superoxide dismutase and catalase and the iron chelator deferoxamine did not modify the pancreatitis.	Ceruletide	16-24	catalase	Canis lupus familiaris	96-104
1717033-4	1991	The administration of FOY with caerulein also reduced the increased lactic dehydrogenase (LDH) discharge significantly and inhibited the cathepsin B leakage from lysosomes in an in vitro incubation system.	Ceruletide	31-40	cathepsin B	Rattus norvegicus	137-148
1798834-8	1991	The CCK agonist caerulein (100 micrograms/kg SC) had a similar antiamphetamine effect.	Ceruletide	16-25	cholecystokinin	Mus musculus	4-7
1996314-3	1991	The intracerebroventricular administration of the nonselective CCK receptor agonist caerulein or the selective CCK-B receptor agonist pentagastrin increased dose dependently the level of anxiety.	Ceruletide	84-93	cholecystokinin	Rattus norvegicus	63-66
1996649-7	1991	Continuous intravenous infusion of 10 mg.kg-1.h-1 loxiglumide completely abolished the effects of 10 ng/kg caerulein, which increases plasma CCK immunoreactivity to postprandial levels.	Ceruletide	107-116	cholecystokinin	Canis lupus familiaris	141-144
1717329-2	1991	In this paper, we have studied the action of caerulein, a peptide that has an active gastrin-like terminal tetrapeptide, on salivary secretion in man.	Ceruletide	45-54	gastrin	Homo sapiens	85-92
1763194-2	1991	Caerulein, an analogue of cholecystokinin (CCK-8), like CCK-8, has been shown to produce hypnotic effects similar to those of benzodiazepine (flunitrazepam).	Ceruletide	0-9	cholecystokinin	Rattus norvegicus	26-41
1705567-4	1991	After 7 h of duct obstruction is relieved, caerulein-stimulated apical secretion of cathepsin B and amylase is increased, but the ratio of cathepsin B to amylase secretion is not different than that following caerulein stimulation of animals never obstructed.	Ceruletide	43-52	cathepsin B	Oryctolagus cuniculus	84-95
1726396-2	1991	The serum amylase levels and water content as well as pancreatic amylase and cathepsin B contents increased significantly in the early stage (0-12 h) after caerulein was administered, however, returned to the normal levels at 36 h. In the early stage, colocalization of lysosomal enzyme and digestive enzyme was found.	Ceruletide	156-165	cathepsin B	Rattus norvegicus	77-88
1722380-10	1991	However, lorglumide, given alone or in combination with caerulein, induced a significant increase in pancreatic amylase content without affecting plasma corticosterone level.	Ceruletide	56-65	amylase 2a3	Rattus norvegicus	101-119
1759047-9	1991	Atropine infusion completely blocked the inhibitory effect of PP on caerulein-stimulated pancreatic protein secretion both in the intact and denervated pancreas and of secretion-evoked bicarbonate output in the denervated gland.	Ceruletide	68-77	pancreatic polypeptide	Canis lupus familiaris	62-64
1798834-11	1991	The opposite effect of devazepide and L-365,260 on caerulein- and apomorphine-induced hypolocomotion is probably related to the antagonistic role of CCK-A and CCK-B receptor subtypes in the regulation of mesencephalic dopaminergic neurons.	Ceruletide	51-60	cholecystokinin B receptor	Mus musculus	159-173
33812911-6	2021	RESULTS: We observed increased expression of Hsp90 in pancreatic tissue of caerulein-induced CP mice.	Ceruletide	75-84	heat shock protein, 3	Mus musculus	45-50
2397417-0	1990	Ceruletide, a cholecystokinin-related peptide, attenuates haloperidol-induced increase in dopamine release from the rat striatum: an in vivo microdialysis study.	Ceruletide	0-10	cholecystokinin	Rattus norvegicus	14-29
1702070-2	1990	In addition, repeated feeding of camostate, a synthetic protease inhibitor which stimulates endogenous CCK release, desensitized the response of the acini to caerulein.	Ceruletide	158-167	cholecystokinin	Rattus norvegicus	103-106
2362955-0	1990	Effect of intracerebroventricular and systemic injections of caerulein, a CCK analogue, on electrical self-stimulation and its interaction with the CCKA receptor antagonist, L-364,718 (MK-329).	Ceruletide	61-70	cholecystokinin	Homo sapiens	74-77
2362955-0	1990	Effect of intracerebroventricular and systemic injections of caerulein, a CCK analogue, on electrical self-stimulation and its interaction with the CCKA receptor antagonist, L-364,718 (MK-329).	Ceruletide	61-70	cholecystokinin A receptor	Homo sapiens	148-152
2087492-4	1990	The suppressive effect of ceruletide on barrel rotation could be partially countered by MK-329, a selective peripheral CCK (CCK-A) receptor antagonist.	Ceruletide	26-36	cholecystokinin	Rattus norvegicus	119-122
2087492-4	1990	The suppressive effect of ceruletide on barrel rotation could be partially countered by MK-329, a selective peripheral CCK (CCK-A) receptor antagonist.	Ceruletide	26-36	cholecystokinin A receptor	Rattus norvegicus	124-139
2087492-6	1990	These findings suggest that ceruletide specifically suppresses the barrel rotation evoked by SMS 201-995 in a long-lasting manner possibly acting through CCK-A receptor.	Ceruletide	28-38	cholecystokinin A receptor	Rattus norvegicus	154-168
2257606-8	1990	The data demonstrate a significant growth response of pancreatic acinar tissue after a single episode of endogenous CCK-release, which is similar in extent, time course and cellular source as previously demonstrated during persistent stimulation of the pancreas by prolonged infusion of the CCK-analogue caerulein.	Ceruletide	304-313	cholecystokinin	Rattus norvegicus	116-119
2257606-8	1990	The data demonstrate a significant growth response of pancreatic acinar tissue after a single episode of endogenous CCK-release, which is similar in extent, time course and cellular source as previously demonstrated during persistent stimulation of the pancreas by prolonged infusion of the CCK-analogue caerulein.	Ceruletide	304-313	cholecystokinin	Rattus norvegicus	291-294
33812911-7	2021	Hsp90 inhibitor 17AAG ameliorated inflammation and pancreatic fibrosis in caerulein-induced CP mice.	Ceruletide	74-83	heat shock protein, 3	Mus musculus	0-5
33812911-10	2021	CONCLUSIONS: The study suggests that an Hsp90 inhibitor 17AAG remarkable prevents the development of pancreatic fibrosis in caerulein-induced CP mice, and suppresses activation and extracellular matrix accumulation of PSCs in vitro.	Ceruletide	124-133	heat shock protein, 3	Mus musculus	40-45
33810973-12	2021	Furthermore, NMN supplementation aggravated caerulein hyperstimulation pancreatitis and alcoholic pancreatitis, and inhibition of NAMPT protected against caerulein hyperstimulation, alcoholic and biliary acute pancreatitis and reducing pancreatic macrophage infiltration in vivo.	Ceruletide	154-163	nicotinamide phosphoribosyltransferase	Mus musculus	130-135
33806041-0	2021	MFG-E8 Plays an Important Role in Attenuating Cerulein-Induced Acute Pancreatitis in Mice.	Ceruletide	46-54	milk fat globule EGF and factor V/VIII domain containing	Mus musculus	0-6
33806041-5	2021	Immunoblot analysis showed that MFG-E8 is constitutively expressed in the murine pancreas and is increased in mice with cerulein-induced acute pancreatitis.	Ceruletide	120-128	milk fat globule EGF and factor V/VIII domain containing	Mus musculus	32-38
33806041-8	2021	Knocking out Mfge8 in mice exacerbated the severity of cerulein-induced acute pancreatitis and delayed its resolution.	Ceruletide	55-63	milk fat globule EGF and factor V/VIII domain containing	Mus musculus	13-18
34850057-11	2021	Besides that, miR-320-3p inhibition impaired caerulein-induced cell apoptosis arrest and inflammation via targeting PTK2.	Ceruletide	45-54	protein tyrosine kinase 2	Rattus norvegicus	116-120
34882521-8	2022	Circ_0073748 was upregulated and miR-132-3p was downregulated in AP patients" plasma and human pancreatic ductal HPDE6-C7 cells with caerulein induction.	Ceruletide	133-142	microRNA 1323	Homo sapiens	33-43
34882521-9	2022	Interfering circ_0073748 and reinforcing miR-132-3p improved cell viability, EdU incorporation, and superoxide dismutase (SOD) activity of caerulein-treated HPDE6-C7 cells but suppressed malonaldehyde (MDA), IL-6 and TNF-alpha levels and apoptosis rate.	Ceruletide	139-148	microRNA 1323	Homo sapiens	41-51
34882521-9	2022	Interfering circ_0073748 and reinforcing miR-132-3p improved cell viability, EdU incorporation, and superoxide dismutase (SOD) activity of caerulein-treated HPDE6-C7 cells but suppressed malonaldehyde (MDA), IL-6 and TNF-alpha levels and apoptosis rate.	Ceruletide	139-148	superoxide dismutase 1	Homo sapiens	100-120
34882521-9	2022	Interfering circ_0073748 and reinforcing miR-132-3p improved cell viability, EdU incorporation, and superoxide dismutase (SOD) activity of caerulein-treated HPDE6-C7 cells but suppressed malonaldehyde (MDA), IL-6 and TNF-alpha levels and apoptosis rate.	Ceruletide	139-148	superoxide dismutase 1	Homo sapiens	122-125
34882521-9	2022	Interfering circ_0073748 and reinforcing miR-132-3p improved cell viability, EdU incorporation, and superoxide dismutase (SOD) activity of caerulein-treated HPDE6-C7 cells but suppressed malonaldehyde (MDA), IL-6 and TNF-alpha levels and apoptosis rate.	Ceruletide	139-148	interleukin 6	Homo sapiens	208-212
34882521-9	2022	Interfering circ_0073748 and reinforcing miR-132-3p improved cell viability, EdU incorporation, and superoxide dismutase (SOD) activity of caerulein-treated HPDE6-C7 cells but suppressed malonaldehyde (MDA), IL-6 and TNF-alpha levels and apoptosis rate.	Ceruletide	139-148	tumor necrosis factor	Homo sapiens	217-226
34882521-10	2022	Moreover, TRAF3 downregulation was allied with circ_0073748 silencing and miR-132-3p overexpression in caerulein-induced HPDE6-C7 cells.	Ceruletide	103-112	TNF receptor associated factor 3	Homo sapiens	10-15
34882521-10	2022	Moreover, TRAF3 downregulation was allied with circ_0073748 silencing and miR-132-3p overexpression in caerulein-induced HPDE6-C7 cells.	Ceruletide	103-112	microRNA 1323	Homo sapiens	74-84
34882521-12	2022	Notably, circ_0073748 blockage could suppress expressions of phosphorylated P65 (p-P65) and p-IkappaB in caerulein-induced HPDE6-C7 cells by promoting miR-132-3p and inhibiting TRAF3.	Ceruletide	105-114	microRNA 1323	Homo sapiens	151-161
34882521-12	2022	Notably, circ_0073748 blockage could suppress expressions of phosphorylated P65 (p-P65) and p-IkappaB in caerulein-induced HPDE6-C7 cells by promoting miR-132-3p and inhibiting TRAF3.	Ceruletide	105-114	TNF receptor associated factor 3	Homo sapiens	177-182
34882521-13	2022	Silencing circ_0073748 and upregulating miR-132-3p could alleviate caerulein-induced HPDE6-C7 injury and inactivate canonical NF-kappaB signal by inhibiting TRAF3.	Ceruletide	67-76	microRNA 1323	Homo sapiens	40-50
34882521-13	2022	Silencing circ_0073748 and upregulating miR-132-3p could alleviate caerulein-induced HPDE6-C7 injury and inactivate canonical NF-kappaB signal by inhibiting TRAF3.	Ceruletide	67-76	nuclear factor kappa B subunit 1	Homo sapiens	126-135
34882521-14	2022	Circ_0073748/miR-132-3p/TRAF3 ceRNA pathway might be one underlying mechanism and therapeutic target of caerulein-induced AP.	Ceruletide	104-113	microRNA 1323	Homo sapiens	13-23
34882521-14	2022	Circ_0073748/miR-132-3p/TRAF3 ceRNA pathway might be one underlying mechanism and therapeutic target of caerulein-induced AP.	Ceruletide	104-113	TNF receptor associated factor 3	Homo sapiens	24-29
34895060-5	2021	We observed the dynamic changes of HBP levels in the pancreas during acute inflammation in the caerulein-induced AP mice model.	Ceruletide	95-104	signal transducing adaptor molecule (SH3 domain and ITAM motif) 2	Mus musculus	35-38
34643253-7	2021	Results showed that AP was observed in the CAE-induced rat model, and that serum IL-1beta and IL-18 levels, and TRAF6, NLR pyrin domain containing 3 (NLRP3), caspase-1 and caspase-3 mRNA and protein expression levels were increased.	Ceruletide	43-46	interleukin 1 alpha	Rattus norvegicus	81-89
34643253-7	2021	Results showed that AP was observed in the CAE-induced rat model, and that serum IL-1beta and IL-18 levels, and TRAF6, NLR pyrin domain containing 3 (NLRP3), caspase-1 and caspase-3 mRNA and protein expression levels were increased.	Ceruletide	43-46	interleukin 18	Rattus norvegicus	94-99
34643253-7	2021	Results showed that AP was observed in the CAE-induced rat model, and that serum IL-1beta and IL-18 levels, and TRAF6, NLR pyrin domain containing 3 (NLRP3), caspase-1 and caspase-3 mRNA and protein expression levels were increased.	Ceruletide	43-46	TNF receptor associated factor 6	Rattus norvegicus	112-117
34643253-7	2021	Results showed that AP was observed in the CAE-induced rat model, and that serum IL-1beta and IL-18 levels, and TRAF6, NLR pyrin domain containing 3 (NLRP3), caspase-1 and caspase-3 mRNA and protein expression levels were increased.	Ceruletide	43-46	NLR family, pyrin domain containing 3	Rattus norvegicus	150-155
34643253-7	2021	Results showed that AP was observed in the CAE-induced rat model, and that serum IL-1beta and IL-18 levels, and TRAF6, NLR pyrin domain containing 3 (NLRP3), caspase-1 and caspase-3 mRNA and protein expression levels were increased.	Ceruletide	43-46	caspase 1	Rattus norvegicus	158-167
34643253-7	2021	Results showed that AP was observed in the CAE-induced rat model, and that serum IL-1beta and IL-18 levels, and TRAF6, NLR pyrin domain containing 3 (NLRP3), caspase-1 and caspase-3 mRNA and protein expression levels were increased.	Ceruletide	43-46	caspase 3	Rattus norvegicus	172-181
34643253-8	2021	Similar in HPDE6C7 cells, CAE treatment caused supernatant IL-1beta level, NLRP3 and caspase-1 mRNA expression levels to significantly increase.	Ceruletide	26-29	interleukin 1 alpha	Homo sapiens	59-67
34643253-8	2021	Similar in HPDE6C7 cells, CAE treatment caused supernatant IL-1beta level, NLRP3 and caspase-1 mRNA expression levels to significantly increase.	Ceruletide	26-29	NLR family pyrin domain containing 3	Homo sapiens	75-80
34643253-8	2021	Similar in HPDE6C7 cells, CAE treatment caused supernatant IL-1beta level, NLRP3 and caspase-1 mRNA expression levels to significantly increase.	Ceruletide	26-29	caspase 1	Homo sapiens	85-94
34643253-12	2021	In conclusion, TRAF6 and caspase-1/3 signaling pathways were involved in the pathogenesis of CAE-induced AP in rats.	Ceruletide	93-96	TNF receptor associated factor 6	Rattus norvegicus	15-20
34643253-12	2021	In conclusion, TRAF6 and caspase-1/3 signaling pathways were involved in the pathogenesis of CAE-induced AP in rats.	Ceruletide	93-96	caspase 1	Rattus norvegicus	25-36
34858995-2	2021	We established caerulein-induced mouse models of SAP-associated lung injury, which showed that GSDMD-mediated pyroptosis was activated in both pancreatic and lung tissues.	Ceruletide	15-24	gasdermin D	Mus musculus	95-100
34840668-3	2021	In our study, we confirmed that the expression of p-CaMK II was increased significantly and consistently in injured pancreatic tissues after caerulein-induced AP.	Ceruletide	141-150	calcium/calmodulin-dependent protein kinase II gamma	Mus musculus	52-59
34464354-4	2021	In caerulein-induced WT mice, miR-29a remained dramatically downregulated at injury.	Ceruletide	3-12	microRNA 29a	Mus musculus	30-37
34498715-11	2021	The data indicated that emodin significantly decreased the levels of IL-1beta and TNF-alpha in the supernatant samples derived from AR42J cells cotreated with caerulein and LPS.	Ceruletide	159-168	interleukin 1 alpha	Rattus norvegicus	69-77
34498715-11	2021	The data indicated that emodin significantly decreased the levels of IL-1beta and TNF-alpha in the supernatant samples derived from AR42J cells cotreated with caerulein and LPS.	Ceruletide	159-168	tumor necrosis factor	Rattus norvegicus	82-91
34498715-12	2021	In addition, emodin significantly promoted the proliferation of AR42J cells cotreated with caerulein and LPS, and inhibited apoptosis, while the effect of emodin was reversed by long non-coding (lnc)RNA taurine upregulated 1 (TUG1) overexpression.	Ceruletide	91-100	taurine up-regulated 1	Rattus norvegicus	226-230
34498715-13	2021	The expression level of TUG1 in AR42J cells or exosomes derived from AR42J cells was significantly increased following treatment of the cells with LPS and caerulein, while this effect was notably reversed by emodin treatment.	Ceruletide	155-164	taurine up-regulated 1	Rattus norvegicus	24-28
34988204-0	2021	GSK-3beta activates NF-kappaB to aggravate caerulein-induced early acute pancreatitis in mice.	Ceruletide	43-52	glycogen synthase kinase 3 alpha	Mus musculus	0-9
34988204-0	2021	GSK-3beta activates NF-kappaB to aggravate caerulein-induced early acute pancreatitis in mice.	Ceruletide	43-52	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	20-29
34246777-9	2021	Moreover, the protective effects of Wed in caerulein-stimulated pancreatic acinar cells were markedly abrogated by the down-regulation of GPX4.	Ceruletide	43-52	glutathione peroxidase 4	Mus musculus	138-142
34358966-5	2021	We applied a Hif1alpha inhibitor PX478 and observed that it could alleviate histological injury of pancreas as well as the levels of serum amylase, lipase and proinflammatory cytokine in the murine model of AP induced by caerulein.	Ceruletide	221-230	hypoxia inducible factor 1, alpha subunit	Mus musculus	13-22
34358966-5	2021	We applied a Hif1alpha inhibitor PX478 and observed that it could alleviate histological injury of pancreas as well as the levels of serum amylase, lipase and proinflammatory cytokine in the murine model of AP induced by caerulein.	Ceruletide	221-230	lipase, endothelial	Mus musculus	148-154
34363008-5	2022	(R)-TML104 markedly attenuated caerulein-induced AP, as evidenced by decreased pancreatic edema, serum amylase levels, serum lipase levels, and pancreatic myeloperoxidase activity.	Ceruletide	31-40	lipase, endothelial	Mus musculus	125-131
34363008-5	2022	(R)-TML104 markedly attenuated caerulein-induced AP, as evidenced by decreased pancreatic edema, serum amylase levels, serum lipase levels, and pancreatic myeloperoxidase activity.	Ceruletide	31-40	myeloperoxidase	Mus musculus	155-170
34131249-4	2021	SETD4+ cells generate newborn acinar cells in response to cerulein-induced pancreatitis in acinar compartments.	Ceruletide	58-66	SET domain containing 4	Mus musculus	0-5
34421598-5	2021	The results showed that knockout of mfge8 gene aggravated pancreatic fibrosis after repeated cerulein injection.	Ceruletide	93-101	milk fat globule EGF and factor V/VIII domain containing	Mus musculus	36-41
34112763-3	2021	In the current study, we administered caerulein to Ripk3- or Mlkl-deficient mice (Ripk3-/- or Mlkl-/- mice, respectively) and assessed the roles of necroptosis in AP.	Ceruletide	38-47	receptor-interacting serine-threonine kinase 3	Mus musculus	51-56
34112763-3	2021	In the current study, we administered caerulein to Ripk3- or Mlkl-deficient mice (Ripk3-/- or Mlkl-/- mice, respectively) and assessed the roles of necroptosis in AP.	Ceruletide	38-47	mixed lineage kinase domain-like	Mus musculus	61-65
34093751-0	2021	miR-9 alleviated the inflammatory response and apoptosis in caerulein-induced acute pancreatitis by regulating FGF10 and the NF-kappaB signaling pathway.	Ceruletide	60-69	fibroblast growth factor 10	Rattus norvegicus	111-116
34093751-10	2021	Results demonstrated increased FGF10 expression in caerulein-treated AR42J cells and that FGF10 overexpression exacerbated the caerulein-induced inflammatory response and apoptosis, while its knockdown had the opposite effect.	Ceruletide	51-60	fibroblast growth factor 10	Rattus norvegicus	31-36
34093751-10	2021	Results demonstrated increased FGF10 expression in caerulein-treated AR42J cells and that FGF10 overexpression exacerbated the caerulein-induced inflammatory response and apoptosis, while its knockdown had the opposite effect.	Ceruletide	51-60	fibroblast growth factor 10	Rattus norvegicus	90-95
34093751-10	2021	Results demonstrated increased FGF10 expression in caerulein-treated AR42J cells and that FGF10 overexpression exacerbated the caerulein-induced inflammatory response and apoptosis, while its knockdown had the opposite effect.	Ceruletide	127-136	fibroblast growth factor 10	Rattus norvegicus	90-95
34093751-11	2021	Additionally, FGF10 reversed the effect of miR-9 on caerulein-induced injury in AR42J cells.	Ceruletide	52-61	fibroblast growth factor 10	Rattus norvegicus	14-19
34349610-7	2021	We aimed to investigate whether resistin amplifies cerulein-induced IL-6 expression and whether astaxanthin (ASX), an antioxidant carotenoid with anti-inflammatory properties, inhibits ceruelin/resistin-induced IL-6 expression in pancreatic acinar AR42J cells.	Ceruletide	51-59	resistin	Rattus norvegicus	32-40
34349610-7	2021	We aimed to investigate whether resistin amplifies cerulein-induced IL-6 expression and whether astaxanthin (ASX), an antioxidant carotenoid with anti-inflammatory properties, inhibits ceruelin/resistin-induced IL-6 expression in pancreatic acinar AR42J cells.	Ceruletide	51-59	interleukin 6	Rattus norvegicus	68-72
34112763-5	2021	Consistently, Mlkl-/- mice were more susceptible to caerulein-induced AP, which occurred in a time- and dose-dependent manner, than control mice.	Ceruletide	52-61	mixed lineage kinase domain-like	Mus musculus	14-18
34176350-0	2021	Protective effects of baicalin on caerulein-induced AR42J pancreatic acinar cells by attenuating oxidative stress through miR-136-5p downregulation.	Ceruletide	34-43	microRNA 136	Rattus norvegicus	122-129
34099862-4	2021	Both Reg3b transgenic mice and REG3B-treated mice with caerulein-induced pancreatitis develop and sustain ADM. Two out of five Reg3b transgenic mice with caerulein-induced pancreatitis show progression from ADM to pancreatic intraepithelial neoplasia (PanIN).	Ceruletide	55-64	regenerating islet-derived 3 beta	Mus musculus	31-36
34099862-4	2021	Both Reg3b transgenic mice and REG3B-treated mice with caerulein-induced pancreatitis develop and sustain ADM. Two out of five Reg3b transgenic mice with caerulein-induced pancreatitis show progression from ADM to pancreatic intraepithelial neoplasia (PanIN).	Ceruletide	154-163	regenerating islet-derived 3 beta	Mus musculus	127-132
35581162-10	2022	Circ_0000284 was upregulated in serum of AP patients and caerulein-induced AR42J cells, while Wnt/beta-catenin pathway was inactivated.	Ceruletide	57-66	catenin beta 1	Rattus norvegicus	98-110
35581162-11	2022	Knockdown of circ_0000284 could decrease apoptosis and inflammation in caerulein-induced AR42J cells, which was attenuated by miR-10a-5p inhibition or Wnt signaling pathway antagonist Dickkopf-related protein 1 (DKK1).	Ceruletide	71-80	microRNA 10a	Rattus norvegicus	126-133
35581162-11	2022	Knockdown of circ_0000284 could decrease apoptosis and inflammation in caerulein-induced AR42J cells, which was attenuated by miR-10a-5p inhibition or Wnt signaling pathway antagonist Dickkopf-related protein 1 (DKK1).	Ceruletide	71-80	dickkopf WNT signaling pathway inhibitor 1	Rattus norvegicus	184-210
35581162-11	2022	Knockdown of circ_0000284 could decrease apoptosis and inflammation in caerulein-induced AR42J cells, which was attenuated by miR-10a-5p inhibition or Wnt signaling pathway antagonist Dickkopf-related protein 1 (DKK1).	Ceruletide	71-80	dickkopf WNT signaling pathway inhibitor 1	Rattus norvegicus	212-216
35581162-12	2022	MiR-10a-5p was sponged by circ_000028 and was downregulated in caerulein-induced AR42J cells.	Ceruletide	63-72	microRNA 10a	Rattus norvegicus	0-7
35182973-7	2022	In addition, specific NLRP3 inhibitor MCC950 eliminated the protective effect of Pae on AP induced by caerulein in mice.	Ceruletide	102-111	NLR family, pyrin domain containing 3	Mus musculus	22-27
35398595-11	2022	Administration of caerulein increased the severity of AP/CP in mice expressing CEL-HYB1 compared to control mice, accompanied by higher levels of endoplasmic reticulum stress.	Ceruletide	18-27	LIM homeobox protein 2	Mus musculus	54-59
35398595-11	2022	Administration of caerulein increased the severity of AP/CP in mice expressing CEL-HYB1 compared to control mice, accompanied by higher levels of endoplasmic reticulum stress.	Ceruletide	18-27	carboxyl ester lipase	Mus musculus	79-87
35431492-0	2022	Loss of LAT1 sex-dependently delays recovery after caerulein-induced acute pancreatitis.	Ceruletide	51-60	solute carrier family 7 (cationic amino acid transporter, y+ system), member 5	Mus musculus	8-12
35620344-4	2022	Methods:  AP was induced in C57BL/6 mice by intraperitoneal administration of cerulein (100mug/kg/h x 7 doses) at intervals of 1 hour.	Ceruletide	78-86	LIM homeobox protein 2	Mus musculus	10-12
35211358-4	2022	Here, we show that miR-301a is highly expressed in activated PSCs in mice, sustained tissue fibrosis in caerulein-induced chronic pancreatitis, and accelerated PanIN formation.	Ceruletide	104-113	microRNA 301	Mus musculus	19-27
35226340-10	2022	Finally, we identified the predicted mechanisms of action of ceruletide and alpha-1 antitrypsin and we demonstrated that CA modulates EGFR and ANGPT-1 levels in circulation within the acute phase after stroke.	Ceruletide	61-71	epidermal growth factor receptor	Mus musculus	134-138
35226340-10	2022	Finally, we identified the predicted mechanisms of action of ceruletide and alpha-1 antitrypsin and we demonstrated that CA modulates EGFR and ANGPT-1 levels in circulation within the acute phase after stroke.	Ceruletide	61-71	angiopoietin 1	Mus musculus	143-150
35159064-4	2022	Knockout of pancreatic Prkci significantly increased pancreatic immune cell infiltration, acinar cell DNA damage, and apoptosis, but reduced sensitivity to caerulein-induced pancreatitis.	Ceruletide	156-165	protein kinase C, iota	Mus musculus	23-28
35163177-0	2022	Triptolide Suppresses NF-kappaB-Mediated Inflammatory Responses and Activates Expression of Nrf2-Mediated Antioxidant Genes to Alleviate Caerulein-Induced Acute Pancreatitis.	Ceruletide	137-146	nuclear factor, erythroid derived 2, like 2	Mus musculus	92-96
35094239-0	2022	Crocetin alleviates the caerulein-induced apoptosis and inflammation in AR42J cells by activating SIRT1 via NF-kappaB.	Ceruletide	24-33	sirtuin 1	Rattus norvegicus	98-103
35094239-10	2022	The decreased expression of SIRT1 was increased in caerulein-induced AR42J cells after exposure to crocetin.	Ceruletide	51-60	sirtuin 1	Rattus norvegicus	28-33
35096831-10	2021	The presence of specific inhibitors of alphavbeta3/5 integrin, FAK or STAT3 abolished MFG-E8"s effect on cerulein + LPS-induced ER stress in pancreatic acinar cells.	Ceruletide	105-113	signal transducer and activator of transcription 3	Mus musculus	70-75
35096831-10	2021	The presence of specific inhibitors of alphavbeta3/5 integrin, FAK or STAT3 abolished MFG-E8"s effect on cerulein + LPS-induced ER stress in pancreatic acinar cells.	Ceruletide	105-113	milk fat globule EGF and factor V/VIII domain containing	Mus musculus	86-92
35366980-3	2022	Repeat injection of cerulein, a cholecystokinin (CCK) analog, is widely used to experimentally induce acute and chronic pancreatitis in vivo.	Ceruletide	20-28	cholecystokinin	Mus musculus	49-52
2622523-7	1989	In contrast to these observations, morphine pre-injection (3h before testing) was found to significantly potentiate caerulein-induced antinociception revealing a differential interaction between opioid and CCK systems at different time points.	Ceruletide	116-125	cholecystokinin	Rattus norvegicus	206-209
2479032-1	1989	Rats infused with a supramaximally stimulating dose of the cholecystokinin (CCK) analog caerulein develop acute edematous pancreatitis.	Ceruletide	88-97	cholecystokinin	Rattus norvegicus	59-74
2470581-0	1989	Epidermal growth factor inhibits rat pancreatic cell proliferation, causes acinar cell hypertrophy, and prevents caerulein-induced desensitization of amylase release.	Ceruletide	113-122	epidermal growth factor like 1	Rattus norvegicus	0-23
2479032-1	1989	Rats infused with a supramaximally stimulating dose of the cholecystokinin (CCK) analog caerulein develop acute edematous pancreatitis.	Ceruletide	88-97	cholecystokinin	Rattus norvegicus	76-79
2479032-2	1989	Using CCK-JMV-180, a recently developed CCK analog that acts as an agonist at high-affinity CCK receptors but antagonizes the effect of CCK at low-affinity receptors, we have determined that caerulein induces pancreatitis by interacting with low-affinity CCK receptors.	Ceruletide	191-200	cholecystokinin	Rattus norvegicus	6-9
2479032-2	1989	Using CCK-JMV-180, a recently developed CCK analog that acts as an agonist at high-affinity CCK receptors but antagonizes the effect of CCK at low-affinity receptors, we have determined that caerulein induces pancreatitis by interacting with low-affinity CCK receptors.	Ceruletide	191-200	cholecystokinin	Rattus norvegicus	40-43
2479032-2	1989	Using CCK-JMV-180, a recently developed CCK analog that acts as an agonist at high-affinity CCK receptors but antagonizes the effect of CCK at low-affinity receptors, we have determined that caerulein induces pancreatitis by interacting with low-affinity CCK receptors.	Ceruletide	191-200	cholecystokinin	Rattus norvegicus	40-43
2479032-2	1989	Using CCK-JMV-180, a recently developed CCK analog that acts as an agonist at high-affinity CCK receptors but antagonizes the effect of CCK at low-affinity receptors, we have determined that caerulein induces pancreatitis by interacting with low-affinity CCK receptors.	Ceruletide	191-200	cholecystokinin	Rattus norvegicus	40-43
2479032-2	1989	Using CCK-JMV-180, a recently developed CCK analog that acts as an agonist at high-affinity CCK receptors but antagonizes the effect of CCK at low-affinity receptors, we have determined that caerulein induces pancreatitis by interacting with low-affinity CCK receptors.	Ceruletide	191-200	cholecystokinin	Rattus norvegicus	40-43
2478134-3	1989	Both of these analogs cause comparable increases in the rate of amylase secretion and in intracellular Ca2+ concentration but their effects on inositol phosphate generation are dramatically different; caerulein stimulates significant production of inositol phosphates within 1 min of its addition, whereas no detectable levels of inositol phosphates were generated within the same time after addition of CCK-JMV-180.	Ceruletide	201-210	cholecystokinin	Rattus norvegicus	404-407
2526762-6	1989	In these diabetic animals, the cholecystokinin (CCK) analogue ceruletide (620 pM) caused a significantly greater increase in IRI release in the presence of 5.6 mM glucose than in the control rats, but ceruletide caused a similar IRG release in both groups.	Ceruletide	62-72	cholecystokinin	Rattus norvegicus	31-46
2526762-6	1989	In these diabetic animals, the cholecystokinin (CCK) analogue ceruletide (620 pM) caused a significantly greater increase in IRI release in the presence of 5.6 mM glucose than in the control rats, but ceruletide caused a similar IRG release in both groups.	Ceruletide	62-72	cholecystokinin	Rattus norvegicus	48-51
2470581-10	1989	Conversely, caerulein reversed the inhibitory effect of EGF on thymidine incorporation.	Ceruletide	12-21	epidermal growth factor like 1	Rattus norvegicus	56-59
2762755-1	1989	It is well established that repeated injections of the cholecystokinin (CCK) analogue caerulein induce pancreatic hypersecretion and growth, but so far the time-specific development of hypersecretory capacity has not been studied.	Ceruletide	86-95	cholecystokinin	Rattus norvegicus	55-70
2762755-1	1989	It is well established that repeated injections of the cholecystokinin (CCK) analogue caerulein induce pancreatic hypersecretion and growth, but so far the time-specific development of hypersecretory capacity has not been studied.	Ceruletide	86-95	cholecystokinin	Rattus norvegicus	72-75
2762755-9	1989	We conclude that chronic administration of the CCK analogue caerulein induces adaptation of the pancreas in a sequential order.	Ceruletide	60-69	cholecystokinin	Rattus norvegicus	47-50
2614728-7	1989	In contrast, CCK antagonists competitively inhibited amylase release induced by caerulein and pentagastrin but not by bombesin or urecholine, indicating that the latter two agents act directly on acinar cells via receptors which are separate from those involved in stimulation induced by caerulein and pentagastrin.	Ceruletide	80-89	cholecystokinin	Rattus norvegicus	13-16
2469859-5	1989	Cholecystokinin octapeptide also produced pancreatitis when given at ten times the dose required for caerulein (50 micrograms/kg.hour instead of 5 micrograms/kg.hour).	Ceruletide	101-110	cholecystokinin	Rattus norvegicus	0-15
2614728-7	1989	In contrast, CCK antagonists competitively inhibited amylase release induced by caerulein and pentagastrin but not by bombesin or urecholine, indicating that the latter two agents act directly on acinar cells via receptors which are separate from those involved in stimulation induced by caerulein and pentagastrin.	Ceruletide	288-297	cholecystokinin	Rattus norvegicus	13-16
2469109-6	1989	Studies in vitro dispersed rat pancreatic acini showed that GRF added to the incubation medium of these acini caused an increase in basal amylase release and shifted to the left the amylase dose-response curve to caerulein and urecholine but failed to affect the amylase response to VIP.	Ceruletide	213-222	growth hormone releasing hormone	Rattus norvegicus	60-63
2480697-6	1989	In combinative administration of caerulein with somatostatin, the stimulatory effect by caerulein was decreased.	Ceruletide	33-42	somatostatin	Rattus norvegicus	48-60
2721558-2	1989	injections of the cholecystokinin (CCK) analogue caerulein was antagonised by a low dose (0.25 mumol/kg s.c.) of the selective CCK antagonist L-364,718.	Ceruletide	49-58	cholecystokinin	Rattus norvegicus	18-33
2721558-2	1989	injections of the cholecystokinin (CCK) analogue caerulein was antagonised by a low dose (0.25 mumol/kg s.c.) of the selective CCK antagonist L-364,718.	Ceruletide	49-58	cholecystokinin	Rattus norvegicus	35-38
2721558-2	1989	injections of the cholecystokinin (CCK) analogue caerulein was antagonised by a low dose (0.25 mumol/kg s.c.) of the selective CCK antagonist L-364,718.	Ceruletide	49-58	cholecystokinin	Rattus norvegicus	127-130
2467044-2	1989	Acute pancreatitis was induced in rats by the CCK-analogue cerulein (5 micrograms/kg.h) for 30 min, 3.5 h, and 12 h. At the end of the infusion, serum enzymes and the lipid peroxidation products conjugated dienes and malondialdehyde in the tissue were measured.	Ceruletide	59-67	cholecystokinin	Rattus norvegicus	46-49
2480697-6	1989	In combinative administration of caerulein with somatostatin, the stimulatory effect by caerulein was decreased.	Ceruletide	88-97	somatostatin	Rattus norvegicus	48-60
2605370-3	1989	This study was undertaken to evaluate the effects of caerulein, a CCK analog, on the different cell populations of the pancreatic tissue and their respective turnover.	Ceruletide	53-62	cholecystokinin	Rattus norvegicus	66-69
2475419-12	1989	Its ability to antagonize the pancreatic secretory and trophic action of a CCK-analogue (i.e. caerulein) supports the view that these physiological actions of CCK are mediated through an interaction of the hormone with specific receptors.	Ceruletide	94-103	cholecystokinin	Rattus norvegicus	75-78
2475419-12	1989	Its ability to antagonize the pancreatic secretory and trophic action of a CCK-analogue (i.e. caerulein) supports the view that these physiological actions of CCK are mediated through an interaction of the hormone with specific receptors.	Ceruletide	94-103	cholecystokinin	Rattus norvegicus	159-162
2544930-6	1989	Administration of the CCK-antagonist L-364,718 twice daily at a dose of 0.1 mg/kg or at 1.0 mg/kg, either s.c. or orally, led dose-dependently to a near-complete inhibition of the caerulein-induced trophic effect.	Ceruletide	180-189	cholecystokinin	Rattus norvegicus	22-25
2481056-4	1989	Stimulation with 10(-10) M caerulein, 10(-5) M carbachol, or 10(-8) M gastrin-releasing peptide (GRP) led to biphasic amylase release and increase in [Ca2+]i.	Ceruletide	27-36	gastrin releasing peptide	Rattus norvegicus	97-100
3208830-0	1988	The novel CCK antagonist L364,718 abolished caerulein- but potentiates morphine-induced antinociception.	Ceruletide	44-53	cholecystokinin	Rattus norvegicus	10-13
2459272-5	1988	PYY in a dose range of 2.5-40 nmol/kg.h also inhibited the response to caerulein in conscious rats but failed to prevent the increment in the postprandial protein secretion in this species.	Ceruletide	71-80	peptide YY	Rattus norvegicus	0-3
3208830-1	1988	The novel CCK antagonist L364,718 was tested on caerulein- and morphine-induced antinociception in rat using the paw pressure test.	Ceruletide	48-57	cholecystokinin	Rattus norvegicus	10-13
3280384-0	1988	Bile duct measurements after ceruletide as an aid to the ultrasound diagnosis of choledocholithiasis.	Ceruletide	29-39	activation induced cytidine deaminase	Homo sapiens	46-49
2906429-1	1988	Rats were trained to discriminate vehicle injections from intraperitoneal injections of 3 micrograms/kg caerulein, a cholecystokinin (CCK) neuropeptide analog.	Ceruletide	104-113	cholecystokinin	Rattus norvegicus	134-137
3368039-3	1988	In cerebellar membranes 125I-BHCCK binding was inhibited by CCK analogues with an order of potency, caerulein greater than CCK-8 greater than CCK-33 greater than gastrin 1-17 = CCK-8 non-sulphated.	Ceruletide	100-109	cholecystokinin	Homo sapiens	31-34
3368039-3	1988	In cerebellar membranes 125I-BHCCK binding was inhibited by CCK analogues with an order of potency, caerulein greater than CCK-8 greater than CCK-33 greater than gastrin 1-17 = CCK-8 non-sulphated.	Ceruletide	100-109	cholecystokinin	Homo sapiens	60-63
2447799-3	1988	The effect of caerulein was inhibited by dibutyryl guanosine 3",5"-cyclic monophosphate (cGMP) and asperlicin, indicating that activation of the Na+-H+ antiport caused by caerulein is mediated by CCK receptors.	Ceruletide	14-23	cholecystokinin	Cavia porcellus	196-199
2841182-6	1988	The simultaneous administration of 10(-3) M dibutyryl cyclic GMP, a specific membrane antagonist against cholecystokinin (CCK), inhibited the first and second phases of caerulein-induced insulin secretion.	Ceruletide	169-178	cholecystokinin	Rattus norvegicus	105-120
2841182-6	1988	The simultaneous administration of 10(-3) M dibutyryl cyclic GMP, a specific membrane antagonist against cholecystokinin (CCK), inhibited the first and second phases of caerulein-induced insulin secretion.	Ceruletide	169-178	cholecystokinin	Rattus norvegicus	122-125
3131747-3	1988	The relative potencies of CCK-related peptides in inhibiting radioligand binding were caerulein greater than gastrin II approximately equal to CCK-8 approximately equal to CCK-33 greater than CCK-8-DS approximately equal to gastrin I. L-364,718, a potent inhibitor of peripheral CCK receptors, was ineffective at competition binding at concentrations up to 1 microM; dibutyryl cyclic GMP was modestly effective at competing (KD approximately 10 mM).	Ceruletide	86-95	cholecystokinin	Rattus norvegicus	26-29
2831729-1	1988	Caerulein, gastrin, and C-terminal fragments of cholecystokinin (CCK) varying in length from eight (CCK-8) to four (CCK-4) amino acids stimulate pepsinogen secretion from dispersed chief cells prepared from guinea pig stomach.	Ceruletide	0-9	cholecystokinin	Homo sapiens	100-103
2831729-1	1988	Caerulein, gastrin, and C-terminal fragments of cholecystokinin (CCK) varying in length from eight (CCK-8) to four (CCK-4) amino acids stimulate pepsinogen secretion from dispersed chief cells prepared from guinea pig stomach.	Ceruletide	0-9	protein tyrosine kinase 7 (inactive)	Homo sapiens	116-121
3368039-3	1988	In cerebellar membranes 125I-BHCCK binding was inhibited by CCK analogues with an order of potency, caerulein greater than CCK-8 greater than CCK-33 greater than gastrin 1-17 = CCK-8 non-sulphated.	Ceruletide	100-109	cholecystokinin	Homo sapiens	60-63
3368039-3	1988	In cerebellar membranes 125I-BHCCK binding was inhibited by CCK analogues with an order of potency, caerulein greater than CCK-8 greater than CCK-33 greater than gastrin 1-17 = CCK-8 non-sulphated.	Ceruletide	100-109	cholecystokinin	Homo sapiens	60-63
3480708-0	1987	Xanthine oxidase activity in mouse pancreas: effects of caerulein-induced acute pancreatitis.	Ceruletide	56-65	xanthine dehydrogenase	Mus musculus	0-16
2446509-5	1987	Acini suspended in Ca2+ free buffer containing 0.1 or 0.2 mM ethylene glycol tetraacetic acid showed 0.21 and 0.10 pH unit alkalinization in response to caerulein (10(-10) M) and carbachol (10(-5) M) but no change in pHi after addition of bromo-A23187.	Ceruletide	153-162	glucose-6-phosphate isomerase 1	Mus musculus	115-117
2446509-2	1987	Acini suspended in pH 7.40 buffer demonstrated cytoplasmic alkalinization of 0.17, 0.14, and 0.15 pH units 2 min after addition of the secretagogues carbachol (10(-5) M), caerulein (10(-10) M), and bromo-A23187 (10(-6) M).	Ceruletide	171-180	glucose-6-phosphate isomerase 1	Mus musculus	19-21
2446509-5	1987	Acini suspended in Ca2+ free buffer containing 0.1 or 0.2 mM ethylene glycol tetraacetic acid showed 0.21 and 0.10 pH unit alkalinization in response to caerulein (10(-10) M) and carbachol (10(-5) M) but no change in pHi after addition of bromo-A23187.	Ceruletide	153-162	glucose-6-phosphate isomerase 1	Mus musculus	217-220
2446509-7	1987	Alkalinization in response to stimulation of secretion was maximal at 10(-8) M caerulein (0.30 pH units at 2 min) but was of lesser magnitude at 10(-7) M. Pancreatic acini demonstrated autoregulation of pHi over a range of external pH from 7.4 to 7.1.	Ceruletide	79-88	glucose-6-phosphate isomerase 1	Mus musculus	95-97
2821825-15	1987	Electron microscopic immunolabeling studies revealed localization of cathepsin D in discrete organelles that, in the samples from animals infused with a supramaximally stimulating dose of caerulein, were larger, more abundant, and more concentrated in the pellet centrifuged at 1,300 g for 15 min than in the controls.	Ceruletide	188-197	cathepsin D	Rattus norvegicus	69-80
3569770-3	1987	Neuropeptide Y also blocked nerve-mediated phasic contractions of the circular muscle, induced by dimethylphenylpiperazinium or ceruletide, and abolished the peristaltic movements of the small intestine.	Ceruletide	128-138	pro-neuropeptide Y	Cavia porcellus	0-14
3026361-3	1986	In permeabilized cells, the Ca2+-mobilizing agonist caerulein stimulated [3H]IP3 formation when the free [Ca2+] was buffered at 140 nM, the cytosolic free [Ca2+] of unstimulated pancreatic acinar cells.	Ceruletide	52-61	carbonic anhydrase 2	Rattus norvegicus	28-31
3309901-2	1987	Ceruletide is a synthetic decapeptide closely resembling the 8-carboxy-terminal peptide of cholecystokinin (CCK-8) with which it shares several biological properties.	Ceruletide	0-10	cholecystokinin	Homo sapiens	91-106
3580706-3	1987	CR 1409 (0.06-2.1 microM) antagonized longitudinal muscle responses to ceruletide (caerulein, a CCK-related decapeptide) in a concentration dependent and competitive manner (pA2 7.77); responses to CCK-octapeptide (CCK-8) were antagonized with a similar potency.	Ceruletide	71-81	cholecystokinin	Cavia porcellus	96-99
3580706-3	1987	CR 1409 (0.06-2.1 microM) antagonized longitudinal muscle responses to ceruletide (caerulein, a CCK-related decapeptide) in a concentration dependent and competitive manner (pA2 7.77); responses to CCK-octapeptide (CCK-8) were antagonized with a similar potency.	Ceruletide	83-92	cholecystokinin	Cavia porcellus	96-99
3026361-3	1986	In permeabilized cells, the Ca2+-mobilizing agonist caerulein stimulated [3H]IP3 formation when the free [Ca2+] was buffered at 140 nM, the cytosolic free [Ca2+] of unstimulated pancreatic acinar cells.	Ceruletide	52-61	carbonic anhydrase 2	Rattus norvegicus	106-109
3026361-3	1986	In permeabilized cells, the Ca2+-mobilizing agonist caerulein stimulated [3H]IP3 formation when the free [Ca2+] was buffered at 140 nM, the cytosolic free [Ca2+] of unstimulated pancreatic acinar cells.	Ceruletide	52-61	carbonic anhydrase 2	Rattus norvegicus	106-109
3026361-13	1986	However, a maximal concentration of caerulein elicited ten times as much IP3 formation as did the highest physiologically relevant [Ca2+].	Ceruletide	36-45	carbonic anhydrase 2	Rattus norvegicus	132-135
2870952-2	1986	The effects of intravenous administration of caerulein on plasma immunoreactive VIP levels were examined, with or without intraduodenal ballooning, to rule out the effect of bile and pancreatic and gastric juice.	Ceruletide	45-54	vasoactive intestinal peptide	Canis lupus familiaris	80-83
2870952-6	1986	Intraileal administration of bile or intravenous caerulein, with or without intraduodenal ballooning, produced a significant increase of plasma VIP in the mesenteric vein.	Ceruletide	49-58	vasoactive intestinal peptide	Canis lupus familiaris	144-147
2870952-7	1986	Pretreatment with atropine completely blocked the bile-stimulated VIP release and significantly inhibited the caerulein-stimulated release of VIP.	Ceruletide	110-119	vasoactive intestinal peptide	Canis lupus familiaris	142-145
2425913-2	1986	Because ornithine decarboxylase (ODC) could be involved in this process, it is of interest to localize and estimate ODC immunoreactivity in rat pancreatic acinar cells from control and caerulein-treated animals.	Ceruletide	185-194	ornithine decarboxylase 1	Rattus norvegicus	8-31
2425913-2	1986	Because ornithine decarboxylase (ODC) could be involved in this process, it is of interest to localize and estimate ODC immunoreactivity in rat pancreatic acinar cells from control and caerulein-treated animals.	Ceruletide	185-194	ornithine decarboxylase 1	Rattus norvegicus	33-36
3817330-3	1986	Adding an intravenous infusion of 0.4 micrograms (300 pmol)/kg/h of caerulein to the infusion of secretin, the jejunal absorption rates of water, sodium and glucose were restored to control values.	Ceruletide	68-77	SCT	Canis lupus familiaris	97-105
3693975-0	1986	Ceruletide-induced acute pancreatitis in the dog and its amelioration by exogenous secretin.	Ceruletide	0-10	SCT	Canis lupus familiaris	83-91
3693975-3	1986	secretin administered for a period of 24 h after cessation of ceruletide infusion resulted in a significant amelioration of the acute pancreatitis compared to non-secretin-treated dogs with acute pancreatitis.	Ceruletide	62-72	SCT	Canis lupus familiaris	0-8
3693975-7	1986	secretin exerts a beneficial effect on pre-established, ceruletide-induced acute pancreatitis in dogs.	Ceruletide	56-66	SCT	Canis lupus familiaris	0-8
2435952-2	1986	The somatostatin analog 008 was found to be more efficient in taurocholate-induced pancreatitis in rats and in ceruletid-induced pancreatitis.	Ceruletide	111-120	somatostatin	Rattus norvegicus	4-16
2999799-7	1985	However, ACTH release in response to caerulein, an agonist of cholecystokinin 8 receptors, was not altered by the PKI treatment.	Ceruletide	37-46	pro-opiomelanocortin-alpha	Mus musculus	9-13
20493063-5	1986	injection of caerulein (an analog of cholecystokinin) did decrease, in a dose-related manner, the rate for brain self-stimulation.	Ceruletide	13-22	cholecystokinin	Rattus norvegicus	37-52
6085177-1	1984	The increases in DNA synthesis and total DNA content after caerulein treatment support the trophic effect of this CCK analog on the pancreas.	Ceruletide	59-68	cholecystokinin	Rattus norvegicus	114-117
2859054-1	1985	Ceruletide, an analog of cholecystokinin (CCK), has been reported to have neuroleptic-like activity in mice, and, in three open studies, to benefit schizophrenic patients.	Ceruletide	0-10	cholecystokinin	Mus musculus	25-40
2859054-1	1985	Ceruletide, an analog of cholecystokinin (CCK), has been reported to have neuroleptic-like activity in mice, and, in three open studies, to benefit schizophrenic patients.	Ceruletide	0-10	cholecystokinin	Mus musculus	42-45
3893997-5	1985	These results indicate that caerulein, at a concentration which stimulate pancreatic exocrine secretion, has a synergistic effect on insulin response to glucose and amino acids and therefore raises the possibility that endogenously released CCK may contribute to the entero-insular axis.	Ceruletide	28-37	cholecystokinin	Rattus norvegicus	241-244
2410315-2	1985	The enzymatic activities of cathepsin B and beta-galactosidase were determined in the pancreas of rats that had been stimulated by either maximal (0.25 microgram X kg-1 h-1) or supramaximal (5 micrograms X kg-1 h-1) concentrations of cerulein.	Ceruletide	234-242	cathepsin B	Rattus norvegicus	28-39
3998145-3	1985	The pancreas was stimulated by a liquid test meal or by either intravenous secretin (1-82 pmol/kg-1 per h-1) or caerulein, a CCK analogue (2.3-37 pmol/kg-1 per h-1), or by a combination of secretin and caerulein.	Ceruletide	112-121	cholecystokinin	Homo sapiens	125-128
2416452-10	1985	This pattern of structural and functional adaptation of acinar cells following secretin infusion corresponds to previously described changes following caerulein and carbamylcholine stimulation.	Ceruletide	151-160	secretin	Rattus norvegicus	79-87
6085177-7	1984	The trophic effect of caerulein was significantly reduced by somatostatin dramatically so with respect to hyperplasia.	Ceruletide	22-31	somatostatin	Rattus norvegicus	61-73
6146550-4	1984	Caerulein produced dose-related increases in PP secretion (maximal, 106% of meal response) but CCK8 and CCK33 had much less effect at doses equivalent for protein secretion.	Ceruletide	0-9	pancreatic polypeptide	Canis lupus familiaris	45-47
6142655-2	1984	The two lowest doses of pancreatic polypeptide (PP), which produced blood levels lower than measured after a meal, significantly inhibited the pancreatic responses to secretin, caerulein, HCl, and L-phenylalanine; the highest dose of PP inhibited the responses to bethanechol and sodium oleate.	Ceruletide	177-186	pancreatic polypeptide	Canis lupus familiaris	24-46
6146548-0	1984	Effect of caerulein administration on portal plasma somatostatin in dogs.	Ceruletide	10-19	somatostatin	Canis lupus familiaris	52-64
6146548-1	1984	The effect of administration of synthetic caerulein on canine plasma somatostatin concentration in the portal vein was investigated using specific radioimmunoassay of acid-acetone extracted plasma.	Ceruletide	42-51	somatostatin	Canis lupus familiaris	69-81
6146548-3	1984	After administration of caerulein (5 ng/kg), the somatostatin level increased significantly while the gastrin level remained unchanged.	Ceruletide	24-33	somatostatin	Canis lupus familiaris	49-61
6146548-3	1984	After administration of caerulein (5 ng/kg), the somatostatin level increased significantly while the gastrin level remained unchanged.	Ceruletide	24-33	gastrin	Canis lupus familiaris	102-109
6199984-5	1984	Ac-CCK-(26-32)-NH2 inhibited the stimulation of amylase secretion caused by CCK-(26-33), caerulein, or gastrin-(2-17) but did not alter the stimulation caused by carbachol, bombesin, physalaemin, A23187, vasoactive intestinal peptide, secretin, or 8-bromoadenosine 3",5"-cyclic monophosphate.	Ceruletide	89-98	cholecystokinin	Cavia porcellus	3-6
6142655-2	1984	The two lowest doses of pancreatic polypeptide (PP), which produced blood levels lower than measured after a meal, significantly inhibited the pancreatic responses to secretin, caerulein, HCl, and L-phenylalanine; the highest dose of PP inhibited the responses to bethanechol and sodium oleate.	Ceruletide	177-186	pancreatic polypeptide	Canis lupus familiaris	48-50
6328330-2	1984	Subcutaneous (SC) injections of ceruletide (caerulein diethylammonium hydrate, CER) and the octapeptide of cholecystokinin (CCK-8) reduced the intake of liquid food in male NMRI mice starved for 18 h. The corresponding ED50 values were 2 micrograms/kg for CER and 24 micrograms/kg for CCK-8; hence, on a molar basis, CER was 14 times more potent than CCK-8.	Ceruletide	32-42	cholecystokinin	Mus musculus	285-288
6328330-2	1984	Subcutaneous (SC) injections of ceruletide (caerulein diethylammonium hydrate, CER) and the octapeptide of cholecystokinin (CCK-8) reduced the intake of liquid food in male NMRI mice starved for 18 h. The corresponding ED50 values were 2 micrograms/kg for CER and 24 micrograms/kg for CCK-8; hence, on a molar basis, CER was 14 times more potent than CCK-8.	Ceruletide	32-42	cholecystokinin	Mus musculus	285-288
6327454-4	1984	Gastrin analogues (tetragastrin, pentagastrin, caerulein, and synthetic human gastrin) inhibited 125I- SHG specific binding.	Ceruletide	47-56	gastrin	Homo sapiens	0-7
6729149-4	1984	Release of PP following increasing doses of caerulein was significantly inhibited by proglumide (P less than 0.01).	Ceruletide	44-53	pancreatic polypeptide	Canis lupus familiaris	11-13
6717857-0	1984	The cholecystokinin analogue, caerulein, does not modulate dopamine release or dopamine-induced locomotor activity in the nucleus accumbens of rat.	Ceruletide	30-39	cholecystokinin	Rattus norvegicus	4-19
6717857-1	1984	We have investigated the effect of the cholecystokinin (CCK) analogue, caerulein, in the nucleus accumbens on dopamine (DA) release and locomotor activity.	Ceruletide	71-80	cholecystokinin	Rattus norvegicus	39-54
6717857-1	1984	We have investigated the effect of the cholecystokinin (CCK) analogue, caerulein, in the nucleus accumbens on dopamine (DA) release and locomotor activity.	Ceruletide	71-80	cholecystokinin	Rattus norvegicus	56-59
6193543-2	1983	Hormonal stimulation by the cholecystokinin analogue, caerulein, induced a marked enhancement of the activities of cathepsin D and N-acetyl-beta-D-glucosaminidase in pancreatic tissue, whereas the activities of amylase and lipase tended to decrease.	Ceruletide	54-63	cathepsin D	Rattus norvegicus	115-126
6529127-2	1984	By means of various pharmacological tools these effects are suggested to be attributable to a direct effect of caerulein on the smooth muscle of these viscera through the involvement of receptors different from those ones on which CCK may be antagonizable by proglumide or cGMP pretreatments.	Ceruletide	111-120	cholecystokinin	Ovis aries	231-234
6715564-1	1984	An investigation was undertaken to test whether the dose-response curve of a cholecystokinin-like agent (ceruletide) could be established by administering it in graded doses sequentially on the same day.	Ceruletide	105-115	cholecystokinin-like	Oryctolagus cuniculus	77-97
6315191-1	1983	Decapeptide ceruletide (CRL), chemically related to cholecystokinin and gastrin, proved to have remarkable analgesic properties when administered to a group of 22 burned patients, 15 patients with acute myocardial infarction, and 8 patients suffering from pain caused by malignant tumours with metastases.	Ceruletide	12-22	gastrin	Homo sapiens	72-79
6310434-0	1983	Cholecystokinin octapeptide (CCK-8), ceruletide and analogues of ceruletide: effects on tremors induced by oxotremorine, harmine and ibogaine.	Ceruletide	65-75	cholecystokinin	Mus musculus	0-15
6640079-3	1983	In calcium treated dogs the pancreatic secretion stimulated by graded doses of either caerulein or urecholine showed: a) an increase in the sensitivity of acinar cells to caerulein and urecholine and potentiation by caerulein of the water and bicarbonate response to secretin, in contrast to the decreased sensitivity to secretin alone reported previously.	Ceruletide	86-95	SCT	Canis lupus familiaris	267-275
6640079-3	1983	In calcium treated dogs the pancreatic secretion stimulated by graded doses of either caerulein or urecholine showed: a) an increase in the sensitivity of acinar cells to caerulein and urecholine and potentiation by caerulein of the water and bicarbonate response to secretin, in contrast to the decreased sensitivity to secretin alone reported previously.	Ceruletide	86-95	SCT	Canis lupus familiaris	321-329
6193543-2	1983	Hormonal stimulation by the cholecystokinin analogue, caerulein, induced a marked enhancement of the activities of cathepsin D and N-acetyl-beta-D-glucosaminidase in pancreatic tissue, whereas the activities of amylase and lipase tended to decrease.	Ceruletide	54-63	lipase G, endothelial type	Rattus norvegicus	223-229
6193543-4	1983	Further, caerulein was found to induce a significant increase of cathepsin D output in bile-pancreatic juice.	Ceruletide	9-18	cathepsin D	Rattus norvegicus	65-76
6291331-7	1982	Alternatively, "codfish gastrin" is itself an inhibitory principle (gastron), the effect of which is mimicked by gastrin 17, caerulein and CCK8.	Ceruletide	125-134	gastrin	Homo sapiens	24-31
6763205-4	1982	Because of this stimulatory effect, ceruletide is useful not only diagnostically as an aid in x-ray examination of the small bowel, but also therapeutically for treatment of postoperative ileus, intestinal atonia, and chronic fecal statis.	Ceruletide	36-46	activation induced cytidine deaminase	Homo sapiens	87-90
6173205-2	1982	CCK (0.25 mU/ml) or caerulein (0.01 ng/ml) potentiated the insulin secretion induced by 5.6 mM glucose; a significant increase in pancreatic exocrine secretion was also observed at these doses of CCK or caerulein.	Ceruletide	203-212	cholecystokinin	Rattus norvegicus	0-3
6260615-8	1981	Pentagastrin, sincalide and caerulein induced a slight but significant hypocalcaemia and a rise of serum CT levels, together with a significant increase of serum PTH.	Ceruletide	28-37	parathyroid hormone	Homo sapiens	162-165
6173205-2	1982	CCK (0.25 mU/ml) or caerulein (0.01 ng/ml) potentiated the insulin secretion induced by 5.6 mM glucose; a significant increase in pancreatic exocrine secretion was also observed at these doses of CCK or caerulein.	Ceruletide	20-29	cholecystokinin	Rattus norvegicus	196-199
7185770-0	1982	Antipsychotic effects of caerulein, a decapeptide chemically related to cholecystokinin octapeptide, on schizophrenia.	Ceruletide	25-34	cholecystokinin	Homo sapiens	72-87
7185770-1	1982	Caerulein, a decapeptide chemically related to CCK-8, was administered intramuscularly to 20 patients with chronic schizophrenia in two different doses of 0.3 and 0.6 microgram/kg.	Ceruletide	0-9	cholecystokinin	Homo sapiens	47-50
6281507-2	1982	injection of C-terminal octapeptide of cholecystokinin (CCK-8) in rats prolonged pentobarbital- and ethanol-induced sleeping time, but non-sulfated CCD-8 (CCK-8-NS) had no effect and caerulein showed a tendency to prolong the pentobarbital narcosis.	Ceruletide	183-192	cholecystokinin	Rattus norvegicus	39-54
6294391-3	1982	Moreover, the suppressive effect of beta-endorphin on TRH-induced body shakes was antagonized by simultaneous administration of caerulein and CCK-8.	Ceruletide	128-137	thyrotropin releasing hormone	Rattus norvegicus	54-57
6166204-5	1981	Using an increase in DNA content as an index of hyperplasia and cellular mass and enzyme and protein concentrations as indices of hypertrophy, we conclude that over a 3-day period 1) caerulein produced pancreatic hypertrophy after weaning while potentiating the hyperplastic and hypertrophic action of hydrocortisone in suckling rats; and 2) hydrocortisone potentiated the hypertrophic effect of caerulein after weaning.	Ceruletide	183-192	period circadian regulator 1	Rattus norvegicus	173-181
7310683-9	1981	Bovine pancreatic polypeptide and its C-terminal hexapeptide also inhibited secretin and caerulein-induced pancreatic secretion in a dose-dependent manner.	Ceruletide	89-98	pancreatic polypeptide	Bos taurus	7-29
7202946-2	1981	The greatest rise in plasma PP concentration expressed as delta PP was achieved with caerulein (327 +/- 37 pM), when taking into account the threefold smaller dose used, followed by CCK-OP (536 +/- 67 pM) and analogues B (343 +/- 51 pM), C (87 +/- 46 pM), and D (32 +/- 15 pM).	Ceruletide	85-94	pancreatic polypeptide	Canis lupus familiaris	28-30
7202946-2	1981	The greatest rise in plasma PP concentration expressed as delta PP was achieved with caerulein (327 +/- 37 pM), when taking into account the threefold smaller dose used, followed by CCK-OP (536 +/- 67 pM) and analogues B (343 +/- 51 pM), C (87 +/- 46 pM), and D (32 +/- 15 pM).	Ceruletide	85-94	pancreatic polypeptide	Canis lupus familiaris	64-66
520418-1	1979	Morphine, beta-endorphin, Met-enkephalin, and Leu-enkephalin antagonized intestinal actions of cholecystokinin octapeptide (CCK-8), caerulein, and pentagastrin in a manner partly suggesting physiologically competitive antagonism.	Ceruletide	132-141	proopiomelanocortin	Homo sapiens	10-24
520418-1	1979	Morphine, beta-endorphin, Met-enkephalin, and Leu-enkephalin antagonized intestinal actions of cholecystokinin octapeptide (CCK-8), caerulein, and pentagastrin in a manner partly suggesting physiologically competitive antagonism.	Ceruletide	132-141	proopiomelanocortin	Homo sapiens	26-40
520418-1	1979	Morphine, beta-endorphin, Met-enkephalin, and Leu-enkephalin antagonized intestinal actions of cholecystokinin octapeptide (CCK-8), caerulein, and pentagastrin in a manner partly suggesting physiologically competitive antagonism.	Ceruletide	132-141	prodynorphin	Homo sapiens	46-60
224710-5	1979	In order to decrease the specific binding of gastrin by 50% the competitors in order of potency are 15-Leu G-17 greater than cholecystokinin greater than caerulein greater than pentagastrin; secretin did not display a response similar to the other four competitors tested, indicating that its inhibition may be non-competitive.	Ceruletide	154-163	gastrin	Rattus norvegicus	45-52
488552-4	1979	Secretin (1 U/kg/h), glucagon (30 microgram/kg/h) and caerulein (0.1 microgram/kg/h) produced significant decreases in gastric acid secretion evoked by bombesin given in a dose of 0.9 microgram/kg/h.	Ceruletide	54-63	gastrin releasing peptide	Homo sapiens	152-160
488552-7	1979	Caerulein administered in a pharmacological dosis, however, can inhibit the effect of gastrin released by bombesin on the parietal cells by a competitive kinetic.	Ceruletide	0-9	gastrin	Homo sapiens	86-93
488552-7	1979	Caerulein administered in a pharmacological dosis, however, can inhibit the effect of gastrin released by bombesin on the parietal cells by a competitive kinetic.	Ceruletide	0-9	gastrin releasing peptide	Homo sapiens	106-114
344181-0	1978	Effect of caerulein upon insulin and glucagon secretion in dogs.	Ceruletide	10-19	insulin	Canis lupus familiaris	25-32
736132-7	1978	Secretin markedly augmented the hypertrophic action of caerulein but did not alter its hyperplastic action.	Ceruletide	55-64	secretin	Rattus norvegicus	0-8
344181-1	1978	In order to investigate the action of caerulein upon insulin and glucagon secretion, experimental studies were carried out using anesthetized dogs, in which graded doses of caerulein were infused into the pancreatic artery, and insulin and glucagon were measured in the blood obtained from the pancreatic vein.	Ceruletide	38-47	insulin	Canis lupus familiaris	53-60
348550-2	1978	The pattern of gastric acid and pepsin secretion after the administration of caerulein was closely resembled to that of gastrin.	Ceruletide	77-86	gastrin	Homo sapiens	120-127
344181-2	1978	When caerulein was administered at a rate of 15 ng/min, neigher changes of blood glucose in the femoral artery nor plasma levels of insulin or glucagon in the pancreatic vein were prominent.	Ceruletide	5-14	insulin	Canis lupus familiaris	132-139
344181-3	1978	Caerulein infusion at a rate of 120, 240 or 480 ng/min caused a prompt rise of plasma insulin and a delayed increase of plasma glucagon in the pancreatin vein.	Ceruletide	0-9	insulin	Canis lupus familiaris	86-93
344181-8	1978	It was concluded from the present experiments that caerulein infusion into the pancreatic artery resulted in increased secretion of insulin and glucagon from the pancreas.	Ceruletide	51-60	insulin	Canis lupus familiaris	132-139
19331-0	1977	Effect of caerulein on gamma-glutamyl transpeptidase and alkaline phosphatase in the duodenal juice in chronic pancreatitis.	Ceruletide	10-19	inactive glutathione hydrolase 2	Homo sapiens	23-52
884386-6	1977	The time course and the dose-response curve for desulphated caerulein was identical with that of gastrin.4 It was confirmed electrophysiologically that the activity of gastrin is exerted by the C-terminal tetrapeptide; but the activity of caerulein depends on the C-terminal heptapeptide, especially the presence in the molecule of the sulphated tyrosyl residue at position 7 (numbering from the C-terminus).	Ceruletide	60-69	gastrin	Mus musculus	168-175
856631-0	1977	[Comparative effects of pentagastrin and caerulein on the insulin secretion in the anesthesized dog].	Ceruletide	41-50	insulin	Canis lupus familiaris	58-65
5409271-0	1969	[Effect of caerulein in rapid venous administration of plasmatic levels of glucagon, insulin and glucose].	Ceruletide	11-20	insulin	Homo sapiens	85-92
4879882-10	1968	In the rat, the activity ratio of caerulein to human gastrin I is 7-30, calculated on a molar basis, and is thus considerably greater than in the dog.	Ceruletide	34-43	gastrin	Homo sapiens	53-60
4879882-13	1968	The activity of caerulein is sharply reduced by pretreatment of the rats with the histamine liberator 48/80 and potentiated by pretreatment with the diamine oxidase inhibitor aminoguanidine.	Ceruletide	16-25	amine oxidase, copper containing 1	Rattus norvegicus	149-164
126910-1	1975	Caerulein is a decapeptide which combines the effects of gastrin and cholecystokinin-pancreozymin.	Ceruletide	0-9	gastrin	Homo sapiens	57-64
5487026-0	1970	The effects of caerulein on insulin secretion in anaesthetized dogs.	Ceruletide	15-24	insulin	Canis lupus familiaris	28-35
5487026-3	1970	Rises in insulin concentration were elicited by rapid intravenous injection of caerulein, as well as by intravenous infusion.	Ceruletide	79-88	insulin	Canis lupus familiaris	9-16
33417179-13	2021	FENDRR knockdown dramatically attenuated caerulein- or TLC-S-induced AR42J cells apoptosis and autophagy suppression.	Ceruletide	41-50	FOXF1 adjacent non-coding developmental regulatory RNA	Rattus norvegicus	0-6
34049483-0	2021	Selective inhibition of soluble TNF using XPro1595 relieves pain and attenuates cerulein-induced pathology in mice.	Ceruletide	80-88	tumor necrosis factor	Mus musculus	32-35
33994067-6	2021	RESULTS: Cerulein-injected ferrets exhibited mild pancreatic edema, neutrophil infiltration, and elevations in serum amylase, lipase, TNF-alpha, IL-6, consistent with AP.	Ceruletide	9-17	tumor necrosis factor	Mustela putorius furo	134-143
34032634-3	2021	We observed significant decreases in pancreatic PTEN and SAV1 levels in 2 murine CP models: repeated caerulein injection and pancreatic ductal ligation.	Ceruletide	101-110	salvador family WW domain containing 1	Mus musculus	57-61
34032634-9	2021	CP in DKO mice was also ameliorated by Ctgf gene deletion, and caerulein-induced CP was alleviated by antibody-mediated CTGF neutralization.	Ceruletide	63-72	cellular communication network factor 2	Mus musculus	120-124
33994067-6	2021	RESULTS: Cerulein-injected ferrets exhibited mild pancreatic edema, neutrophil infiltration, and elevations in serum amylase, lipase, TNF-alpha, IL-6, consistent with AP.	Ceruletide	9-17	interleukin-6	Mustela putorius furo	145-149
33994067-8	2021	Plasma glucagon, GLP-1 and PP were significantly higher in cerulein-injected animals, while plasma insulin was significantly lower compared to controls.	Ceruletide	59-67	pro-glucagon	Mustela putorius furo	7-15
33521935-3	2021	AP was induced by caerulein treatment in mice with global TLR3 deficiency (TLR3OFF ) or in mice re-expressing TLR3 exclusively in the myeloid cell lineage (TLR3Mye ).	Ceruletide	18-27	toll-like receptor 3	Mus musculus	58-62
33051781-0	2021	Quercetin inhibits caerulein-induced acute pancreatitis through regulating miR-216b by targeting MAP2K6 and NEAT1.	Ceruletide	19-28	microRNA 216b	Mus musculus	75-83
33639565-4	2021	METHODS: We induced AP in mice by intraperitoneal injection of cerulein.	Ceruletide	63-71	LIM homeobox protein 2	Mus musculus	20-22
33051781-0	2021	Quercetin inhibits caerulein-induced acute pancreatitis through regulating miR-216b by targeting MAP2K6 and NEAT1.	Ceruletide	19-28	mitogen-activated protein kinase kinase 6	Mus musculus	97-103
33051781-0	2021	Quercetin inhibits caerulein-induced acute pancreatitis through regulating miR-216b by targeting MAP2K6 and NEAT1.	Ceruletide	19-28	nuclear paraspeckle assembly transcript 1 (non-protein coding)	Mus musculus	108-113
33051781-5	2021	In this case, caerulein (CAE) induced AP cell and mice model were used.	Ceruletide	14-23	LIM homeobox protein 2	Mus musculus	38-40
33051781-5	2021	In this case, caerulein (CAE) induced AP cell and mice model were used.	Ceruletide	25-28	LIM homeobox protein 2	Mus musculus	38-40
33603729-6	2020	Genetic ablation or specific antagonism of P2RX1 markedly alleviated inflammatory responses in caerulein-induced AP mice.	Ceruletide	95-104	purinergic receptor P2X, ligand-gated ion channel, 1	Mus musculus	43-48
33781829-10	2021	After activation of AMPK by metformin, expressions of p-AMPKalpha, SIRT1 were significantly raised, while expressions of Beclin-1, LC3 II/I, p62, TNF-alpha, IL-6 were reduced, and the number of autophagosome was decreased significantly in caerulein-stimulated AR42J cells.	Ceruletide	239-248	protein kinase AMP-activated catalytic subunit alpha 2	Rattus norvegicus	20-24
33603729-6	2020	Genetic ablation or specific antagonism of P2RX1 markedly alleviated inflammatory responses in caerulein-induced AP mice.	Ceruletide	95-104	LIM homeobox protein 2	Mus musculus	113-115
33308902-7	2021	In addition, TLR4 deficiency eliminated the protective effect of AS on AP induced by caerulein in mice.	Ceruletide	85-94	LIM homeobox protein 2	Mus musculus	71-73
33310297-4	2021	AP was induced in Swiss albino mice by six-hourly intraperitoneal exposures of cerulein (50 microg/kg/hr) and pre-treatment of NB (0.3 and 1 mg/kg) 7 days prior to the cerulein exposure.	Ceruletide	79-87	LIM homeobox protein 2	Mus musculus	0-2
32856219-0	2021	LncRNA MEG3 Participates in Caerulein-Induced Inflammatory Injury in Human Pancreatic Cells via Regulating miR-195-5p/FGFR2 Axis and Inactivating NF-kappaB Pathway.	Ceruletide	28-37	maternally expressed 3	Homo sapiens	7-11
32856219-10	2021	As a result, the expression of MEG3 and FGFR2 was decreased in caerulein-induced HPDE cells, while the expression of miR-195-5p was increased.	Ceruletide	63-72	maternally expressed 3	Homo sapiens	31-35
32856219-10	2021	As a result, the expression of MEG3 and FGFR2 was decreased in caerulein-induced HPDE cells, while the expression of miR-195-5p was increased.	Ceruletide	63-72	fibroblast growth factor receptor 2	Homo sapiens	40-45
32856219-11	2021	MEG3 overexpression inhibited cell apoptosis and inflammatory responses that were induced by caerulein.	Ceruletide	93-102	maternally expressed 3	Homo sapiens	0-4
32856219-16	2021	Collectively, MEG3 participates in caerulein-induced inflammatory injuries by targeting the miR-195-5p/FGFR2 regulatory axis via mediating the NF-kappaB pathway in HPDE cells.	Ceruletide	35-44	maternally expressed 3	Homo sapiens	14-18
32856219-16	2021	Collectively, MEG3 participates in caerulein-induced inflammatory injuries by targeting the miR-195-5p/FGFR2 regulatory axis via mediating the NF-kappaB pathway in HPDE cells.	Ceruletide	35-44	microRNA 195	Homo sapiens	92-99
32856219-16	2021	Collectively, MEG3 participates in caerulein-induced inflammatory injuries by targeting the miR-195-5p/FGFR2 regulatory axis via mediating the NF-kappaB pathway in HPDE cells.	Ceruletide	35-44	fibroblast growth factor receptor 2	Homo sapiens	103-108
32856219-16	2021	Collectively, MEG3 participates in caerulein-induced inflammatory injuries by targeting the miR-195-5p/FGFR2 regulatory axis via mediating the NF-kappaB pathway in HPDE cells.	Ceruletide	35-44	nuclear factor kappa B subunit 1	Homo sapiens	143-152
33414424-5	2021	Firstly, we validated the effect of ATF4 on pancreatic acinar cell proliferation, apoptosis, and inflammation through in vitro experiments on cellular models of caerulein-induced AP.	Ceruletide	161-170	activating transcription factor 4	Mus musculus	36-40
33414424-5	2021	Firstly, we validated the effect of ATF4 on pancreatic acinar cell proliferation, apoptosis, and inflammation through in vitro experiments on cellular models of caerulein-induced AP.	Ceruletide	161-170	LIM homeobox protein 2	Mus musculus	179-181
33414424-7	2021	Finally, the regulatory role of ATF4 in AP was further assessed by determination of pathological conditions, biochemical indicators and inflammation through in vivo experiments on caerulein-induced AP mouse models.	Ceruletide	180-189	LIM homeobox protein 2	Mus musculus	198-200
33565802-0	2021	MiR-204-5p Performs a Protective Effect on Cerulein-Induced Rat Pancreatic Acinar Cell AR42J Cell Damage by Targeting Tyrosine 3-Monooxygenase/Tryptophan 5-Monooxygenase Activation Protein Gamma and Regulating PI3K/Hippo Pathways.	Ceruletide	43-51	tyrosine hydroxylase	Rattus norvegicus	118-142
33565802-12	2021	CONCLUSIONS: These observations indicated that the alleviation impact of miR-204-5p on cerulein-induced AR42J cell damage was mediated via YWHAG and PI3K/Hippo signaling pathways.	Ceruletide	87-95	tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, gamma	Rattus norvegicus	139-144
33493150-13	2021	CN treatment resulted in increased TNF-alpha production but not secretion and did not influence IL-6 mRNA.	Ceruletide	0-2	tumor necrosis factor	Rattus norvegicus	35-44
32725692-0	2021	Serum amyloid A 3 is required for caerulein-induced acute pancreatitis through induction of RIP3-dependent necroptosis.	Ceruletide	34-43	serum amyloid A 3	Mus musculus	0-17
32725692-0	2021	Serum amyloid A 3 is required for caerulein-induced acute pancreatitis through induction of RIP3-dependent necroptosis.	Ceruletide	34-43	receptor-interacting serine-threonine kinase 3	Mus musculus	92-96
32725692-3	2021	In our study, we found that the expression of a specific SAA isoform, SAA3, was significantly elevated in a caerulein-induced AP animal model.	Ceruletide	108-117	serum amyloid A 3	Mus musculus	70-74
32725692-4	2021	In addition, SAA3-knockout (Saa3-/- ) mice showed lower serum levels of amylase and lipase, tissue damage, and pro-inflammatory cytokine production in the pancreas compared with that of wild-type mice in response to caerulein administration.	Ceruletide	216-225	serum amyloid A 3	Mus musculus	13-17
32725692-4	2021	In addition, SAA3-knockout (Saa3-/- ) mice showed lower serum levels of amylase and lipase, tissue damage, and pro-inflammatory cytokine production in the pancreas compared with that of wild-type mice in response to caerulein administration.	Ceruletide	216-225	serum amyloid A 3	Mus musculus	28-32
33310297-11	2021	Inhibition of pancreatic inflammation and apoptosis resulted in attenuation of cerulein-induced AP.	Ceruletide	79-87	LIM homeobox protein 2	Mus musculus	96-98
32717220-11	2020	KPouC and KHC mice had increased pancreatic injury, following administration of caerulein, significantly less normal tissue, more extracellular matrix deposition, and higher PanIN grade than KC mice.	Ceruletide	80-89	kinesin family member 5C	Mus musculus	10-13
33213278-9	2021	Consequently, pancreatic SNAP23-KD rats were protected from caerulein and alcoholic pancreatitis.	Ceruletide	60-69	synaptosome associated protein 23	Rattus norvegicus	25-31
33230218-8	2020	Following caerulein treatment, the pancreases of the LSL-KrasG12D/--Pdx-1-Cre transgenic mice exhibited more extensive pancreatic intraepithelial neoplasia (PanIN) formation.	Ceruletide	10-19	pancreatic and duodenal homeobox 1	Mus musculus	68-73
32860805-8	2020	Next, we verified DHK suppressed the level of Keap1 and promoted transcriptional activation of nuclear Nrf2 in the presence of CER + LPS.	Ceruletide	127-130	nuclear factor, erythroid derived 2, like 2	Mus musculus	103-107
33244198-9	2020	Compared with PSGL-1 +/+ mice, PSGL-1 -/- AP mice induced by caerulein exhibited lower serum amylase, less Interleukin-1beta (IL-1beta) and Interleukin-6 (IL-6) expression, less neutrophil and macrophage infiltration, and reduced peripheral neutrophil and monocyte accounts.	Ceruletide	61-70	selectin, platelet (p-selectin) ligand	Mus musculus	31-37
33244198-9	2020	Compared with PSGL-1 +/+ mice, PSGL-1 -/- AP mice induced by caerulein exhibited lower serum amylase, less Interleukin-1beta (IL-1beta) and Interleukin-6 (IL-6) expression, less neutrophil and macrophage infiltration, and reduced peripheral neutrophil and monocyte accounts.	Ceruletide	61-70	interleukin 1 beta	Mus musculus	107-124
33244198-9	2020	Compared with PSGL-1 +/+ mice, PSGL-1 -/- AP mice induced by caerulein exhibited lower serum amylase, less Interleukin-1beta (IL-1beta) and Interleukin-6 (IL-6) expression, less neutrophil and macrophage infiltration, and reduced peripheral neutrophil and monocyte accounts.	Ceruletide	61-70	interleukin 1 alpha	Mus musculus	126-134
33244198-9	2020	Compared with PSGL-1 +/+ mice, PSGL-1 -/- AP mice induced by caerulein exhibited lower serum amylase, less Interleukin-1beta (IL-1beta) and Interleukin-6 (IL-6) expression, less neutrophil and macrophage infiltration, and reduced peripheral neutrophil and monocyte accounts.	Ceruletide	61-70	interleukin 6	Mus musculus	140-153
33244198-9	2020	Compared with PSGL-1 +/+ mice, PSGL-1 -/- AP mice induced by caerulein exhibited lower serum amylase, less Interleukin-1beta (IL-1beta) and Interleukin-6 (IL-6) expression, less neutrophil and macrophage infiltration, and reduced peripheral neutrophil and monocyte accounts.	Ceruletide	61-70	interleukin 6	Mus musculus	155-159
32822908-0	2020	MiR-92b-3p ameliorates inflammation and autophagy by targeting TRAF3 and suppressing MKK3-p38 pathway in caerulein-induced AR42J cells.	Ceruletide	105-114	mitogen activated protein kinase kinase 3	Rattus norvegicus	85-89
32822908-0	2020	MiR-92b-3p ameliorates inflammation and autophagy by targeting TRAF3 and suppressing MKK3-p38 pathway in caerulein-induced AR42J cells.	Ceruletide	105-114	mitogen activated protein kinase 14	Rattus norvegicus	90-93
32822908-8	2020	The expression level of miR-92b-3p was decreased and TRAF3 expression was increased in AR42J cells stimulated with caerulein.	Ceruletide	115-124	Tnf receptor-associated factor 3	Rattus norvegicus	53-58
32822908-10	2020	In addition, overexpression of miR-92b-3p or knockdown of TRAF3 significantly suppressed the release of pro-inflammatory cytokines and autophagy in caerulein-induced AR42J cells.	Ceruletide	148-157	Tnf receptor-associated factor 3	Rattus norvegicus	58-63
32822908-13	2020	In conclusion, miR-92b-3p attenuated inflammatory response and autophagy by downregulating TRAF3 and suppressing MKK3-p38 pathway in caerulein-induced AR42J cells, providing a novel avenue for treatment of AP.	Ceruletide	133-142	microRNA 9-2	Rattus norvegicus	15-24
32822908-13	2020	In conclusion, miR-92b-3p attenuated inflammatory response and autophagy by downregulating TRAF3 and suppressing MKK3-p38 pathway in caerulein-induced AR42J cells, providing a novel avenue for treatment of AP.	Ceruletide	133-142	mitogen activated protein kinase kinase 3	Rattus norvegicus	113-117
32822908-13	2020	In conclusion, miR-92b-3p attenuated inflammatory response and autophagy by downregulating TRAF3 and suppressing MKK3-p38 pathway in caerulein-induced AR42J cells, providing a novel avenue for treatment of AP.	Ceruletide	133-142	mitogen activated protein kinase 14	Rattus norvegicus	118-121
33817278-0	2020	miR-339-3p regulated acute pancreatitis induced by caerulein through targeting TNF receptor-associated factor 3 in AR42J cells.	Ceruletide	51-60	Tnf receptor-associated factor 3	Rattus norvegicus	79-111
33817278-9	2020	Meanwhile, caerulein also reduced the expression of miR-339-3p and induced the expression of TRAF3 in rat pancreatic acinar cells.	Ceruletide	11-20	Tnf receptor-associated factor 3	Rattus norvegicus	93-98
33817278-13	2020	In addition, the suppression effects of miR-339-3p on cell inflammation and apoptosis in caerulein-induced AP were reversed by enhancing TRAF3 expression.	Ceruletide	89-98	Tnf receptor-associated factor 3	Rattus norvegicus	137-142
33817278-16	2020	Overexpression of miR-339-3p inhibited cell inflammation and cell apoptosis in caerulein-induced AP through modulating TRAF3 expression via the p38 pathway, providing a new therapeutic target in the treatment of AP.	Ceruletide	79-88	Tnf receptor-associated factor 3	Rattus norvegicus	119-124
33817278-16	2020	Overexpression of miR-339-3p inhibited cell inflammation and cell apoptosis in caerulein-induced AP through modulating TRAF3 expression via the p38 pathway, providing a new therapeutic target in the treatment of AP.	Ceruletide	79-88	mitogen activated protein kinase 14	Rattus norvegicus	144-147
33244070-7	2020	Rgs16::GFP is expressed in response to caerulein-induced acinar cell dedifferentiation, early neoplasia, and throughout PDA progression.	Ceruletide	39-48	regulator of G protein signaling 16	Homo sapiens	0-5
33154390-5	2020	Hic-5-knockout and wild type mice were subjected to caerulein injection to induce CP.	Ceruletide	52-61	transforming growth factor beta 1 induced transcript 1	Mus musculus	0-5
33154390-6	2020	Hic-5 expression was strongly upregulated in activated PSCs from human CP tissue and from mouse pancreatic fibrosis in caerulein-induced CP.	Ceruletide	119-128	transforming growth factor beta 1 induced transcript 1	Homo sapiens	0-5
32717220-13	2020	CONCLUSIONS: In mice with KRAS-induced pancreatic tumorigenesis, loss of tuft cells accelerates tumorigenesis and increases the severity of caerulein-induced pancreatic injury, via decreased production of PGD2.	Ceruletide	140-149	Kirsten rat sarcoma viral oncogene homolog	Mus musculus	26-30
33095758-4	2020	The AP model was prepared by intraperitoneal injection of cerulein and lipopolysaccharide (LPS).	Ceruletide	58-66	LIM homeobox protein 2	Mus musculus	4-6
32445858-8	2020	RESULTS: Mice with hematopoietic-specific deletion of CNB1 developed the same level of local pancreatic inflammation as control mice after administration of caerulein or infusion of radiocontrast into biliopancreatic ducts.	Ceruletide	157-166	protein phosphatase 3, regulatory subunit B, alpha isoform (calcineurin B, type I)	Mus musculus	54-58
32445858-9	2020	Cnb1UBC /  mice or mice with pancreas-specific deletion of CNB1 developed less severe pancreatitis and reduced pancreatic inflammation after administration of caerulein or infusion of radiocontrast into biliopancreatic ducts compared with control mice.	Ceruletide	159-168	protein phosphatase 3, regulatory subunit B, alpha isoform (calcineurin B, type I)	Mus musculus	59-63
32563781-3	2020	In pancreatitis model induced by caerulein, intra-gastrical administration of 100 mg/kg alpha/beta-ABA relieved inflammatory cells infiltration significantly and attenuated the serum elevation of amylase TNF-alpha and IL-6 remarkably in mice.	Ceruletide	33-42	amyloid beta (A4) precursor protein	Mus musculus	88-98
32506441-5	2020	Wild type (WT) and Stat2-/- mice were injected intraperitoneally with caerulein or L-arginine.	Ceruletide	70-79	signal transducer and activator of transcription 2	Mus musculus	19-24
32506441-10	2020	Stat2-/- mice were protected from caerulein- and L-arginine-induced pancreatitis.	Ceruletide	34-43	signal transducer and activator of transcription 2	Mus musculus	0-5
32506441-13	2020	Inhibition of TNFalpha improved (inhibition of IL-10 worsened) caerulein-induced pancreatitis in WT but not Stat2-/- mice.	Ceruletide	63-72	tumor necrosis factor	Mus musculus	14-22
32506441-13	2020	Inhibition of TNFalpha improved (inhibition of IL-10 worsened) caerulein-induced pancreatitis in WT but not Stat2-/- mice.	Ceruletide	63-72	interleukin 10	Mus musculus	47-52
32724472-5	2020	Humanized PRSS1 transgenic mice were treated with caerulein to mimic the SAP development, which was crossed to an ATF6 knockout mouse line, and pancreatic tissues from the resulting pups were screened by proteomics.	Ceruletide	50-59	protease, serine 1 (trypsin 1)	Mus musculus	10-15
32577948-9	2020	Here, our study showed that the expression of IRF9 and Ac-p53 was increased, SIRT1 was decreased, and cell apoptosis, proliferation, and migration of AR42J cells were increased after caerulein induced.	Ceruletide	183-192	interferon regulatory factor 9	Rattus norvegicus	46-50
32577948-9	2020	Here, our study showed that the expression of IRF9 and Ac-p53 was increased, SIRT1 was decreased, and cell apoptosis, proliferation, and migration of AR42J cells were increased after caerulein induced.	Ceruletide	183-192	Wistar clone pR53P1 p53 pseudogene	Rattus norvegicus	58-61
32577948-9	2020	Here, our study showed that the expression of IRF9 and Ac-p53 was increased, SIRT1 was decreased, and cell apoptosis, proliferation, and migration of AR42J cells were increased after caerulein induced.	Ceruletide	183-192	sirtuin 1	Rattus norvegicus	77-82
32923091-5	2020	We firstly found the expression of TAB3 was significantly increased in caerulein-induced AP rat and cell model compared with control group, especially at 8 h. Furthermore, the increasing expression of TAB3 in AP group was also accompanied by increased levels of pro-inflammatory mediators (TNF-alpha, IL-6 and LDH).	Ceruletide	71-80	tumor necrosis factor	Rattus norvegicus	290-299
32923091-5	2020	We firstly found the expression of TAB3 was significantly increased in caerulein-induced AP rat and cell model compared with control group, especially at 8 h. Furthermore, the increasing expression of TAB3 in AP group was also accompanied by increased levels of pro-inflammatory mediators (TNF-alpha, IL-6 and LDH).	Ceruletide	71-80	interleukin 6	Rattus norvegicus	301-305
32194177-6	2020	Cerulein-induced CP was significantly controlled by NB treatment, as shown by the downregulation of beta-catenin/Smad signaling in a SIRT1 dependent manner.	Ceruletide	0-8	catenin (cadherin associated protein), beta 1	Mus musculus	100-112
32415356-8	2020	Legumain was found to be upregulated in the serum and pancreatic tissues of mice with caerulein-induced CP.	Ceruletide	86-95	legumain	Mus musculus	0-8
32194177-6	2020	Cerulein-induced CP was significantly controlled by NB treatment, as shown by the downregulation of beta-catenin/Smad signaling in a SIRT1 dependent manner.	Ceruletide	0-8	sirtuin 1	Mus musculus	133-138
32322336-4	2020	Methods: Mouse models of AP were established by caerulein, sodium taurocholate, and L-arginine, separately.	Ceruletide	48-57	LIM homeobox protein 2	Mus musculus	25-27
31363815-6	2020	Supramaximal caerulein stimulation of primary pancreatic acini derived from LC3-GFP mice revealed that trypsinogen activation is independent of autophagolysosome formation already during the first 15 min of exposure to caerulein.	Ceruletide	13-22	microtubule-associated protein 1 light chain 3 alpha	Mus musculus	76-79
32411205-8	2020	Results: Pancreatic MMP-9 was markedly upregulated and serum MMP-9 was increased in caerulein-induced pancreatitis.	Ceruletide	84-93	matrix metallopeptidase 9	Mus musculus	20-25
32411205-8	2020	Results: Pancreatic MMP-9 was markedly upregulated and serum MMP-9 was increased in caerulein-induced pancreatitis.	Ceruletide	84-93	matrix metallopeptidase 9	Mus musculus	61-66
32411205-11	2020	Conclusions: Our results showed that inhibition of MMP with BB-94 protected against pancreatic inflammatory responses in caerulein-induced pancreatitis via modulating neutrophil and macrophage activation.	Ceruletide	121-130	matrix metallopeptidase 9	Mus musculus	51-54
32070876-0	2020	Serotonin-RhoA/ROCK axis promotes acinar-to-ductal metaplasia in caerulein-induced chronic pancreatitis.	Ceruletide	65-74	ras homolog family member A	Mus musculus	10-19
33361031-4	2020	table Significantly increased, Bcl-2, FGF21 and Klotho protein expression was significantly increased, Bax protein was significantly decreased; the FGF21 inhibitor can be significantly reduced on galactose these caerulein-induced AR42J cells.	Ceruletide	212-221	BCL2, apoptosis regulator	Rattus norvegicus	31-36
33361031-4	2020	table Significantly increased, Bcl-2, FGF21 and Klotho protein expression was significantly increased, Bax protein was significantly decreased; the FGF21 inhibitor can be significantly reduced on galactose these caerulein-induced AR42J cells.	Ceruletide	212-221	Klotho	Rattus norvegicus	48-54
33361031-4	2020	table Significantly increased, Bcl-2, FGF21 and Klotho protein expression was significantly increased, Bax protein was significantly decreased; the FGF21 inhibitor can be significantly reduced on galactose these caerulein-induced AR42J cells.	Ceruletide	212-221	BCL2 associated X, apoptosis regulator	Rattus norvegicus	103-106
33361031-4	2020	table Significantly increased, Bcl-2, FGF21 and Klotho protein expression was significantly increased, Bax protein was significantly decreased; the FGF21 inhibitor can be significantly reduced on galactose these caerulein-induced AR42J cells.	Ceruletide	212-221	fibroblast growth factor 21	Rattus norvegicus	148-153
32156729-4	2020	Men1 loss causes increased injury and impaired regeneration following acute caerulein-induced pancreatitis, leading to more severe damage, loss of the normal acinar compartment, and increased cytokeratin 19-positive metaplasias and immune cell infiltration.	Ceruletide	76-85	multiple endocrine neoplasia 1	Mus musculus	0-4
32318575-6	2020	We found that the expression of circHIPK3 was significantly elevated in serum of patients with AP and in caerulein-stimulated AR42J cells and was associated with caspase-1 and caspase-11 activation.	Ceruletide	105-114	caspase 1	Rattus norvegicus	162-171
32318575-6	2020	We found that the expression of circHIPK3 was significantly elevated in serum of patients with AP and in caerulein-stimulated AR42J cells and was associated with caspase-1 and caspase-11 activation.	Ceruletide	105-114	caspase 4	Rattus norvegicus	176-186
32318575-7	2020	circHIPK3 silencing ameliorated caerulein-induced cell damage and reduced the release of inflammatory factors IL-1beta, IL-6, IL-8, and TNF-alpha and inhibited the activation of caspase-1 and caspase-11.	Ceruletide	32-41	caspase 1	Rattus norvegicus	178-187
32318575-12	2020	Silencing GSDMD reversed the effects of miR-193a-5p inhibitors on caerulein-induced damage.	Ceruletide	66-75	gasdermin D	Homo sapiens	10-15
31654716-15	2020	In caerulein-treated AR42J cells, co-culturing of BMSCs-miR-181a-5p alleviated caerulein-induced increase of amylase and lipase, and apoptosis via PTEN/Akt/TGF-beta1 signaling.	Ceruletide	3-12	lipase G, endothelial type	Rattus norvegicus	121-127
32293245-8	2020	This study aimed to investigate whether DHA induces Parkin and inhibits vATPase activity, resulting in zymogen inactivation in pancreatic acinar AR42J cells stimulated with cerulein, a CCK analog.	Ceruletide	173-181	cholecystokinin	Rattus norvegicus	185-188
31751559-9	2020	Injection of cerulein for 2 days induced progressive pancreatitis in T7K24R mice, but not in control mice, with typical features of chronic pancreatitis CONCLUSIONS: Introduction of a mutation into mice that is analogous to the p.K23R mutation in PRSS1 increases pancreatic activation of trypsinogen during secretagogue-induced pancreatitis.	Ceruletide	13-21	protease, serine 1 (trypsin 1)	Mus musculus	247-252
31419436-13	2020	Increased expression of PRSS1 or PRSS1R122H increased focal damage in pancreatic tissues and increased the severity of acute pancreatitis after caerulein injection.	Ceruletide	144-153	protease, serine 1 (trypsin 1)	Mus musculus	24-29
31991372-5	2020	In addition, DADS reduced caerulein-induced I-kappaB degradation and subsequent translocation of NF-kappaB in the pancreas and lung.	Ceruletide	26-35	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	97-106
31784085-8	2020	In conclusion, ALDH2 activation by Alda-1 has a protective effect in cerulein-induced AP by mitigating apoptosis in pancreatic acinar cells by alleviating lipid peroxidation.	Ceruletide	69-77	aldehyde dehydrogenase 2, mitochondrial	Mus musculus	15-20
31784085-8	2020	In conclusion, ALDH2 activation by Alda-1 has a protective effect in cerulein-induced AP by mitigating apoptosis in pancreatic acinar cells by alleviating lipid peroxidation.	Ceruletide	69-77	LIM homeobox protein 2	Mus musculus	86-88
31654716-15	2020	In caerulein-treated AR42J cells, co-culturing of BMSCs-miR-181a-5p alleviated caerulein-induced increase of amylase and lipase, and apoptosis via PTEN/Akt/TGF-beta1 signaling.	Ceruletide	3-12	phosphatase and tensin homolog	Rattus norvegicus	147-151
31654716-15	2020	In caerulein-treated AR42J cells, co-culturing of BMSCs-miR-181a-5p alleviated caerulein-induced increase of amylase and lipase, and apoptosis via PTEN/Akt/TGF-beta1 signaling.	Ceruletide	3-12	AKT serine/threonine kinase 1	Rattus norvegicus	152-155
31654716-15	2020	In caerulein-treated AR42J cells, co-culturing of BMSCs-miR-181a-5p alleviated caerulein-induced increase of amylase and lipase, and apoptosis via PTEN/Akt/TGF-beta1 signaling.	Ceruletide	3-12	transforming growth factor, beta 1	Rattus norvegicus	156-165
31654716-15	2020	In caerulein-treated AR42J cells, co-culturing of BMSCs-miR-181a-5p alleviated caerulein-induced increase of amylase and lipase, and apoptosis via PTEN/Akt/TGF-beta1 signaling.	Ceruletide	79-88	lipase G, endothelial type	Rattus norvegicus	121-127
31654716-15	2020	In caerulein-treated AR42J cells, co-culturing of BMSCs-miR-181a-5p alleviated caerulein-induced increase of amylase and lipase, and apoptosis via PTEN/Akt/TGF-beta1 signaling.	Ceruletide	79-88	phosphatase and tensin homolog	Rattus norvegicus	147-151
31654716-15	2020	In caerulein-treated AR42J cells, co-culturing of BMSCs-miR-181a-5p alleviated caerulein-induced increase of amylase and lipase, and apoptosis via PTEN/Akt/TGF-beta1 signaling.	Ceruletide	79-88	AKT serine/threonine kinase 1	Rattus norvegicus	152-155
31654716-15	2020	In caerulein-treated AR42J cells, co-culturing of BMSCs-miR-181a-5p alleviated caerulein-induced increase of amylase and lipase, and apoptosis via PTEN/Akt/TGF-beta1 signaling.	Ceruletide	79-88	transforming growth factor, beta 1	Rattus norvegicus	156-165
32011533-1	2020	OBJECTIVE: The aim of this study was to investigate the effects of eupatilin on protein kinase D1 (PKD1) and nuclear factor kappa B (NF-kappaB) signaling pathways in cerulein-induced in vitro pancreatitis.	Ceruletide	166-174	protein kinase D1	Mus musculus	80-97
32011533-9	2020	Eupatilin inhibited cerulein-induced activation of PKD1/NF-kappaB and the nuclear translocation of NF-kappaB.	Ceruletide	20-28	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	56-65
32011533-9	2020	Eupatilin inhibited cerulein-induced activation of PKD1/NF-kappaB and the nuclear translocation of NF-kappaB.	Ceruletide	20-28	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	99-108
32011533-1	2020	OBJECTIVE: The aim of this study was to investigate the effects of eupatilin on protein kinase D1 (PKD1) and nuclear factor kappa B (NF-kappaB) signaling pathways in cerulein-induced in vitro pancreatitis.	Ceruletide	166-174	protein kinase D1	Mus musculus	99-103
32011533-1	2020	OBJECTIVE: The aim of this study was to investigate the effects of eupatilin on protein kinase D1 (PKD1) and nuclear factor kappa B (NF-kappaB) signaling pathways in cerulein-induced in vitro pancreatitis.	Ceruletide	166-174	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	109-131
32011533-1	2020	OBJECTIVE: The aim of this study was to investigate the effects of eupatilin on protein kinase D1 (PKD1) and nuclear factor kappa B (NF-kappaB) signaling pathways in cerulein-induced in vitro pancreatitis.	Ceruletide	166-174	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	133-142
32011533-6	2020	Eupatilin treatment downregulated cerulein-induced expression of interleukin (IL)-1beta, IL-6, and CC chemokine ligands 2 and 5, but it upregulated expression of IL-4 and IL-10.	Ceruletide	34-42	interleukin 1 alpha	Mus musculus	65-87
32011533-6	2020	Eupatilin treatment downregulated cerulein-induced expression of interleukin (IL)-1beta, IL-6, and CC chemokine ligands 2 and 5, but it upregulated expression of IL-4 and IL-10.	Ceruletide	34-42	interleukin 6	Mus musculus	89-93
32011533-6	2020	Eupatilin treatment downregulated cerulein-induced expression of interleukin (IL)-1beta, IL-6, and CC chemokine ligands 2 and 5, but it upregulated expression of IL-4 and IL-10.	Ceruletide	34-42	interleukin 4	Mus musculus	162-166
32011533-6	2020	Eupatilin treatment downregulated cerulein-induced expression of interleukin (IL)-1beta, IL-6, and CC chemokine ligands 2 and 5, but it upregulated expression of IL-4 and IL-10.	Ceruletide	34-42	interleukin 10	Mus musculus	171-176
32011533-9	2020	Eupatilin inhibited cerulein-induced activation of PKD1/NF-kappaB and the nuclear translocation of NF-kappaB.	Ceruletide	20-28	protein kinase D1	Mus musculus	51-55
32274733-5	2020	Our results provide keen evidence that Hpa expression and activity are significantly increased following cerulein-induced AP in wild type mice.	Ceruletide	105-113	heparanase	Mus musculus	39-42
32071789-3	2020	Here, we found that increased TMEM16A expression in the pancreatic tissue was correlated with the interleukin-6 (IL-6) level in the pancreatic tissue and in the serum of a cerulein-induced AP mouse model.	Ceruletide	172-180	anoctamin 1, calcium activated chloride channel	Mus musculus	30-37
32071789-3	2020	Here, we found that increased TMEM16A expression in the pancreatic tissue was correlated with the interleukin-6 (IL-6) level in the pancreatic tissue and in the serum of a cerulein-induced AP mouse model.	Ceruletide	172-180	interleukin 6	Mus musculus	113-117
32071789-6	2020	TMEM16A inhibition reduced the IP3R-mediated Ca2+ release induced by cerulein.	Ceruletide	69-77	anoctamin 1	Rattus norvegicus	0-7
32071789-6	2020	TMEM16A inhibition reduced the IP3R-mediated Ca2+ release induced by cerulein.	Ceruletide	69-77	inositol 1,4,5-trisphosphate receptor, type 1	Rattus norvegicus	31-35
32071789-8	2020	TMEM16A knockdown by shRNAs reduced the cerulein-induced NFkappaB activation by Ca2+.	Ceruletide	40-48	anoctamin 1	Rattus norvegicus	0-7
32071789-8	2020	TMEM16A knockdown by shRNAs reduced the cerulein-induced NFkappaB activation by Ca2+.	Ceruletide	40-48	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	57-65
32071789-9	2020	TMEM16A inhibitors inhibited NFkappaB activation by decreasing channel activity and reducing TMEM16A protein levels in AR42J cells, and it ameliorated pancreatic damage in cerulein-induced AP mice.	Ceruletide	172-180	anoctamin 1	Rattus norvegicus	0-7
32274733-5	2020	Our results provide keen evidence that Hpa expression and activity are significantly increased following cerulein-induced AP in wild type mice.	Ceruletide	105-113	LIM homeobox protein 2	Mus musculus	122-124
31923844-4	2020	In the murine pancreas harboring K-rasG12D mutation (KC mice), following acute inflammation induced by cerulein, increased ETAR and ETBR expression is observed in the amylase and CK19 double positive cells that represent cells undergoing pancreatic acinar to ductal metaplasia (ADM).	Ceruletide	103-111	keratin 19	Mus musculus	179-183
31923844-5	2020	As compared to the wild type (WT) mice, cerulein treatment in KC mice resulted in significantly higher levels of ECE-1, ET-1, ETAR and ETBR, transcripts in the pancreas.	Ceruletide	40-48	endothelin converting enzyme 1	Mus musculus	113-118
31923844-5	2020	As compared to the wild type (WT) mice, cerulein treatment in KC mice resulted in significantly higher levels of ECE-1, ET-1, ETAR and ETBR, transcripts in the pancreas.	Ceruletide	40-48	endothelin 1	Mus musculus	120-124
31923844-5	2020	As compared to the wild type (WT) mice, cerulein treatment in KC mice resulted in significantly higher levels of ECE-1, ET-1, ETAR and ETBR, transcripts in the pancreas.	Ceruletide	40-48	endothelin receptor type A	Mus musculus	126-130
31923844-5	2020	As compared to the wild type (WT) mice, cerulein treatment in KC mice resulted in significantly higher levels of ECE-1, ET-1, ETAR and ETBR, transcripts in the pancreas.	Ceruletide	40-48	endothelin receptor type B	Mus musculus	135-139
31923844-7	2020	In addition to the expression in the precursor pancreatic intraepithelial neoplasm (PanIN lesions) in cigarette smoke-exposure model and metaplastic ducts in cerulein-treatment model, ETAR and ETBR expression is also observed in infiltrating F4/80 positive macrophages and alpha-SMA positive fibroblasts and high co-localization was seen in the presence of oncogenic K-ras.	Ceruletide	158-166	endothelin receptor type A	Mus musculus	184-188
31923844-7	2020	In addition to the expression in the precursor pancreatic intraepithelial neoplasm (PanIN lesions) in cigarette smoke-exposure model and metaplastic ducts in cerulein-treatment model, ETAR and ETBR expression is also observed in infiltrating F4/80 positive macrophages and alpha-SMA positive fibroblasts and high co-localization was seen in the presence of oncogenic K-ras.	Ceruletide	158-166	endothelin receptor type B	Mus musculus	193-197
31177837-9	2019	Moreover, it was determined that miR-203 showed a downside expression by B3GALT5-AS1 regulation, and the overexpression of B3GALT5-AS1 retrained caerulein-produced injury through the suppression of miR-203.	Ceruletide	145-154	Beta-1,3-galactosyltransferase 5	Rattus norvegicus	123-130
31849712-4	2019	We found that YAP is expressed at low levels in normal mouse pancreas, but protein levels significantly increased after pancreas inflammatory damage induced by repeated cerulein administration in wild-type mice or upon initiation of neoplastic transformation of the pancreas parenchyma in Ptf1-Cre;LSL-KrasG12D/+ (KC) mice.	Ceruletide	169-177	yes-associated protein 1	Mus musculus	14-17
31177837-8	2019	Overexpression of B3GALT5-AS1 alleviated the caerulein-produced injury in the AR42J cells.	Ceruletide	45-54	Beta-1,3-galactosyltransferase 5	Rattus norvegicus	18-29
32901688-10	2020	Pre-incubation of human bronchial epithelial cells with an NF-kappaB signaling specific activator, ceruletide, significantly blunted lapiferin-mediated inhibition of pro-inflammatory cytokines secretion in an air-liquid-interface cell culture experiment.	Ceruletide	99-109	nuclear factor kappa B subunit 1	Homo sapiens	59-68
31797546-0	2020	Hic-5 deficiency protects cerulein-induced chronic pancreatitis via down-regulation of the NF-kappaB (p65)/IL-6 signalling pathway.	Ceruletide	26-34	transforming growth factor beta 1 induced transcript 1	Mus musculus	0-5
31797546-0	2020	Hic-5 deficiency protects cerulein-induced chronic pancreatitis via down-regulation of the NF-kappaB (p65)/IL-6 signalling pathway.	Ceruletide	26-34	v-rel reticuloendotheliosis viral oncogene homolog A (avian)	Mus musculus	102-105
31797546-0	2020	Hic-5 deficiency protects cerulein-induced chronic pancreatitis via down-regulation of the NF-kappaB (p65)/IL-6 signalling pathway.	Ceruletide	26-34	interleukin 6	Mus musculus	107-111
31797546-6	2020	CP induced by cerulein injection was ameliorated in Hic-5 knockout (KO) mice, as shown by staining of tissue level.	Ceruletide	14-22	transforming growth factor beta 1 induced transcript 1	Mus musculus	52-57
31797546-8	2020	We also found that the Hic-5 up-regulation by cerulein activated the NF-kappaB (p65)/IL-6 signalling pathway and regulated the downstream extracellular matrix (ECM) genes such as alpha-SMA and Col1a1.	Ceruletide	46-54	transforming growth factor beta 1 induced transcript 1	Mus musculus	23-28
31797546-8	2020	We also found that the Hic-5 up-regulation by cerulein activated the NF-kappaB (p65)/IL-6 signalling pathway and regulated the downstream extracellular matrix (ECM) genes such as alpha-SMA and Col1a1.	Ceruletide	46-54	v-rel reticuloendotheliosis viral oncogene homolog A (avian)	Mus musculus	80-83
31797546-8	2020	We also found that the Hic-5 up-regulation by cerulein activated the NF-kappaB (p65)/IL-6 signalling pathway and regulated the downstream extracellular matrix (ECM) genes such as alpha-SMA and Col1a1.	Ceruletide	46-54	interleukin 6	Mus musculus	85-89
31797546-8	2020	We also found that the Hic-5 up-regulation by cerulein activated the NF-kappaB (p65)/IL-6 signalling pathway and regulated the downstream extracellular matrix (ECM) genes such as alpha-SMA and Col1a1.	Ceruletide	46-54	collagen, type I, alpha 1	Mus musculus	193-199
31797546-9	2020	Therefore, we determined whether suppressing NF-kappaB/p65 alleviated CP by treating mice with the NF-kappaB/p65 inhibitor triptolide in the cerulein-induced CP model and found that pancreatic fibrosis was alleviated by NF-kappaB/p65 inhibition.	Ceruletide	141-149	v-rel reticuloendotheliosis viral oncogene homolog A (avian)	Mus musculus	55-58
31177837-9	2019	Moreover, it was determined that miR-203 showed a downside expression by B3GALT5-AS1 regulation, and the overexpression of B3GALT5-AS1 retrained caerulein-produced injury through the suppression of miR-203.	Ceruletide	145-154	microRNA 203	Rattus norvegicus	33-40
31177837-9	2019	Moreover, it was determined that miR-203 showed a downside expression by B3GALT5-AS1 regulation, and the overexpression of B3GALT5-AS1 retrained caerulein-produced injury through the suppression of miR-203.	Ceruletide	145-154	prostaglandin D2 receptor	Homo sapiens	131-134
31177837-9	2019	Moreover, it was determined that miR-203 showed a downside expression by B3GALT5-AS1 regulation, and the overexpression of B3GALT5-AS1 retrained caerulein-produced injury through the suppression of miR-203.	Ceruletide	145-154	microRNA 203	Rattus norvegicus	198-205
31177837-11	2019	Lastly, the impacts of B3GALT5-AS1 on caerulein-induced cell injury were manifested through the NF-kappaB signalling pathway.	Ceruletide	38-47	Beta-1,3-galactosyltransferase 5	Rattus norvegicus	23-30
31177837-11	2019	Lastly, the impacts of B3GALT5-AS1 on caerulein-induced cell injury were manifested through the NF-kappaB signalling pathway.	Ceruletide	38-47	prostaglandin D2 receptor	Homo sapiens	31-34
31177837-13	2019	Overexpression of B3GALT5-AS1 may alleviate caerulein-induced cell injury in AR42J cells through the regulation of miR-203/NFIL3 axis and by inhibiting the activation of the NF-kappaB signals.	Ceruletide	44-53	Beta-1,3-galactosyltransferase 5	Rattus norvegicus	18-29
31177837-13	2019	Overexpression of B3GALT5-AS1 may alleviate caerulein-induced cell injury in AR42J cells through the regulation of miR-203/NFIL3 axis and by inhibiting the activation of the NF-kappaB signals.	Ceruletide	44-53	microRNA 203	Rattus norvegicus	115-122
31177837-13	2019	Overexpression of B3GALT5-AS1 may alleviate caerulein-induced cell injury in AR42J cells through the regulation of miR-203/NFIL3 axis and by inhibiting the activation of the NF-kappaB signals.	Ceruletide	44-53	nuclear factor, interleukin 3 regulated	Rattus norvegicus	123-128
31493399-12	2019	By contrast, pancreatic levels of Saraf messenger RNA and SARAF protein initially markedly increased but then decreased during cell stimulation or injection of mice with caerulein, resulting in excessive Ca2+ influx.	Ceruletide	170-179	store-operated calcium entry-associated regulatory factor	Mus musculus	34-39
31950023-5	2019	It has been shown to inhibit NF-kappaB activity in cerulein-stimulated pancreatic acinar cells which is a cellular model of CP.	Ceruletide	51-59	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	29-38
31950023-11	2019	Additionally, DHA inhibited cerulein-induced fibrotic mediators like alpha-smooth muscle actin and fibronectin in pancreas.	Ceruletide	28-36	fibronectin 1	Mus musculus	99-110
31950023-12	2019	DHA reduced expression of PKC-delta and NF-kappaB p65 in pancreatic tissues of cerulein-treated mice.	Ceruletide	79-87	protein kinase C, delta	Mus musculus	26-35
31493399-15	2019	SARAF knockout mice developed more severe pancreatitis than control mice after administration of caerulein or L-arginine, and pancreatic acinar cells from these mice had significant increases in Ca2+ influx.	Ceruletide	97-106	store-operated calcium entry-associated regulatory factor	Mus musculus	0-5
31950023-12	2019	DHA reduced expression of PKC-delta and NF-kappaB p65 in pancreatic tissues of cerulein-treated mice.	Ceruletide	79-87	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	40-49
32084646-9	2019	To determine whether the cerulein-induced NF-kappaB activation involves PAP-1 expression, cells were transfected to overexpress the MAD3 double-point IkappaBalpha mutant.	Ceruletide	25-33	regenerating family member 3 beta	Rattus norvegicus	72-77
31950023-12	2019	DHA reduced expression of PKC-delta and NF-kappaB p65 in pancreatic tissues of cerulein-treated mice.	Ceruletide	79-87	v-rel reticuloendotheliosis viral oncogene homolog A (avian)	Mus musculus	50-53
32084646-9	2019	To determine whether the cerulein-induced NF-kappaB activation involves PAP-1 expression, cells were transfected to overexpress the MAD3 double-point IkappaBalpha mutant.	Ceruletide	25-33	Max dimerization protein 3	Rattus norvegicus	132-136
32084646-9	2019	To determine whether the cerulein-induced NF-kappaB activation involves PAP-1 expression, cells were transfected to overexpress the MAD3 double-point IkappaBalpha mutant.	Ceruletide	25-33	NFKB inhibitor alpha	Rattus norvegicus	150-162
32084646-11	2019	Lastly, we observed that the cerulein-induced reduction in cell viability and increase in apoptosis are reversed by overexpression of PAP-1 in PAP-1-transfected cells.	Ceruletide	29-37	regenerating family member 3 beta	Rattus norvegicus	134-139
32084646-11	2019	Lastly, we observed that the cerulein-induced reduction in cell viability and increase in apoptosis are reversed by overexpression of PAP-1 in PAP-1-transfected cells.	Ceruletide	29-37	regenerating family member 3 beta	Rattus norvegicus	143-148
31493386-5	2019	We found that SPOP was downregulated in the pancreatic tissues of cerulein-induced CP mice.	Ceruletide	66-74	speckle-type BTB/POZ protein	Mus musculus	14-18
31729558-0	2019	miR-135a deficiency inhibits the AR42J cells damage in cerulein-induced acute pancreatitis through targeting FAM129A.	Ceruletide	55-63	microRNA 135a	Rattus norvegicus	0-8
31729558-0	2019	miR-135a deficiency inhibits the AR42J cells damage in cerulein-induced acute pancreatitis through targeting FAM129A.	Ceruletide	55-63	niban apoptosis regulator 1	Rattus norvegicus	109-116
31729558-10	2019	In addition, mRNA and protein expression of FAM129A were negatively regulated by miR-135a, and over-expression of FAM129A could strengthen the relief effect of miR-135a inhibitor in AP induced by cerulein.	Ceruletide	196-204	niban apoptosis regulator 1	Rattus norvegicus	44-51
31729558-10	2019	In addition, mRNA and protein expression of FAM129A were negatively regulated by miR-135a, and over-expression of FAM129A could strengthen the relief effect of miR-135a inhibitor in AP induced by cerulein.	Ceruletide	196-204	microRNA 135a	Rattus norvegicus	81-89
31729558-10	2019	In addition, mRNA and protein expression of FAM129A were negatively regulated by miR-135a, and over-expression of FAM129A could strengthen the relief effect of miR-135a inhibitor in AP induced by cerulein.	Ceruletide	196-204	niban apoptosis regulator 1	Rattus norvegicus	114-121
31729558-10	2019	In addition, mRNA and protein expression of FAM129A were negatively regulated by miR-135a, and over-expression of FAM129A could strengthen the relief effect of miR-135a inhibitor in AP induced by cerulein.	Ceruletide	196-204	microRNA 135a	Rattus norvegicus	160-168
31729558-11	2019	In summary, our data demonstrates that silencing miR-135a reduces AR42J cells injury and inflammatory response in AP induced by cerulein through targeting FAM129A.	Ceruletide	128-136	microRNA 135a	Rattus norvegicus	49-57
31729558-11	2019	In summary, our data demonstrates that silencing miR-135a reduces AR42J cells injury and inflammatory response in AP induced by cerulein through targeting FAM129A.	Ceruletide	128-136	niban apoptosis regulator 1	Rattus norvegicus	155-162
31518341-8	2019	RESULTS The results showed that YAP1 and MALAT1 were the targets of miR-194 and were upregulated in caerulein-treated AR42J cells.	Ceruletide	100-109	Yes1 associated transcriptional regulator	Rattus norvegicus	32-36
31248019-3	2019	Pancreatitis induced by cerulein, an analogue of cholecystokinin, causes premature activation of digestive enzymes and enhanced accumulation of cytokines and Ca2+ in the pancreas and, as such, it is a good model of acute pancreatitis.	Ceruletide	24-32	cholecystokinin	Rattus norvegicus	49-64
31404030-0	2019	Detection of Reg3gamma by Immunohistochemistry in Cerulein-Induced Model of Acute Pancreatic Injury in Mice and Rats.	Ceruletide	50-58	regenerating islet-derived 3 gamma	Mus musculus	13-22
31401195-9	2019	Consequently, mice afflicted with painful cerulein-induced CP could be significantly relieved upon treatment with the specific nNOS inhibitor NPLA.	Ceruletide	42-50	nitric oxide synthase 1, neuronal	Mus musculus	127-131
31506423-6	2019	A humanized PRSS1 transgenic mouse was established and treated with caerulein to mimic the development of CP, as evidenced by pathogenic alterations, collagen deposition, and increased expression of the inflammatory factors IL-6, IL-1beta, and TNF-alpha.	Ceruletide	68-77	protease, serine 1 (trypsin 1)	Mus musculus	12-17
31506423-6	2019	A humanized PRSS1 transgenic mouse was established and treated with caerulein to mimic the development of CP, as evidenced by pathogenic alterations, collagen deposition, and increased expression of the inflammatory factors IL-6, IL-1beta, and TNF-alpha.	Ceruletide	68-77	interleukin 6	Mus musculus	224-228
31506423-6	2019	A humanized PRSS1 transgenic mouse was established and treated with caerulein to mimic the development of CP, as evidenced by pathogenic alterations, collagen deposition, and increased expression of the inflammatory factors IL-6, IL-1beta, and TNF-alpha.	Ceruletide	68-77	interleukin 1 alpha	Mus musculus	230-238
31506423-6	2019	A humanized PRSS1 transgenic mouse was established and treated with caerulein to mimic the development of CP, as evidenced by pathogenic alterations, collagen deposition, and increased expression of the inflammatory factors IL-6, IL-1beta, and TNF-alpha.	Ceruletide	68-77	tumor necrosis factor	Mus musculus	244-253
31312351-6	2019	Klotho attenuated the severity of pancreatic inflammation after caerulein treatment.	Ceruletide	64-73	Klotho	Rattus norvegicus	0-6
30326193-0	2019	Role of Wnt/beta-catenin pathway agonist SKL2001 in Caerulein-induced acute pancreatitis.	Ceruletide	52-61	Wnt family member 2	Rattus norvegicus	8-11
30685119-7	2019	Moreover, menadione inhibited caerulein-induced cystathionine-gamma-lyase, preprotachykinin-A (PPTA) and neurokinin-1 receptor (NK-1R) expression in pancreas and lungs.	Ceruletide	30-39	tachykinin 1	Mus musculus	75-93
30685119-7	2019	Moreover, menadione inhibited caerulein-induced cystathionine-gamma-lyase, preprotachykinin-A (PPTA) and neurokinin-1 receptor (NK-1R) expression in pancreas and lungs.	Ceruletide	30-39	tachykinin 1	Mus musculus	95-99
30685119-7	2019	Moreover, menadione inhibited caerulein-induced cystathionine-gamma-lyase, preprotachykinin-A (PPTA) and neurokinin-1 receptor (NK-1R) expression in pancreas and lungs.	Ceruletide	30-39	tachykinin receptor 1	Mus musculus	105-126
30685119-7	2019	Moreover, menadione inhibited caerulein-induced cystathionine-gamma-lyase, preprotachykinin-A (PPTA) and neurokinin-1 receptor (NK-1R) expression in pancreas and lungs.	Ceruletide	30-39	tachykinin receptor 1	Mus musculus	128-133
31100090-0	2019	Protective effects of urocortin 2 against caerulein-induced acute pancreatitis.	Ceruletide	42-51	urocortin 2	Rattus norvegicus	22-33
31100090-1	2019	Because little is known about the role of corticotropin-releasing factor (CRF) agonists in regulating responses in pancreatitis, we evaluated the effects of urocortin 2 (UCN2) and stressin1 in caerulein-induced acute pancreatitis (AP) model in rats.	Ceruletide	193-202	urocortin 2	Rattus norvegicus	157-168
31100090-6	2019	NF-kappaB activity in pancreatic nuclear extracts increased in AP and UCN2 treatment reduced caerulein-induced increases in NF-kappaB activity by 42%.	Ceruletide	93-102	urocortin 2	Rattus norvegicus	70-74
31100090-7	2019	UCN2 treatment prevented caerulein-induced degradation of IkappaB-alpha in the cytosolic fraction as well as increased levels of p65 subunit of NF-kappaB in the cytosolic fraction.	Ceruletide	25-34	urocortin 2	Rattus norvegicus	0-4
31100090-7	2019	UCN2 treatment prevented caerulein-induced degradation of IkappaB-alpha in the cytosolic fraction as well as increased levels of p65 subunit of NF-kappaB in the cytosolic fraction.	Ceruletide	25-34	NFKB inhibitor alpha	Rattus norvegicus	58-71
31100090-9	2019	UCN2 evoked [Ca2+]i responses in primary acinar cells and abolished caerulein-evoked [Ca2+]i responses at 0.1nM, and decreased by ~50% at 1.0nM caerulein.	Ceruletide	68-77	urocortin 2	Rattus norvegicus	0-4
31100090-9	2019	UCN2 evoked [Ca2+]i responses in primary acinar cells and abolished caerulein-evoked [Ca2+]i responses at 0.1nM, and decreased by ~50% at 1.0nM caerulein.	Ceruletide	144-153	urocortin 2	Rattus norvegicus	0-4
31100090-11	2019	UCN2 prevented the massive redistribution of F-actin observed with supraphysiologic doses of caerulein.	Ceruletide	93-102	urocortin 2	Rattus norvegicus	0-4
30412288-2	2019	Previous studies in mice have demonstrated that pancreatitis contributes to oncogenic Kras-driven carcinogenesis, probably initiated in acinar cells; however, oncogenic Kras alone or in combination with caerulein-induced pancreatitis is not sufficient in initiating PDAC from the ductal compartment.	Ceruletide	203-212	Kirsten rat sarcoma viral oncogene homolog	Mus musculus	86-90
31130960-0	2019	TLR3 Ligand PolyI:C Prevents Acute Pancreatitis Through the Interferon-beta/Interferon-alpha/beta Receptor Signaling Pathway in a Caerulein-Induced Pancreatitis Mouse Model.	Ceruletide	130-139	toll-like receptor 3	Mus musculus	0-4
31130960-5	2019	Our current study indicates that polyI:C exerted excellent anti-inflammatory effects in a caerulein-induced AP mouse model and taurocholate-induced pancreatic acinar cell line injury model.	Ceruletide	90-99	LIM homeobox protein 2	Mus musculus	108-110
31130960-7	2019	Knockout of IFN-beta and IFNAR in mice abolished the preventive effects of polyI:C on caerulein-induced AP symptoms, which include pancreatic edema, neutrophil infiltration, the accumulation of reactive oxygen species (ROS), and inflammatory gene expression.	Ceruletide	86-95	interferon alpha	Mus musculus	12-20
31130960-7	2019	Knockout of IFN-beta and IFNAR in mice abolished the preventive effects of polyI:C on caerulein-induced AP symptoms, which include pancreatic edema, neutrophil infiltration, the accumulation of reactive oxygen species (ROS), and inflammatory gene expression.	Ceruletide	86-95	interferon (alpha and beta) receptor 1	Mus musculus	25-30
30833212-13	2019	In AR42J cells subjected to caerulein with addition of chemerin signal for TNFalpha was reduced comparing to the cultures treated with caerulein alone.	Ceruletide	28-37	retinoic acid receptor responder 2	Rattus norvegicus	55-63
30833212-13	2019	In AR42J cells subjected to caerulein with addition of chemerin signal for TNFalpha was reduced comparing to the cultures treated with caerulein alone.	Ceruletide	28-37	tumor necrosis factor	Rattus norvegicus	75-83
30685119-0	2019	Menadione (vitamin K3) inhibits hydrogen sulfide and substance P via NF-kB pathway in caerulein-induced acute pancreatitis and associated lung injury in mice.	Ceruletide	86-95	tachykinin 1	Mus musculus	53-64
30326193-0	2019	Role of Wnt/beta-catenin pathway agonist SKL2001 in Caerulein-induced acute pancreatitis.	Ceruletide	52-61	catenin beta 1	Rattus norvegicus	12-24
30326193-1	2019	The goal of this study was to clarify the protective role of the Wnt/beta-catenin pathway agonist SKL2001 in a rat model of Caerulein-induced acute pancreatitis.	Ceruletide	124-133	Wnt family member 2	Rattus norvegicus	65-68
30326193-1	2019	The goal of this study was to clarify the protective role of the Wnt/beta-catenin pathway agonist SKL2001 in a rat model of Caerulein-induced acute pancreatitis.	Ceruletide	124-133	catenin beta 1	Rattus norvegicus	69-81
30326193-6	2019	In vitro results showed that Caerulein promoted cell necrosis, inhibited the Wnt/beta-catenin pathway, and increased the level of inflammatory cytokines.	Ceruletide	29-38	Wnt family member 2	Rattus norvegicus	77-80
30326193-6	2019	In vitro results showed that Caerulein promoted cell necrosis, inhibited the Wnt/beta-catenin pathway, and increased the level of inflammatory cytokines.	Ceruletide	29-38	catenin beta 1	Rattus norvegicus	81-93
30031606-7	2018	Furthermore, cerulein induced the phosphorylation and nuclear translocation of P65, which indicated the activation of NF-kappaB, while PKR knockdown hindered NF-kappaB activation to alleviate pancreatic cell injury.	Ceruletide	13-21	synaptotagmin 1	Rattus norvegicus	79-82
30584237-5	2018	Dunnione treatment significantly reduced the cellular NADPH/NADP+ ratio and NOX activity through the enzymatic action of NQO1 in the pancreas of the caerulein-injection group.	Ceruletide	149-158	2,4-dienoyl CoA reductase 1, mitochondrial	Mus musculus	54-59
30584237-5	2018	Dunnione treatment significantly reduced the cellular NADPH/NADP+ ratio and NOX activity through the enzymatic action of NQO1 in the pancreas of the caerulein-injection group.	Ceruletide	149-158	NAD(P)H dehydrogenase, quinone 1	Mus musculus	121-125
30474876-0	2018	The interaction between ANXA2 and lncRNA Fendrr promotes cell apoptosis in caerulein-induced acute pancreatitis.	Ceruletide	75-84	annexin A2	Rattus norvegicus	24-29
30474876-0	2018	The interaction between ANXA2 and lncRNA Fendrr promotes cell apoptosis in caerulein-induced acute pancreatitis.	Ceruletide	75-84	FOXF1 adjacent non-coding developmental regulatory RNA	Rattus norvegicus	41-47
30337411-4	2018	DNGR-1 deficiency leads to exacerbated caerulein-induced necrotizing pancreatitis and increased pathology during systemic Candida albicans infection without affecting fungal burden.	Ceruletide	39-48	C-type lectin domain family 9, member a	Mus musculus	0-6
30139658-9	2018	RESULTS: We identified a number of novel genes, including Regulator of calcineurin 1 (Rcan1) and Sestrin 2 (Sesn2) and demonstrated that they are induced by oxidative stress, by stimulation with H2O2 and by inhibiting caerulein stimulated expression with the antioxidant N-acetylcysteine.	Ceruletide	218-227	regulator of calcineurin 1	Mus musculus	58-84
30139658-9	2018	RESULTS: We identified a number of novel genes, including Regulator of calcineurin 1 (Rcan1) and Sestrin 2 (Sesn2) and demonstrated that they are induced by oxidative stress, by stimulation with H2O2 and by inhibiting caerulein stimulated expression with the antioxidant N-acetylcysteine.	Ceruletide	218-227	regulator of calcineurin 1	Mus musculus	86-91
30139658-9	2018	RESULTS: We identified a number of novel genes, including Regulator of calcineurin 1 (Rcan1) and Sestrin 2 (Sesn2) and demonstrated that they are induced by oxidative stress, by stimulation with H2O2 and by inhibiting caerulein stimulated expression with the antioxidant N-acetylcysteine.	Ceruletide	218-227	sestrin 2	Mus musculus	97-106
30139658-9	2018	RESULTS: We identified a number of novel genes, including Regulator of calcineurin 1 (Rcan1) and Sestrin 2 (Sesn2) and demonstrated that they are induced by oxidative stress, by stimulation with H2O2 and by inhibiting caerulein stimulated expression with the antioxidant N-acetylcysteine.	Ceruletide	218-227	sestrin 2	Mus musculus	108-113
30325112-5	2018	Described in this article is a protocol for using KrasG12D ; Pdx1-Cre (KC) mice stimulated with caerulein, a small oligopeptide that increases secretion of digestive enzymes, as a model for pancreatitis.	Ceruletide	96-105	pancreatic and duodenal homeobox 1	Mus musculus	61-69
30405152-0	2018	Loss of Sirt2 increases and prolongs a caerulein-induced pancreatitis permissive phenotype and induces spontaneous oncogenic Kras mutations in mice.	Ceruletide	39-48	sirtuin 2	Mus musculus	8-13
30405152-2	2018	Here, we report that after caerulein-induced pancreatitis, Sirt2-deficient mice exhibited an increased inflammatory phenotype and delayed pancreatic tissue recovery.	Ceruletide	27-36	sirtuin 2	Mus musculus	59-64
30405152-6	2018	Importantly, an accumulation of a cell population with spontaneous cancerous KrasG12D mutations was observed in the Sirt2-/- mice that is enhanced in the recovering pancreas after exposure to caerulein.	Ceruletide	192-201	sirtuin 2	Mus musculus	116-121
29971769-1	2018	OBJECTIVES: In the present study, we have elaborated the anti-inflammatory mechanism of MSM through homing of CD34+ stem cells towards an inflamed region by regulating hydrogen sulfide (H2 S) in an in vivo model of caerulein-induced acute pancreatitis (AP) and associated lung injury.	Ceruletide	215-224	CD34 antigen	Mus musculus	110-114
29971769-6	2018	Furthermore, MSM reduced caerulein-induced H2 S levels by alleviating the expression of CSE in pancreas and lungs and increased CD34 expression and inhibited nuclear factor (NF)-kappaB translocation in caerulein-induced AP and associated lung injury.	Ceruletide	202-211	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	158-184
29890468-0	2018	Calycosin alleviates cerulein-induced acute pancreatitis by inhibiting the inflammatory response and oxidative stress via the p38 MAPK and NF-kappaB signal pathways in mice.	Ceruletide	21-29	mitogen-activated protein kinase 14	Mus musculus	126-134
29890468-0	2018	Calycosin alleviates cerulein-induced acute pancreatitis by inhibiting the inflammatory response and oxidative stress via the p38 MAPK and NF-kappaB signal pathways in mice.	Ceruletide	21-29	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	139-148
29971769-5	2018	KEY FINDINGS: Methylsulfonylmethane significantly ameliorated pancreas and lung histopathological changes, decreased serum amylase, MPO activity and inhibited caerulein-induced IL-1beta expression.	Ceruletide	159-168	interleukin 1 beta	Mus musculus	177-185
29971769-6	2018	Furthermore, MSM reduced caerulein-induced H2 S levels by alleviating the expression of CSE in pancreas and lungs and increased CD34 expression and inhibited nuclear factor (NF)-kappaB translocation in caerulein-induced AP and associated lung injury.	Ceruletide	25-34	cystathionase (cystathionine gamma-lyase)	Mus musculus	88-91
29971769-6	2018	Furthermore, MSM reduced caerulein-induced H2 S levels by alleviating the expression of CSE in pancreas and lungs and increased CD34 expression and inhibited nuclear factor (NF)-kappaB translocation in caerulein-induced AP and associated lung injury.	Ceruletide	25-34	CD34 antigen	Mus musculus	128-132
29748382-5	2018	Importantly, however, DNA damage was increased in pancreatic tissues induced by caerulein treatment or high-fat diet, which may be due to impaired nuclear localization of Y-Box Binding Protein 1 (YBX1), a component of the DNA damage repair machinery.	Ceruletide	80-89	Y box protein 1	Mus musculus	171-194
29748382-5	2018	Importantly, however, DNA damage was increased in pancreatic tissues induced by caerulein treatment or high-fat diet, which may be due to impaired nuclear localization of Y-Box Binding Protein 1 (YBX1), a component of the DNA damage repair machinery.	Ceruletide	80-89	Y box protein 1	Mus musculus	196-200
29409830-4	2018	Cerulein administration resulted in activation and stabilization of hypoxia-inducible factor-1alpha (HIF1alpha) in pancreata of oxygen-dependent degradation domain-luciferase HIF1alpha reporter mice.	Ceruletide	0-8	hypoxia inducible factor 1, alpha subunit	Mus musculus	68-99
29409830-4	2018	Cerulein administration resulted in activation and stabilization of hypoxia-inducible factor-1alpha (HIF1alpha) in pancreata of oxygen-dependent degradation domain-luciferase HIF1alpha reporter mice.	Ceruletide	0-8	hypoxia inducible factor 1, alpha subunit	Mus musculus	101-110
29409830-4	2018	Cerulein administration resulted in activation and stabilization of hypoxia-inducible factor-1alpha (HIF1alpha) in pancreata of oxygen-dependent degradation domain-luciferase HIF1alpha reporter mice.	Ceruletide	0-8	hypoxia inducible factor 1, alpha subunit	Mus musculus	175-184
29409830-6	2018	Expression of tissue factor, which is regulated by vascular endothelial growth factor, also increased following cerulein administration.	Ceruletide	112-120	coagulation factor III	Mus musculus	14-27
30537729-8	2018	In addition, we found Hmgb1 stimulation resulted in the overexpression of miR-21 in peripheral blood mononuclear cells, and deletion of miR-21 led to a reduction of caerulein-induced acute pancreatitis-associated lung injury by repressing Hmgb1 expression.	Ceruletide	165-174	microRNA 21a	Mus musculus	136-142
29286117-7	2018	CAE-induced expression of TLR4 and NF-kappaB within AR42J cells was abrogated by 10-5 mmol/l Ang 1-7; however, TLR4 and NF-kappaB expression was enhanced with the addition of A779, particularly 10-5 mmol/l.	Ceruletide	0-3	toll-like receptor 4	Rattus norvegicus	26-30
29286117-7	2018	CAE-induced expression of TLR4 and NF-kappaB within AR42J cells was abrogated by 10-5 mmol/l Ang 1-7; however, TLR4 and NF-kappaB expression was enhanced with the addition of A779, particularly 10-5 mmol/l.	Ceruletide	0-3	angiogenin	Rattus norvegicus	93-98
29286117-7	2018	CAE-induced expression of TLR4 and NF-kappaB within AR42J cells was abrogated by 10-5 mmol/l Ang 1-7; however, TLR4 and NF-kappaB expression was enhanced with the addition of A779, particularly 10-5 mmol/l.	Ceruletide	0-3	toll-like receptor 4	Rattus norvegicus	111-115
29286117-8	2018	In addition, treatment with 10-6 and 10-5 mmol/l Ang 1-7 significantly mitigated CAE-induced expression of IL-6, IL-8 and TNF-alpha, whereas it enhanced IL-10 expression.	Ceruletide	81-84	angiogenin	Rattus norvegicus	49-54
29286117-8	2018	In addition, treatment with 10-6 and 10-5 mmol/l Ang 1-7 significantly mitigated CAE-induced expression of IL-6, IL-8 and TNF-alpha, whereas it enhanced IL-10 expression.	Ceruletide	81-84	interleukin 6	Rattus norvegicus	107-111
29286117-8	2018	In addition, treatment with 10-6 and 10-5 mmol/l Ang 1-7 significantly mitigated CAE-induced expression of IL-6, IL-8 and TNF-alpha, whereas it enhanced IL-10 expression.	Ceruletide	81-84	tumor necrosis factor	Rattus norvegicus	122-131
29286117-9	2018	Conversely, A779 treatment enhanced the CAE-induced expression of IL-6, IL-8 and TNF-alpha, and reduced IL-10 expression in AR42J cells.	Ceruletide	40-43	interleukin 6	Rattus norvegicus	66-70
29286117-9	2018	Conversely, A779 treatment enhanced the CAE-induced expression of IL-6, IL-8 and TNF-alpha, and reduced IL-10 expression in AR42J cells.	Ceruletide	40-43	tumor necrosis factor	Rattus norvegicus	81-90
29286117-10	2018	In conclusion, these results suggested that Ang 1-7 may attenuate CAE-induced inflammation by downregulating TLR4, NF-kappaB and proinflammatory cytokine expression within AR42J cells.	Ceruletide	66-69	angiogenin	Rattus norvegicus	44-49
29286117-10	2018	In conclusion, these results suggested that Ang 1-7 may attenuate CAE-induced inflammation by downregulating TLR4, NF-kappaB and proinflammatory cytokine expression within AR42J cells.	Ceruletide	66-69	toll-like receptor 4	Rattus norvegicus	109-113
29229780-5	2018	Supramaximal caerulein stimulation induced subcellular redistribution of CTSD from the lysosomal to the zymogen-containing subcellular compartment of acinar cells and activation of CTSD, CTSB, and trypsinogen.	Ceruletide	13-22	cathepsin D	Mus musculus	73-77
29229780-5	2018	Supramaximal caerulein stimulation induced subcellular redistribution of CTSD from the lysosomal to the zymogen-containing subcellular compartment of acinar cells and activation of CTSD, CTSB, and trypsinogen.	Ceruletide	13-22	cathepsin D	Mus musculus	181-185
29229780-5	2018	Supramaximal caerulein stimulation induced subcellular redistribution of CTSD from the lysosomal to the zymogen-containing subcellular compartment of acinar cells and activation of CTSD, CTSB, and trypsinogen.	Ceruletide	13-22	cathepsin B	Mus musculus	187-191
30537729-2	2018	METHODS: We used next generation sequencing to analyze gene expression profiles of pancreatic tissues from wild-type (WT) and miR-21 knockout (KO) mice treated with caerulein by using a 1-day treatment protocol.	Ceruletide	165-174	microRNA 21a	Mus musculus	126-132
30497068-10	2018	In addition, we treated caerulein- and TLC-S-induced AR42J cells with the Rela inhibitor helenalin and found that the expression of Rela, Traf3 and Ptgs2 decreased compared with the NC, while the expression of miR-155-5p did not show any significant difference.	Ceruletide	24-33	RELA proto-oncogene, NF-kB subunit	Rattus norvegicus	74-78
30497068-10	2018	In addition, we treated caerulein- and TLC-S-induced AR42J cells with the Rela inhibitor helenalin and found that the expression of Rela, Traf3 and Ptgs2 decreased compared with the NC, while the expression of miR-155-5p did not show any significant difference.	Ceruletide	24-33	RELA proto-oncogene, NF-kB subunit	Rattus norvegicus	132-136
30497068-10	2018	In addition, we treated caerulein- and TLC-S-induced AR42J cells with the Rela inhibitor helenalin and found that the expression of Rela, Traf3 and Ptgs2 decreased compared with the NC, while the expression of miR-155-5p did not show any significant difference.	Ceruletide	24-33	Tnf receptor-associated factor 3	Rattus norvegicus	138-143
30497068-10	2018	In addition, we treated caerulein- and TLC-S-induced AR42J cells with the Rela inhibitor helenalin and found that the expression of Rela, Traf3 and Ptgs2 decreased compared with the NC, while the expression of miR-155-5p did not show any significant difference.	Ceruletide	24-33	prostaglandin-endoperoxide synthase 2	Rattus norvegicus	148-153
30497068-10	2018	In addition, we treated caerulein- and TLC-S-induced AR42J cells with the Rela inhibitor helenalin and found that the expression of Rela, Traf3 and Ptgs2 decreased compared with the NC, while the expression of miR-155-5p did not show any significant difference.	Ceruletide	24-33	microRNA 155	Mus musculus	210-217
30537729-8	2018	In addition, we found Hmgb1 stimulation resulted in the overexpression of miR-21 in peripheral blood mononuclear cells, and deletion of miR-21 led to a reduction of caerulein-induced acute pancreatitis-associated lung injury by repressing Hmgb1 expression.	Ceruletide	165-174	high mobility group box 1	Mus musculus	239-244
28639695-4	2017	We show that GSK-3beta promotes TGF-alpha-induced ADM in 3D cultured primary acinar cells, whereas deletion of GSK-3beta attenuates caerulein-induced ADM formation and PanIN progression in KrasG12D transgenic mice.	Ceruletide	132-141	glycogen synthase kinase 3 beta	Mus musculus	111-120
28713987-9	2017	The results demonstrated that the cleaved caspase-3 levels were increased in the CAE group (P<0.05), peaking at 24 h, and declined when incubated with Ang-(1-7).	Ceruletide	81-84	caspase 3	Mus musculus	42-51
29018784-5	2017	Treatment with cerulein induced the activation of JAK2/STAT3 and PPAR-gamma expression in AR42J cells.	Ceruletide	15-23	Janus kinase 2	Rattus norvegicus	50-54
29018784-5	2017	Treatment with cerulein induced the activation of JAK2/STAT3 and PPAR-gamma expression in AR42J cells.	Ceruletide	15-23	signal transducer and activator of transcription 3	Rattus norvegicus	55-60
29018784-5	2017	Treatment with cerulein induced the activation of JAK2/STAT3 and PPAR-gamma expression in AR42J cells.	Ceruletide	15-23	peroxisome proliferator-activated receptor gamma	Rattus norvegicus	65-75
28713987-12	2017	In addition, the cleaved caspase-3 levels, and the ratio of Bax to Bcl-2 in the CAE + A779 group presented a significant rise compared with the CAE group.	Ceruletide	80-83	BCL2-associated X protein	Mus musculus	60-63
28713987-12	2017	In addition, the cleaved caspase-3 levels, and the ratio of Bax to Bcl-2 in the CAE + A779 group presented a significant rise compared with the CAE group.	Ceruletide	80-83	B cell leukemia/lymphoma 2	Mus musculus	67-72
28704954-10	2017	Pretreatment with DHA reduced cerulein-induced activation of NF-kappaB, PKCdelta, and IL-6 in pancreatic tissues of rats.	Ceruletide	30-38	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	61-70
28754974-4	2017	Our data revealed that the HMGB1 expression was significantly increased in AP mice induced by caerulein and LPS, and the inhibition of HMGB1 played a protective role in intestinal mucosal barrier dysfunction, reduced the serum level of other proinflammatory cytokines include IL-1beta, IL-6, TNF-alpha.	Ceruletide	94-103	high mobility group box 1	Mus musculus	27-32
28704954-10	2017	Pretreatment with DHA reduced cerulein-induced activation of NF-kappaB, PKCdelta, and IL-6 in pancreatic tissues of rats.	Ceruletide	30-38	protein kinase C, delta	Mus musculus	72-80
28704954-10	2017	Pretreatment with DHA reduced cerulein-induced activation of NF-kappaB, PKCdelta, and IL-6 in pancreatic tissues of rats.	Ceruletide	30-38	interleukin 6	Rattus norvegicus	86-90
28218693-0	2017	Propylene Glycol Alginate Sodium Sulfate Alleviates  Cerulein-Induced Acute Pancreatitis by Modulating  the MEK/ERK Pathway in Mice.	Ceruletide	53-61	midkine	Mus musculus	108-111
28468316-8	2017	RESULTS: Incubation of isolated acinar cells with caerulein inhibited GHS-R and GHRL expression at the level of mRNA and protein in those cells.	Ceruletide	50-59	growth hormone secretagogue receptor	Rattus norvegicus	70-75
28468316-8	2017	RESULTS: Incubation of isolated acinar cells with caerulein inhibited GHS-R and GHRL expression at the level of mRNA and protein in those cells.	Ceruletide	50-59	ghrelin and obestatin prepropeptide	Rattus norvegicus	80-84
28468316-9	2017	Either in rats with intact SN or with CDSN, administration of GHRL before isolation of acinar cells increased expression of GHRL and GHS-R in those cells and reversed the caerulein-induced reduction in expression of those parameters.	Ceruletide	171-180	ghrelin and obestatin prepropeptide	Rattus norvegicus	62-66
28483666-8	2017	Troglitazone inhibited the cerulein-induced increase in ROS and IL-6 expression, but induced catalase expression similar to DHA in AR42J cells.	Ceruletide	27-35	interleukin 6	Rattus norvegicus	64-68
28592850-5	2017	We demonstrated for the first time that the activities and expression of SIRT1 were suppressed by reduction of intracellular NAD+ levels and the p53-microRNA-34a pathway in caerulein-induced AP.	Ceruletide	173-182	sirtuin 1	Homo sapiens	73-78
28592850-5	2017	We demonstrated for the first time that the activities and expression of SIRT1 were suppressed by reduction of intracellular NAD+ levels and the p53-microRNA-34a pathway in caerulein-induced AP.	Ceruletide	173-182	tumor protein p53	Homo sapiens	145-148
28592850-6	2017	Moreover, we confirmed that the increase of cellular NAD+ by NQO1 enzymatic action using the substrate beta-Lapachone suppressed caerulein-induced AP with down-regulating TLR4-mediated inflammasome signalling, and thereby reducing the inflammatory responses and pancreatic cell death.	Ceruletide	129-138	NAD(P)H quinone dehydrogenase 1	Homo sapiens	61-65
28592850-6	2017	Moreover, we confirmed that the increase of cellular NAD+ by NQO1 enzymatic action using the substrate beta-Lapachone suppressed caerulein-induced AP with down-regulating TLR4-mediated inflammasome signalling, and thereby reducing the inflammatory responses and pancreatic cell death.	Ceruletide	129-138	toll like receptor 4	Homo sapiens	171-175
28218693-0	2017	Propylene Glycol Alginate Sodium Sulfate Alleviates  Cerulein-Induced Acute Pancreatitis by Modulating  the MEK/ERK Pathway in Mice.	Ceruletide	53-61	mitogen-activated protein kinase 1	Mus musculus	112-115
28013573-4	2017	Our results revealed that miR-216a and miR-217 were almost exclusively expressed in rat pancreas and that circulating miR-216a and miR-217 were significantly increased in rats following administration of established exocrine pancreatic toxicants caerulein (CL) and 1-cyano-2-hydroxy-3-butene (CHB) as well as in rats administered a proprietary molecule known to primarily affect the exocrine pancreas.	Ceruletide	246-255	microRNA 216a	Rattus norvegicus	26-34
28013573-4	2017	Our results revealed that miR-216a and miR-217 were almost exclusively expressed in rat pancreas and that circulating miR-216a and miR-217 were significantly increased in rats following administration of established exocrine pancreatic toxicants caerulein (CL) and 1-cyano-2-hydroxy-3-butene (CHB) as well as in rats administered a proprietary molecule known to primarily affect the exocrine pancreas.	Ceruletide	246-255	microRNA 217	Rattus norvegicus	39-46
28013573-4	2017	Our results revealed that miR-216a and miR-217 were almost exclusively expressed in rat pancreas and that circulating miR-216a and miR-217 were significantly increased in rats following administration of established exocrine pancreatic toxicants caerulein (CL) and 1-cyano-2-hydroxy-3-butene (CHB) as well as in rats administered a proprietary molecule known to primarily affect the exocrine pancreas.	Ceruletide	246-255	microRNA 216a	Rattus norvegicus	118-126
28013573-4	2017	Our results revealed that miR-216a and miR-217 were almost exclusively expressed in rat pancreas and that circulating miR-216a and miR-217 were significantly increased in rats following administration of established exocrine pancreatic toxicants caerulein (CL) and 1-cyano-2-hydroxy-3-butene (CHB) as well as in rats administered a proprietary molecule known to primarily affect the exocrine pancreas.	Ceruletide	246-255	microRNA 217	Rattus norvegicus	131-138
27408338-0	2016	Changes in gene expression of tumor necrosis factor alpha and interleukin 6 in a canine model of caerulein-induced pancreatitis.	Ceruletide	97-106	tumor necrosis factor	Canis lupus familiaris	30-57
29262394-19	2017	SAP intestinal injury induced by cerulein combined with lipopolysaccharides was concomitant with increased expression of JAM-C and MMP9, and reduced expression of AQP-1 in intestinal tissue.	Ceruletide	33-41	junctional adhesion molecule 3	Rattus norvegicus	121-126
29262394-19	2017	SAP intestinal injury induced by cerulein combined with lipopolysaccharides was concomitant with increased expression of JAM-C and MMP9, and reduced expression of AQP-1 in intestinal tissue.	Ceruletide	33-41	matrix metallopeptidase 9	Rattus norvegicus	131-135
29262394-19	2017	SAP intestinal injury induced by cerulein combined with lipopolysaccharides was concomitant with increased expression of JAM-C and MMP9, and reduced expression of AQP-1 in intestinal tissue.	Ceruletide	33-41	aquaporin 1	Rattus norvegicus	163-168
27686613-5	2016	In particular, we found significant overexpression of miR-21-3p in acini treated with caerulein and TLC-S. We further looked at the expression of miR-21-3p in caerulein, l-arginine, and caerulein + LPS-induced acute pancreatitis mouse models and found 12-, 21-, and 50-fold increased expression in the pancreas, respectively.	Ceruletide	86-95	microRNA 181a-1	Mus musculus	54-63
27686613-5	2016	In particular, we found significant overexpression of miR-21-3p in acini treated with caerulein and TLC-S. We further looked at the expression of miR-21-3p in caerulein, l-arginine, and caerulein + LPS-induced acute pancreatitis mouse models and found 12-, 21-, and 50-fold increased expression in the pancreas, respectively.	Ceruletide	159-168	microRNA 181a-1	Mus musculus	146-155
27514475-7	2016	Compared with healthy controls, legumain activity in the pancreas of caerulein-treated mice was increased in a time-dependent manner.	Ceruletide	69-78	legumain	Mus musculus	32-40
27521901-8	2016	Caerulein-induced injury was associated with increases in serum amylase/lipase (4h), miR-216a/b (4, 24h).	Ceruletide	0-9	lipase G, endothelial type	Rattus norvegicus	72-78
27521901-8	2016	Caerulein-induced injury was associated with increases in serum amylase/lipase (4h), miR-216a/b (4, 24h).	Ceruletide	0-9	microRNA 216a	Rattus norvegicus	85-93
27085321-8	2016	RESULTS: CD19-/- mice, which lack B10 cells, suffered a more severe inflammation in pancreas compared with wild-type mice after caerulein injection.	Ceruletide	128-137	CD19 antigen	Mus musculus	9-13
27886058-7	2016	Furthermore, acute inflammation was stimulated by trigger such as caerulein in vivo, which resulted in increased fluorescent signal of the cy5.5-EpCAM/muc1 ALB during cancer metastasis due to exogenous expression of EpCAM/muc1 in Panc02-implanted mouse model.	Ceruletide	66-75	epithelial cell adhesion molecule	Mus musculus	145-150
27886058-7	2016	Furthermore, acute inflammation was stimulated by trigger such as caerulein in vivo, which resulted in increased fluorescent signal of the cy5.5-EpCAM/muc1 ALB during cancer metastasis due to exogenous expression of EpCAM/muc1 in Panc02-implanted mouse model.	Ceruletide	66-75	mucin 1, transmembrane	Mus musculus	151-155
27886058-7	2016	Furthermore, acute inflammation was stimulated by trigger such as caerulein in vivo, which resulted in increased fluorescent signal of the cy5.5-EpCAM/muc1 ALB during cancer metastasis due to exogenous expression of EpCAM/muc1 in Panc02-implanted mouse model.	Ceruletide	66-75	epithelial cell adhesion molecule	Mus musculus	216-221
27886058-7	2016	Furthermore, acute inflammation was stimulated by trigger such as caerulein in vivo, which resulted in increased fluorescent signal of the cy5.5-EpCAM/muc1 ALB during cancer metastasis due to exogenous expression of EpCAM/muc1 in Panc02-implanted mouse model.	Ceruletide	66-75	mucin 1, transmembrane	Mus musculus	222-226
27408338-0	2016	Changes in gene expression of tumor necrosis factor alpha and interleukin 6 in a canine model of caerulein-induced pancreatitis.	Ceruletide	97-106	interleukin 6	Canis lupus familiaris	62-75
27105999-10	2016	Moreover, flow cytometry indicated that treatment with caerulein induced a significant decrease of apoptotic index and increase of necrosis index in TRAM1-siRNA cells, compared with control groups, as indicated by downregulated expression of cleaved caspase-3, caspase-8, and caspase-9 mRNA expression activity in TRAM1-siRNA cells.	Ceruletide	55-64	translocation associated membrane protein 1	Rattus norvegicus	149-154
27244456-6	2016	Caerulein administration to Gdeg;Pdx-1-Cre;LSL-Kras(G12D) mice induced constitutive elevation of proteasome activity in pancreatic tissues and accelerated PanIN formation.	Ceruletide	0-9	pancreatic and duodenal homeobox 1	Mus musculus	33-38
27244456-6	2016	Caerulein administration to Gdeg;Pdx-1-Cre;LSL-Kras(G12D) mice induced constitutive elevation of proteasome activity in pancreatic tissues and accelerated PanIN formation.	Ceruletide	0-9	Kirsten rat sarcoma viral oncogene homolog	Mus musculus	47-51
27207309-0	2016	Caerulein-induced pancreatitis augments the expression and phosphorylation of collapsin response mediator protein 4.	Ceruletide	0-9	dihydropyrimidinase-like 3	Mus musculus	78-115
27105999-10	2016	Moreover, flow cytometry indicated that treatment with caerulein induced a significant decrease of apoptotic index and increase of necrosis index in TRAM1-siRNA cells, compared with control groups, as indicated by downregulated expression of cleaved caspase-3, caspase-8, and caspase-9 mRNA expression activity in TRAM1-siRNA cells.	Ceruletide	55-64	caspase 8	Rattus norvegicus	261-270
27105999-10	2016	Moreover, flow cytometry indicated that treatment with caerulein induced a significant decrease of apoptotic index and increase of necrosis index in TRAM1-siRNA cells, compared with control groups, as indicated by downregulated expression of cleaved caspase-3, caspase-8, and caspase-9 mRNA expression activity in TRAM1-siRNA cells.	Ceruletide	55-64	caspase 9	Rattus norvegicus	276-285
27105999-10	2016	Moreover, flow cytometry indicated that treatment with caerulein induced a significant decrease of apoptotic index and increase of necrosis index in TRAM1-siRNA cells, compared with control groups, as indicated by downregulated expression of cleaved caspase-3, caspase-8, and caspase-9 mRNA expression activity in TRAM1-siRNA cells.	Ceruletide	55-64	translocation associated membrane protein 1	Rattus norvegicus	314-319
26992918-9	2016	Furthermore, we discovered that Prox1-heterozygosis increases tissue damage and delays recovery from inflammation in pancreata of mice injected with caerulein.	Ceruletide	149-158	prospero homeobox 1	Mus musculus	32-37
26608971-1	2016	In their recent publication in Journal of Pathology, Grabliauskaite and Sapanora and their colleagues in Zurich use a conditional ablation of the TGFbeta type II receptor (TBRII) to analyse its specific role in pancreatic epithelial cells in response to a caerulein-induced model of acute pancreatitis.	Ceruletide	256-265	transforming growth factor, beta receptor II	Mus musculus	146-170
26608971-1	2016	In their recent publication in Journal of Pathology, Grabliauskaite and Sapanora and their colleagues in Zurich use a conditional ablation of the TGFbeta type II receptor (TBRII) to analyse its specific role in pancreatic epithelial cells in response to a caerulein-induced model of acute pancreatitis.	Ceruletide	256-265	transforming growth factor, beta receptor II	Mus musculus	172-177
26526450-14	2016	Knocking down KPNA2 hindered cerulein-induced nuclear transportation of p65 and alleviated the subsequent inflammatory response in rat pancreatic acinar cells.	Ceruletide	29-37	karyopherin subunit alpha 2	Rattus norvegicus	14-19
26526450-14	2016	Knocking down KPNA2 hindered cerulein-induced nuclear transportation of p65 and alleviated the subsequent inflammatory response in rat pancreatic acinar cells.	Ceruletide	29-37	synaptotagmin 1	Rattus norvegicus	72-75
26411454-5	2016	MPO activity increased in caerulein-induced acute pancreatitis (16.21 +- 3.571 SD fold increase over control) and treatment with siRNA significantly reduced this (mean 3.555 +- 2.522 SD fold increase over control) (p < 0.0001).	Ceruletide	26-35	myeloperoxidase	Mus musculus	0-3
26526716-11	2016	Bcl3(-/-) mice developed more severe AP after administration of cerulein or sodium taurocholate than control mice; pancreata from the Bcl3(-/-) mice with AP had greater numbers of macrophages, myeloid-derived suppressor cells, dendritic cells, and granulocytes than control mice with AP.	Ceruletide	64-72	B cell leukemia/lymphoma 3	Mus musculus	0-4
26411454-6	2016	Similarly, lung MPO activity increased following treatment with caerulein (3.56 +- 0.941 SD fold increase over control) while siRNA treatment significantly reduced MPO activity (0.8243 +- 0.4353 SD fold increase over control) (p < 0.0001).	Ceruletide	64-73	myeloperoxidase	Mus musculus	16-19
26411454-6	2016	Similarly, lung MPO activity increased following treatment with caerulein (3.56 +- 0.941 SD fold increase over control) while siRNA treatment significantly reduced MPO activity (0.8243 +- 0.4353 SD fold increase over control) (p < 0.0001).	Ceruletide	64-73	myeloperoxidase	Mus musculus	164-167
26407569-14	2015	Lowering O-GlcNAcylation by OGT knockdown attenuated p65 activating phosphorylation, nuclear translocation, NF-kappaB transcriptional activity and levels of NF-kappaB transcriptional targets TNF-alpha and NO; on the contrary, elevating O-GlcNAc through PUGNAc increased IKKalpha and p65 O-GlcNAcylation accompanied by increased p65 phosphorylation, activity and levels of TNF-alpha and NO in caerulein-treated cells.	Ceruletide	392-401	O-linked N-acetylglucosamine (GlcNAc) transferase	Rattus norvegicus	28-31
26407569-10	2015	To determine the biological functions of OGT in caerulein-induced inflammatory response, RNA interference and PUGNAc, the inhibitor of O-GlcNAcase (OGA) was employed to regulate OGT expression in AR42 J cells.	Ceruletide	48-57	O-linked N-acetylglucosamine (GlcNAc) transferase	Rattus norvegicus	41-44
26407569-12	2015	Reduction of OGT by small interfering RNA (siRNA) inhibited caerulein-triggered inflammation, assessed by the production of pro-inflammatory mediators (TNF-alpha and NO).	Ceruletide	60-69	O-linked N-acetylglucosamine (GlcNAc) transferase	Rattus norvegicus	13-16
26407569-12	2015	Reduction of OGT by small interfering RNA (siRNA) inhibited caerulein-triggered inflammation, assessed by the production of pro-inflammatory mediators (TNF-alpha and NO).	Ceruletide	60-69	tumor necrosis factor	Rattus norvegicus	152-161
26633718-4	2015	In contrast, only Traf6 protein but not mRNA was downregulated in the severe ANP induced by combination treatment of caerulein and LPS.	Ceruletide	117-126	TNF receptor-associated factor 6	Mus musculus	18-23
25975747-11	2015	The DEGs, including Cdc6, Mcm6, Msh6 and Wdr1 are closely associated with the regulation of caerulein-induced pancreatitis.	Ceruletide	92-101	cell division cycle 6	Mus musculus	20-24
26618925-4	2015	Pancreas-specific ablation of interferon (alpha and beta) receptor 1 (Ifnar1) partially protected animals from caerulein-induced pancreatitis, as demonstrated by reduced tissue damage.	Ceruletide	111-120	interferon (alpha and beta) receptor 1	Mus musculus	70-76
26444748-13	2015	The Ang II to Ang-(1-7) ratio was increased in the pancreas but was decreased in the lung following caerulein treatment.	Ceruletide	100-109	angiogenin, ribonuclease, RNase A family, 5	Mus musculus	4-7
26444748-13	2015	The Ang II to Ang-(1-7) ratio was increased in the pancreas but was decreased in the lung following caerulein treatment.	Ceruletide	100-109	angiogenin, ribonuclease, RNase A family, 5	Mus musculus	14-17
25916208-7	2015	CXCL12/CXCR4, CCL2/CCR2, and several cytokines, such as interleukin (IL)-1beta, IL-6, and tumor necrosis factor (TNF)-alpha were upregulated in the tumor tissue of DMBA and caerulein-induced PDAC mice.	Ceruletide	173-182	chemokine (C-X-C motif) ligand 12	Mus musculus	0-6
25975747-11	2015	The DEGs, including Cdc6, Mcm6, Msh6 and Wdr1 are closely associated with the regulation of caerulein-induced pancreatitis.	Ceruletide	92-101	WD repeat domain 1	Mus musculus	41-45
25975747-11	2015	The DEGs, including Cdc6, Mcm6, Msh6 and Wdr1 are closely associated with the regulation of caerulein-induced pancreatitis.	Ceruletide	92-101	minichromosome maintenance complex component 6	Mus musculus	26-30
25975747-11	2015	The DEGs, including Cdc6, Mcm6, Msh6 and Wdr1 are closely associated with the regulation of caerulein-induced pancreatitis.	Ceruletide	92-101	mutS homolog 6	Mus musculus	32-36
25323957-0	2015	Tetraspanin CD9 is involved in pancreatic damage during caerulein-induced acute pancreatitis in mice.	Ceruletide	56-65	CD9 antigen	Mus musculus	12-15
25267397-6	2015	In the mice with cerulein-induced acute pancreatitis, the referred hyperalgesia was suppressed by NNC 55-0396 (NNC), a selective T-channel inhibitor; zinc chloride; or ascorbic acid, known to inhibit Ca(v)3.2 selectively among three T-channel isoforms; and knockdown of Ca(v)3.2.	Ceruletide	17-25	calcium channel, voltage-dependent, T type, alpha 1H subunit	Mus musculus	200-208
25267397-6	2015	In the mice with cerulein-induced acute pancreatitis, the referred hyperalgesia was suppressed by NNC 55-0396 (NNC), a selective T-channel inhibitor; zinc chloride; or ascorbic acid, known to inhibit Ca(v)3.2 selectively among three T-channel isoforms; and knockdown of Ca(v)3.2.	Ceruletide	17-25	calcium channel, voltage-dependent, T type, alpha 1H subunit	Mus musculus	270-278
25948069-3	2015	The aim of this study was to explore the effect of SEW2871, a S1P1-selective agonist, on caerulein-induced AP in mice.	Ceruletide	89-98	sphingosine-1-phosphate receptor 1	Mus musculus	62-66
25990308-5	2015	miR-21 deficiency protects against caerulein- or L-arginine-induced acute pancreatitis in mice.	Ceruletide	35-44	microRNA 21a	Mus musculus	0-6
25802340-7	2015	Unlike transgenic mice that globally express NF-kappaB-luciferase, AAV-infused mice showed a 15-fold increase in pancreas-specific NF-kappaB bioluminescence following 12 h of caerulein compared with baseline luminescence (p < 0.05).	Ceruletide	175-184	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	131-140
25459565-3	2014	METHODS: Caerulein (100 nM) induced trypsinogen activation (TGA), CXCL1, CXCL2 mRNA levels, cell injury were studied at 37  C, 34  C, 31  C, 29  C and 25  C in acinar cells.	Ceruletide	9-18	C-X-C motif chemokine ligand 2	Homo sapiens	73-78
25222135-0	2015	Role of Kinase Epidermal Growth Factor Receptor and SRC in the Caerulein-Induced Acute Pancreatitis in Mice.	Ceruletide	63-72	epidermal growth factor receptor	Mus musculus	15-47
25222135-0	2015	Role of Kinase Epidermal Growth Factor Receptor and SRC in the Caerulein-Induced Acute Pancreatitis in Mice.	Ceruletide	63-72	Rous sarcoma oncogene	Mus musculus	52-55
22902233-3	2012	Pancreatitis induced by high-dose cerulein (a cholecystokinin receptor agonist) administration depends on NOD1 stimulation by gut microflora.	Ceruletide	34-42	nucleotide binding oligomerization domain containing 1	Homo sapiens	106-110
26461340-8	2014	Further, sEH KO mice exhibited decreased cerulein- and arginine-induced NF-?B inflammatory response, MAPKs activation and decreased cell death.	Ceruletide	41-49	epoxide hydrolase 2, cytoplasmic	Mus musculus	9-12
25152324-7	2014	Glyburide administration in ob/ob mice with cerulein-induced SAP also resulted in significantly reduced serum levels of interleukin 6, lipase, and amylase and led to lower production of lipopolysaccharide-stimulated interleukin 1beta release in cultured peritoneal cells, compared with vehicle-treated ob/ob mice with SAP.	Ceruletide	44-52	lipase, endothelial	Mus musculus	135-141
25152324-7	2014	Glyburide administration in ob/ob mice with cerulein-induced SAP also resulted in significantly reduced serum levels of interleukin 6, lipase, and amylase and led to lower production of lipopolysaccharide-stimulated interleukin 1beta release in cultured peritoneal cells, compared with vehicle-treated ob/ob mice with SAP.	Ceruletide	44-52	interleukin 1 beta	Mus musculus	216-233
24008358-0	2013	The effect of CSE gene deletion in caerulein-induced acute pancreatitis in the mouse.	Ceruletide	35-44	cystathionase (cystathionine gamma-lyase)	Mus musculus	14-17
24008358-2	2013	In this study, we sought to determine whether endogenously synthesized H2S via cystathionine-gamma-lyase (CSE) plays a pro- or anti-inflammatory role in caerulein-induced pancreatitis.	Ceruletide	153-162	cystathionase (cystathionine gamma-lyase)	Mus musculus	79-104
24008358-2	2013	In this study, we sought to determine whether endogenously synthesized H2S via cystathionine-gamma-lyase (CSE) plays a pro- or anti-inflammatory role in caerulein-induced pancreatitis.	Ceruletide	153-162	cystathionase (cystathionine gamma-lyase)	Mus musculus	106-109
24008358-3	2013	To investigate this, we used mice genetically deficient in CSE to elucidate the function of CSE in caerulein-induced acute pancreatitis.	Ceruletide	99-108	cystathionase (cystathionine gamma-lyase)	Mus musculus	92-95
24008358-7	2013	Additionally, in WT mice, there was a greater level of pancreatic CSE expression and sulfide-synthesizing activity in caerulein-induced pancreatitis compared with the saline control.	Ceruletide	118-127	cystathionase (cystathionine gamma-lyase)	Mus musculus	66-69
23954400-1	2013	Poly(ADP-ribose) polymerase (Parp) 1 is a key regulator of cell death, its inhibition prevented streptozotocin-induced diabetes and attenuated caerulein-induced acute pancreatitis.	Ceruletide	143-152	poly (ADP-ribose) polymerase family, member 1	Mus musculus	0-36
24648970-3	2013	In the present study, in order to investigate the mechanisms of hyper-lipidemic acute pancreatitis (HLP), we established an animal model using lipoprotein lipase (LPL)-deficient heterozygous mice injected with caerulein.	Ceruletide	210-219	lipoprotein lipase	Mus musculus	143-161
24648970-3	2013	In the present study, in order to investigate the mechanisms of hyper-lipidemic acute pancreatitis (HLP), we established an animal model using lipoprotein lipase (LPL)-deficient heterozygous mice injected with caerulein.	Ceruletide	210-219	lipoprotein lipase	Mus musculus	163-166
23041330-13	2013	CONCLUSIONS: Pancreas-specific deletion of IkappaBalpha results in nuclear translocation of RelA and reduces AP induction and trypsin activation in mice after administration of cerulein or L-arginine.	Ceruletide	177-185	nuclear factor of kappa light polypeptide gene enhancer in B cells inhibitor, alpha	Mus musculus	43-55
23064197-0	2012	Pancreatic STAT3 protects mice against caerulein-induced pancreatitis via PAP1 induction.	Ceruletide	39-48	signal transducer and activator of transcription 3	Mus musculus	11-16
23064197-0	2012	Pancreatic STAT3 protects mice against caerulein-induced pancreatitis via PAP1 induction.	Ceruletide	39-48	regenerating islet-derived 3 beta	Mus musculus	74-78
23064197-4	2012	Caerulein administration activated pancreatic STAT3 and induced acute pancreatitis as early as 3 hours in wild-type mice, and full recovery from the induced pancreatic injury was observed within 7 days.	Ceruletide	0-9	signal transducer and activator of transcription 3	Mus musculus	46-51
23170143-2	2012	High serum levels of cholecystokinin (CCK) have been reported in patients with acute pancreatitis, and treatment with cerulein, a CCK analogue, induces acute pancreatitis in a rodent model.	Ceruletide	118-126	cholecystokinin	Homo sapiens	130-133
24726914-4	2014	The examination of caerulein-induced pancreatic injury and tumorigenesis in a Kras-driven mouse model confirmed the activation and gradual increase of SULF1/SULF2 variants during pancreatitis and tumorigenesis but with reduced levels in Stat3 conditional knockout mice with reduced inflammation.	Ceruletide	19-28	sulfatase 1	Mus musculus	151-156
24726914-4	2014	The examination of caerulein-induced pancreatic injury and tumorigenesis in a Kras-driven mouse model confirmed the activation and gradual increase of SULF1/SULF2 variants during pancreatitis and tumorigenesis but with reduced levels in Stat3 conditional knockout mice with reduced inflammation.	Ceruletide	19-28	sulfatase 2	Mus musculus	157-162
23142317-7	2013	In the adult pancreas we identified rare ALDH1B1(+) cells that become abundant following pancreas injury in either the caerulein or streptozotocin paradigms.	Ceruletide	119-128	aldehyde dehydrogenase 1 family member B1	Homo sapiens	41-48
21948943-13	2012	Dispersed acini from Hnf1alpha(-/-) mice showed suboptimal secretory responses to caerulein.	Ceruletide	82-91	HNF1 homeobox A	Mus musculus	21-30
22040127-3	2012	Previously, we showed that caerulein treatment increased SP/NK1R expression in mouse pancreatic acinar cells, but the effect of SP treatment was not evaluated.	Ceruletide	27-36	tachykinin 1	Mus musculus	57-59
22040127-3	2012	Previously, we showed that caerulein treatment increased SP/NK1R expression in mouse pancreatic acinar cells, but the effect of SP treatment was not evaluated.	Ceruletide	27-36	tachykinin receptor 1	Mus musculus	60-64
22374261-8	2012	Caerulein administration increased leukocyte and platelet interactions in the pancreatic microvasculature, increased tissue damage and expression of P-selectin mRNA in the pancreas as well as platelet-neutrophil complexes in the circulation.	Ceruletide	0-9	selectin, platelet	Mus musculus	149-159
22374261-10	2012	Interestingly, depletion of platelets significantly decreased caerulein-induced gene expression of P-selectin in the pancreas.	Ceruletide	62-71	selectin, platelet	Mus musculus	99-109
22685683-12	2012	Subsequent caerulein stimulation increased TLR4, Bcl-2, and caspases, but diminished HSP60 and Bax proteins in pancreatic acinar cells.	Ceruletide	11-20	toll-like receptor 4	Rattus norvegicus	43-47
22280800-11	2012	The effects of cerulein and ethanol on levels of IL-6 and procollagen I are suppressed by the PTH1R antagonist, PTHrP (7-34).	Ceruletide	15-23	parathyroid hormone 1 receptor	Rattus norvegicus	94-99
22280800-11	2012	The effects of cerulein and ethanol on levels of IL-6 and procollagen I are suppressed by the PTH1R antagonist, PTHrP (7-34).	Ceruletide	15-23	parathyroid hormone-like hormone	Rattus norvegicus	112-117
22076497-6	2012	In addition, in cerulein-treated rats, sesamol inhibited serum amylase and lipase levels, pancreatic edema, and lipid peroxidation, but it increased pancreatic glutathione and nitric oxide levels.	Ceruletide	16-24	lipase G, endothelial type	Rattus norvegicus	75-81
22280800-11	2012	The effects of cerulein and ethanol on levels of IL-6 and procollagen I are suppressed by the PTH1R antagonist, PTHrP (7-34).	Ceruletide	15-23	interleukin 6	Rattus norvegicus	49-53
22281291-0	2012	Recombinant human interleukin-1 receptor antagonist (rhIL-1Ra) attenuates caerulein-induced chronic pancreatitis in mice.	Ceruletide	74-83	interleukin 1 receptor antagonist	Homo sapiens	18-51
22281291-3	2012	After finding a connection between interleukin-1beta (IL-1beta) and interleukin-1 receptor antagonist (IL-1Ra) in caerulein-induced chronic pancreatitis, we assumed that recombinant human IL-1Ra (rhIL-1Ra), the natural antagonist of IL-1beta, might have a protective role in chronic pancreatitis in mice.	Ceruletide	114-123	interleukin 1 beta	Homo sapiens	54-62
22281291-3	2012	After finding a connection between interleukin-1beta (IL-1beta) and interleukin-1 receptor antagonist (IL-1Ra) in caerulein-induced chronic pancreatitis, we assumed that recombinant human IL-1Ra (rhIL-1Ra), the natural antagonist of IL-1beta, might have a protective role in chronic pancreatitis in mice.	Ceruletide	114-123	interleukin 1 receptor antagonist	Homo sapiens	68-101
22281291-3	2012	After finding a connection between interleukin-1beta (IL-1beta) and interleukin-1 receptor antagonist (IL-1Ra) in caerulein-induced chronic pancreatitis, we assumed that recombinant human IL-1Ra (rhIL-1Ra), the natural antagonist of IL-1beta, might have a protective role in chronic pancreatitis in mice.	Ceruletide	114-123	interleukin 1 receptor antagonist	Homo sapiens	103-109
22685683-12	2012	Subsequent caerulein stimulation increased TLR4, Bcl-2, and caspases, but diminished HSP60 and Bax proteins in pancreatic acinar cells.	Ceruletide	11-20	BCL2, apoptosis regulator	Rattus norvegicus	49-54
22685683-12	2012	Subsequent caerulein stimulation increased TLR4, Bcl-2, and caspases, but diminished HSP60 and Bax proteins in pancreatic acinar cells.	Ceruletide	11-20	caspase 9	Rattus norvegicus	60-68
22685683-12	2012	Subsequent caerulein stimulation increased TLR4, Bcl-2, and caspases, but diminished HSP60 and Bax proteins in pancreatic acinar cells.	Ceruletide	11-20	heat shock protein family D (Hsp60) member 1	Rattus norvegicus	85-90
22685683-12	2012	Subsequent caerulein stimulation increased TLR4, Bcl-2, and caspases, but diminished HSP60 and Bax proteins in pancreatic acinar cells.	Ceruletide	11-20	BCL2 associated X, apoptosis regulator	Rattus norvegicus	95-98
22792201-0	2012	Hsp72 overexpression accelerates the recovery from caerulein-induced pancreatitis.	Ceruletide	51-60	heat shock protein 1A	Mus musculus	0-5
22792201-7	2012	In both models, elevated Hsp72 did not protect from development of acute pancreatitis and the pancreatitis-associated lung injury, but accelerated recovery from caerulein-induced tissue injury (lower lipase levels, edema, inflammation and necrosis 36 h after caerulein administration).	Ceruletide	161-170	heat shock protein 1A	Mus musculus	25-30
22792201-7	2012	In both models, elevated Hsp72 did not protect from development of acute pancreatitis and the pancreatitis-associated lung injury, but accelerated recovery from caerulein-induced tissue injury (lower lipase levels, edema, inflammation and necrosis 36 h after caerulein administration).	Ceruletide	259-268	heat shock protein 1A	Mus musculus	25-30
22792201-8	2012	The observed protective function of Hsp72 in caerulein-induced pancreatitis is likely due to an attenuated NF-kappaB signalling.	Ceruletide	45-54	heat shock protein 1A	Mus musculus	36-41
22013111-10	2011	Our results suggest that NEP is anti-inflammatory in caerulein-induced AP.	Ceruletide	53-62	membrane metallo endopeptidase	Mus musculus	25-28
21968137-4	2011	It has been reported that CGRP(8-37), an antagonist of the CGRP receptor, could reverse the protective effect of leptin on rats with CIP (caerulein-induced pancreatitis).	Ceruletide	138-147	calcitonin-related polypeptide alpha	Rattus norvegicus	26-30
21968137-4	2011	It has been reported that CGRP(8-37), an antagonist of the CGRP receptor, could reverse the protective effect of leptin on rats with CIP (caerulein-induced pancreatitis).	Ceruletide	138-147	calcitonin-related polypeptide alpha	Rattus norvegicus	59-63
21968137-4	2011	It has been reported that CGRP(8-37), an antagonist of the CGRP receptor, could reverse the protective effect of leptin on rats with CIP (caerulein-induced pancreatitis).	Ceruletide	138-147	leptin	Rattus norvegicus	113-119
22013111-0	2011	The role of neutral endopeptidase in caerulein-induced acute pancreatitis.	Ceruletide	37-46	membrane metallo endopeptidase	Mus musculus	12-33
22013111-11	2011	Acute inhibition of NEP contributes to increased SP levels in caerulein-induced AP, which leads to augmented inflammatory responses in the pancreas and associated lung injury.	Ceruletide	62-71	membrane metallo endopeptidase	Mus musculus	20-23
22013111-5	2011	Male BALB/c mice (20-25 g) subjected to 3-10 hourly injections of caerulein (50 mug/kg) exhibited reduced NEP activity and protein expression in the pancreas and lungs.	Ceruletide	66-75	membrane metallo endopeptidase	Mus musculus	106-109
22013111-11	2011	Acute inhibition of NEP contributes to increased SP levels in caerulein-induced AP, which leads to augmented inflammatory responses in the pancreas and associated lung injury.	Ceruletide	62-71	tachykinin 1	Mus musculus	49-51
21778463-8	2011	Furthermore, TUDCA prevented caerulein-induced BiP upregulation, reduced XBP-1 splicing, and caspase 12 and 3 activation.	Ceruletide	29-38	heat shock protein family A (Hsp70) member 5	Rattus norvegicus	47-50
21778463-8	2011	Furthermore, TUDCA prevented caerulein-induced BiP upregulation, reduced XBP-1 splicing, and caspase 12 and 3 activation.	Ceruletide	29-38	X-box binding protein 1	Rattus norvegicus	73-78
21484151-8	2011	Our results showed that cerulein induced IL-6 expression in a time-dependent manner.	Ceruletide	24-32	interleukin 6	Homo sapiens	41-45
20973912-9	2011	Inhibition of PKC-alpha or PKC-delta also affected caerulein-induced transcription factor activation, as represented by nuclear factor-kappaB and AP-1 DNA-binding activity.	Ceruletide	51-60	protein kinase C, alpha	Mus musculus	14-23
20973912-9	2011	Inhibition of PKC-alpha or PKC-delta also affected caerulein-induced transcription factor activation, as represented by nuclear factor-kappaB and AP-1 DNA-binding activity.	Ceruletide	51-60	protein kinase C, delta	Mus musculus	27-36
20973912-10	2011	The findings in this study suggested that PKC is upstream of the mitogen-activated protein kinases and transcription factors, which then lead to the up-regulation of SP/NK1R expression in caerulein-treated mouse pancreatic acinar cells.	Ceruletide	188-197	protein kinase C, alpha	Mus musculus	42-45
20973912-10	2011	The findings in this study suggested that PKC is upstream of the mitogen-activated protein kinases and transcription factors, which then lead to the up-regulation of SP/NK1R expression in caerulein-treated mouse pancreatic acinar cells.	Ceruletide	188-197	tachykinin receptor 1	Mus musculus	169-173
21509626-10	2011	Cerulein-induced activation of Jak2/Stat3 and increases in MAPKs and TGF-beta1 levels were inhibited in the cells transfected with AS ODN for p22(phox) and p47(phox) compared to S ODN controls.	Ceruletide	0-8	Janus kinase 2	Rattus norvegicus	31-35
21509626-10	2011	Cerulein-induced activation of Jak2/Stat3 and increases in MAPKs and TGF-beta1 levels were inhibited in the cells transfected with AS ODN for p22(phox) and p47(phox) compared to S ODN controls.	Ceruletide	0-8	signal transducer and activator of transcription 3	Rattus norvegicus	36-41
21509626-10	2011	Cerulein-induced activation of Jak2/Stat3 and increases in MAPKs and TGF-beta1 levels were inhibited in the cells transfected with AS ODN for p22(phox) and p47(phox) compared to S ODN controls.	Ceruletide	0-8	transforming growth factor, beta 1	Rattus norvegicus	69-78
21509626-10	2011	Cerulein-induced activation of Jak2/Stat3 and increases in MAPKs and TGF-beta1 levels were inhibited in the cells transfected with AS ODN for p22(phox) and p47(phox) compared to S ODN controls.	Ceruletide	0-8	NSFL1 cofactor	Rattus norvegicus	156-159
21484880-3	2011	After repeated injections of caerulein (50 mug/kg and 6 times), mice showed edema in the pancreas, and blood concentrations of pancreatic enzymes (amylase and lipase) were clearly elevated.	Ceruletide	29-38	lipase, endothelial	Mus musculus	159-165
21419763-7	2011	Caerulein and taurocholate challenge caused a clear-cut pancreatic damage characterized by increased acinar cell necrosis, neutrophil infiltration, focal hemorrhage, edema formation as well as increased levels of serum amylase and MIP-2 in the pancreas and lung MPO and histological damage.	Ceruletide	0-9	chemokine (C-X-C motif) ligand 2	Mus musculus	231-236
21419763-7	2011	Caerulein and taurocholate challenge caused a clear-cut pancreatic damage characterized by increased acinar cell necrosis, neutrophil infiltration, focal hemorrhage, edema formation as well as increased levels of serum amylase and MIP-2 in the pancreas and lung MPO and histological damage.	Ceruletide	0-9	myeloperoxidase	Mus musculus	262-265
21419763-8	2011	Notably, CD40L gene-deficient animals exhibited a similar phenotype as wild-type mice after challenge with caerulein and taurocholate.	Ceruletide	107-116	CD40 ligand	Mus musculus	9-14
21801698-4	2011	METHODS: Acute pancreatitis was induced in CD11c.DTR mice using caerulein or L-arginine; DCs were depleted by administration of diphtheria toxin.	Ceruletide	64-73	integrin alpha X	Mus musculus	43-48
20973912-0	2011	Role of protein kinase C in caerulein induced expression of substance P and neurokinin-1-receptors in murine pancreatic acinar cells.	Ceruletide	28-37	tachykinin 1	Mus musculus	60-71
20973912-4	2011	In this study, we showed the role of protein kinase C (PKC) in caerulein-induced SP and NK1R production in isolated mouse pancreatic acinar cells.	Ceruletide	63-72	protein kinase C, alpha	Mus musculus	55-58
20973912-4	2011	In this study, we showed the role of protein kinase C (PKC) in caerulein-induced SP and NK1R production in isolated mouse pancreatic acinar cells.	Ceruletide	63-72	tachykinin receptor 1	Mus musculus	88-92
20973912-5	2011	Caerulein (10(-7)  M) stimulation rapidly activated the conventional PKC-alpha and novel PKC-delta as observed by the phosphorylation of these molecules.	Ceruletide	0-9	protein kinase C, alpha	Mus musculus	69-78
20973912-5	2011	Caerulein (10(-7)  M) stimulation rapidly activated the conventional PKC-alpha and novel PKC-delta as observed by the phosphorylation of these molecules.	Ceruletide	0-9	protein kinase C, delta	Mus musculus	89-98
20973912-7	2011	At these concentrations used, PKC-alpha and PKC-delta inhibition reversed the caerulein-induced up-regulation of SP and NK1R, indicating an important role of PKCs in the modulation of SP and NK1R expression.	Ceruletide	78-87	protein kinase C, alpha	Mus musculus	30-39
20973912-7	2011	At these concentrations used, PKC-alpha and PKC-delta inhibition reversed the caerulein-induced up-regulation of SP and NK1R, indicating an important role of PKCs in the modulation of SP and NK1R expression.	Ceruletide	78-87	protein kinase C, delta	Mus musculus	44-53
20973912-7	2011	At these concentrations used, PKC-alpha and PKC-delta inhibition reversed the caerulein-induced up-regulation of SP and NK1R, indicating an important role of PKCs in the modulation of SP and NK1R expression.	Ceruletide	78-87	tachykinin receptor 1	Mus musculus	120-124
20973912-7	2011	At these concentrations used, PKC-alpha and PKC-delta inhibition reversed the caerulein-induced up-regulation of SP and NK1R, indicating an important role of PKCs in the modulation of SP and NK1R expression.	Ceruletide	78-87	tachykinin receptor 1	Mus musculus	191-195
21484151-10	2011	Lycopene inhibited the cerulein-induced increase in intracellular ROS, NF-kappaB activation, and IL-6 expression in pancreatic acinar cells in a dose-dependent manner.	Ceruletide	23-31	nuclear factor kappa B subunit 1	Homo sapiens	71-80
21484151-10	2011	Lycopene inhibited the cerulein-induced increase in intracellular ROS, NF-kappaB activation, and IL-6 expression in pancreatic acinar cells in a dose-dependent manner.	Ceruletide	23-31	interleukin 6	Homo sapiens	97-101
20959124-8	2011	Our results demonstrated that treatment with caerulein, a cholecystokinin receptor agonist, induced hypersecretion and NFkappaB activation, as demonstrated by elevated amylase secretion and degradation of inhibitor of NFkappaB (IkappaBbeta).	Ceruletide	45-54	NFKB inhibitor beta	Rattus norvegicus	228-239
20959124-9	2011	Angiotensin II, either alone or in combination with caerulein, augmented IkappaBbeta degradation.	Ceruletide	52-61	NFKB inhibitor beta	Rattus norvegicus	73-84
20959124-12	2011	Preliminary data further demonstrated that angiotensin II could extend caerulein-induced ERK1/2 activation in acinar cells.	Ceruletide	71-80	angiotensinogen	Rattus norvegicus	43-57
20959124-12	2011	Preliminary data further demonstrated that angiotensin II could extend caerulein-induced ERK1/2 activation in acinar cells.	Ceruletide	71-80	mitogen activated protein kinase 3	Rattus norvegicus	89-95
20959124-14	2011	In contrast, stimulation of the AT2 receptor protects against caerulein-induced NFkappaB activation.	Ceruletide	62-71	angiotensin II receptor, type 2	Rattus norvegicus	32-35
20110462-7	2010	We have shown that targeted transgenic expression of the rat Psti1 gene to acinar cells in mice [TgN(Psti1)] protects mice against caerulein-induced pancreatitis.	Ceruletide	131-140	serine peptidase inhibitor, Kazal type 1	Rattus norvegicus	61-66
20882560-11	2011	Platelet depletion abolished caerulein-induced MIP-2 generation in the pancreas and circulation.	Ceruletide	29-38	chemokine (C-X-C motif) ligand 2	Mus musculus	47-52
20211170-6	2010	Inhibition of SFKs impaired H(2)S-induced NF-kappaB activity and ICAM-1 expression in caerulein treated acinar cells.	Ceruletide	86-95	intercellular adhesion molecule 1	Homo sapiens	65-71
20567937-1	2011	In our previous study, we reported that cerulein-induced acute pancreatitis is aggravated in pancreatic beta-cell-specific pituitary adenylate cyclase-activating polypeptide (PACAP) transgenic mice, showing that an increase in pancreatic PACAP is a risk factor for progression of acute pancreatitis.	Ceruletide	40-48	adenylate cyclase activating polypeptide 1	Mus musculus	123-173
20567937-1	2011	In our previous study, we reported that cerulein-induced acute pancreatitis is aggravated in pancreatic beta-cell-specific pituitary adenylate cyclase-activating polypeptide (PACAP) transgenic mice, showing that an increase in pancreatic PACAP is a risk factor for progression of acute pancreatitis.	Ceruletide	40-48	adenylate cyclase activating polypeptide 1	Mus musculus	175-180
20567937-1	2011	In our previous study, we reported that cerulein-induced acute pancreatitis is aggravated in pancreatic beta-cell-specific pituitary adenylate cyclase-activating polypeptide (PACAP) transgenic mice, showing that an increase in pancreatic PACAP is a risk factor for progression of acute pancreatitis.	Ceruletide	40-48	adenylate cyclase activating polypeptide 1	Mus musculus	238-243
20923958-10	2010	Exenatide attenuated CRN-induced release of amylase and lipase in normal rats and ob/ob mice but did not modify the response to ST infusion.	Ceruletide	21-24	lipase G, endothelial type	Rattus norvegicus	56-62
20582580-0	2010	PKC delta mediates pro-inflammatory responses in a mouse model of caerulein-induced acute pancreatitis.	Ceruletide	66-75	protein kinase C, delta	Mus musculus	0-9
20110462-7	2010	We have shown that targeted transgenic expression of the rat Psti1 gene to acinar cells in mice [TgN(Psti1)] protects mice against caerulein-induced pancreatitis.	Ceruletide	131-140	serine peptidase inhibitor, Kazal type 1	Rattus norvegicus	101-106
19959964-4	2010	Cerulein (Cae), a CCK-1R agonist, and pentagastrin, a CCK-2R agonist, dose-dependently increased SS release, 3-fold at 1 mumol/L Cae, 2.5-fold at 10 mumol/L pentagastrin, with occupation of both CCKRs confirmed by L-364,178 and L-365,260 inhibition of CCK receptors 1 and 2.	Ceruletide	0-8	cholecystokinin A receptor	Rattus norvegicus	18-24
20007404-0	2010	Extracellular signal-regulated kinase 1/2 and c-Jun NH2-terminal kinase, through nuclear factor-kappaB and activator protein-1, contribute to caerulein-induced expression of substance P and neurokinin-1 receptors in pancreatic acinar cells.	Ceruletide	142-151	mitogen-activated protein kinase 3	Mus musculus	0-41
20007404-0	2010	Extracellular signal-regulated kinase 1/2 and c-Jun NH2-terminal kinase, through nuclear factor-kappaB and activator protein-1, contribute to caerulein-induced expression of substance P and neurokinin-1 receptors in pancreatic acinar cells.	Ceruletide	142-151	jun proto-oncogene	Mus musculus	107-126
20007404-0	2010	Extracellular signal-regulated kinase 1/2 and c-Jun NH2-terminal kinase, through nuclear factor-kappaB and activator protein-1, contribute to caerulein-induced expression of substance P and neurokinin-1 receptors in pancreatic acinar cells.	Ceruletide	142-151	tachykinin 1	Mus musculus	174-185
20007404-9	2010	Taken together, our results suggest that supraphysiological concentrations of caerulein up-regulate the expression of SP and NK1R in pancreatic acinar cells, and the signaling molecules that are involved in this up-regulation include ERK1/2, JNK, NF-kappaB, and AP-1.	Ceruletide	78-87	tachykinin receptor 1	Mus musculus	125-129
20007404-9	2010	Taken together, our results suggest that supraphysiological concentrations of caerulein up-regulate the expression of SP and NK1R in pancreatic acinar cells, and the signaling molecules that are involved in this up-regulation include ERK1/2, JNK, NF-kappaB, and AP-1.	Ceruletide	78-87	mitogen-activated protein kinase 3	Mus musculus	234-240
20007404-9	2010	Taken together, our results suggest that supraphysiological concentrations of caerulein up-regulate the expression of SP and NK1R in pancreatic acinar cells, and the signaling molecules that are involved in this up-regulation include ERK1/2, JNK, NF-kappaB, and AP-1.	Ceruletide	78-87	mitogen-activated protein kinase 8	Mus musculus	242-245
20007404-9	2010	Taken together, our results suggest that supraphysiological concentrations of caerulein up-regulate the expression of SP and NK1R in pancreatic acinar cells, and the signaling molecules that are involved in this up-regulation include ERK1/2, JNK, NF-kappaB, and AP-1.	Ceruletide	78-87	jun proto-oncogene	Mus musculus	262-266
19959964-4	2010	Cerulein (Cae), a CCK-1R agonist, and pentagastrin, a CCK-2R agonist, dose-dependently increased SS release, 3-fold at 1 mumol/L Cae, 2.5-fold at 10 mumol/L pentagastrin, with occupation of both CCKRs confirmed by L-364,178 and L-365,260 inhibition of CCK receptors 1 and 2.	Ceruletide	0-8	cholecystokinin	Rattus norvegicus	18-21
20026013-5	2010	Caerulein-exposed pancreatic acinar cells were immunohistochemically stained for claudin 4, cadherin 1, integrin beta 4, heat shock protein b1, and Serpinb6a.	Ceruletide	0-9	claudin 4	Mus musculus	81-90
19900448-6	2010	In vitro, genetic deletion of Gpbar1 is associated with markedly reduced generation of pathological calcium transients, intracellular activation of digestive zymogens, and cell injury when these responses are induced by exposure to TLCS, but not when they are induced by exposure to caerulein.	Ceruletide	283-292	G protein-coupled bile acid receptor 1	Mus musculus	30-36
19944731-0	2010	The combination of neurokinin-1 and galanin receptor antagonists ameliorates caerulein-induced acute pancreatitis in mice.	Ceruletide	77-86	tachykinin 1	Mus musculus	19-31
19944731-0	2010	The combination of neurokinin-1 and galanin receptor antagonists ameliorates caerulein-induced acute pancreatitis in mice.	Ceruletide	77-86	galanin and GMAP prepropeptide	Mus musculus	36-43
20026013-5	2010	Caerulein-exposed pancreatic acinar cells were immunohistochemically stained for claudin 4, cadherin 1, integrin beta 4, heat shock protein b1, and Serpinb6a.	Ceruletide	0-9	cadherin 1	Mus musculus	92-102
20026013-5	2010	Caerulein-exposed pancreatic acinar cells were immunohistochemically stained for claudin 4, cadherin 1, integrin beta 4, heat shock protein b1, and Serpinb6a.	Ceruletide	0-9	integrin beta 4	Mus musculus	104-119
19726746-0	2009	Pancreas-specific aquaporin 12 null mice showed increased susceptibility to caerulein-induced acute pancreatitis.	Ceruletide	76-85	aquaporin 12	Mus musculus	18-30
19904222-6	2010	RESULTS: Cerulein administration to nontransgenic mice produced histological evidence of inflammatory infiltrate, glandular atrophy, and parenchymal fibrosis and increased collagen production, MPO activity, and collagen I and fibronectin mRNA levels.	Ceruletide	9-17	myeloperoxidase	Mus musculus	193-196
19904222-6	2010	RESULTS: Cerulein administration to nontransgenic mice produced histological evidence of inflammatory infiltrate, glandular atrophy, and parenchymal fibrosis and increased collagen production, MPO activity, and collagen I and fibronectin mRNA levels.	Ceruletide	9-17	fibronectin 1	Mus musculus	211-237
19779018-1	2009	Galanin inhibits pancreatic amylase secretion from mouse lobules induced by physiological concentrations of caerulein via an insulin-dependent mechanism.	Ceruletide	108-117	galanin and GMAP prepropeptide	Mus musculus	0-7
19779018-2	2009	We aimed to determine the effect and elucidate the mechanism of action of exogenous galanin on pancreatic amylase secretion induced by supramaximal concentrations of caerulein.	Ceruletide	166-175	galanin and GMAP prepropeptide	Mus musculus	84-91
19201768-12	2009	Either the activity or protein expression of pancreatic CSE increased after the development of caerulein-induced pancreatitis in mice.	Ceruletide	95-104	cystathionase (cystathionine gamma-lyase)	Mus musculus	56-59
19201771-8	2009	RESULTS: It was found that administering caerulein and L-arginine to wild-type mice resulted in acute pancreatitis (as assessed by hyperamylasaemia, oedema, increased pancreatic MPO activity, and pancreatic necrosis) and associated lung injury.	Ceruletide	41-50	myeloperoxidase	Mus musculus	178-181
18690472-9	2009	RESULTS: Perfusion of isolated rat pancreas with supramaximal concentrations of caerulein or retrograde injection of taurocholate (3.5%) resulted in acinar cell injury indicated by elevated levels of amylase and lipase into the perfusate and into the transudation fluid.	Ceruletide	80-89	lipase G, endothelial type	Rattus norvegicus	212-218
19258518-9	2009	We found that H(2)S-mediated activation of PI3K in caerulein-treated acinar cells correlated with the down-regulation of extracellular signal-regulated kinase 1/2 phosphorylation, whereas phosphorylation of p38 and c-Jun NH(2)-terminal kinase and mitogen-activated protein kinases was unchanged.	Ceruletide	51-60	mitogen-activated protein kinase 3	Mus musculus	121-162
18688721-7	2009	MDA levels, CAT, SOD, GPx, and GSH activities were significantly altered (P < 0.05, P < 0.005) in the caerulein group and indicated increased oxidative stress.	Ceruletide	108-117	catalase	Rattus norvegicus	12-15
18688721-9	2009	Caerulein administration resulted in significant increase (P < 0.05) in amylase and lipase levels; pentoxifylline reduced the levels of these enzymes.	Ceruletide	0-9	lipase G, endothelial type	Rattus norvegicus	87-93
18755806-6	2008	Caerulein treatment activated extracellular signal-regulated kinase (ERK) and c-Jun NH(2)-terminal kinase (JNK) within 15 min and maintained phosphorylation of ERK and JNK for 2 h in the rat pancreas.	Ceruletide	0-9	Eph receptor B1	Rattus norvegicus	30-67
20011057-5	2009	Occupation of the CCK-1 receptors by caerulein, a CCK analog, led to inhibition of cell proliferation, an effect prevented by a specific CCK-1 receptor antagonist.	Ceruletide	37-46	cholecystokinin	Homo sapiens	18-21
20011057-5	2009	Occupation of the CCK-1 receptors by caerulein, a CCK analog, led to inhibition of cell proliferation, an effect prevented by a specific CCK-1 receptor antagonist.	Ceruletide	37-46	cholecystokinin	Homo sapiens	50-53
20011057-5	2009	Occupation of the CCK-1 receptors by caerulein, a CCK analog, led to inhibition of cell proliferation, an effect prevented by a specific CCK-1 receptor antagonist.	Ceruletide	37-46	cholecystokinin	Homo sapiens	50-53
18755806-7	2008	Although PAR2 activation by the pretreatment with PAR2-activating peptide (AP) itself increased ERK phosphorylation in rat pancreas, the same treatment remarkably decreased caerulein-induced activation of ERK and JNK principally by accelerating their dephosphorylation.	Ceruletide	173-182	F2R like trypsin receptor 1	Rattus norvegicus	9-13
18755806-6	2008	Caerulein treatment activated extracellular signal-regulated kinase (ERK) and c-Jun NH(2)-terminal kinase (JNK) within 15 min and maintained phosphorylation of ERK and JNK for 2 h in the rat pancreas.	Ceruletide	0-9	Eph receptor B1	Rattus norvegicus	69-72
18755806-7	2008	Although PAR2 activation by the pretreatment with PAR2-activating peptide (AP) itself increased ERK phosphorylation in rat pancreas, the same treatment remarkably decreased caerulein-induced activation of ERK and JNK principally by accelerating their dephosphorylation.	Ceruletide	173-182	F2R like trypsin receptor 1	Rattus norvegicus	50-54
18755806-7	2008	Although PAR2 activation by the pretreatment with PAR2-activating peptide (AP) itself increased ERK phosphorylation in rat pancreas, the same treatment remarkably decreased caerulein-induced activation of ERK and JNK principally by accelerating their dephosphorylation.	Ceruletide	173-182	Eph receptor B1	Rattus norvegicus	205-208
18755806-6	2008	Caerulein treatment activated extracellular signal-regulated kinase (ERK) and c-Jun NH(2)-terminal kinase (JNK) within 15 min and maintained phosphorylation of ERK and JNK for 2 h in the rat pancreas.	Ceruletide	0-9	mitogen-activated protein kinase 8	Rattus norvegicus	78-105
18755806-7	2008	Although PAR2 activation by the pretreatment with PAR2-activating peptide (AP) itself increased ERK phosphorylation in rat pancreas, the same treatment remarkably decreased caerulein-induced activation of ERK and JNK principally by accelerating their dephosphorylation.	Ceruletide	173-182	mitogen-activated protein kinase 8	Rattus norvegicus	213-216
18755806-6	2008	Caerulein treatment activated extracellular signal-regulated kinase (ERK) and c-Jun NH(2)-terminal kinase (JNK) within 15 min and maintained phosphorylation of ERK and JNK for 2 h in the rat pancreas.	Ceruletide	0-9	mitogen-activated protein kinase 8	Rattus norvegicus	107-110
18755806-8	2008	Inhibition of ERK and JNK phosphorylation by the pretreatment with MAP/ERK kinase (MEK) or JNK inhibitors decreased caerulein-induced pancreatic damage that was similar to the effect induced by PAR2-AP.	Ceruletide	116-125	Eph receptor B1	Rattus norvegicus	14-17
18755806-8	2008	Inhibition of ERK and JNK phosphorylation by the pretreatment with MAP/ERK kinase (MEK) or JNK inhibitors decreased caerulein-induced pancreatic damage that was similar to the effect induced by PAR2-AP.	Ceruletide	116-125	mitogen-activated protein kinase 8	Rattus norvegicus	22-25
18755806-8	2008	Inhibition of ERK and JNK phosphorylation by the pretreatment with MAP/ERK kinase (MEK) or JNK inhibitors decreased caerulein-induced pancreatic damage that was similar to the effect induced by PAR2-AP.	Ceruletide	116-125	Eph receptor B1	Rattus norvegicus	71-74
18755806-8	2008	Inhibition of ERK and JNK phosphorylation by the pretreatment with MAP/ERK kinase (MEK) or JNK inhibitors decreased caerulein-induced pancreatic damage that was similar to the effect induced by PAR2-AP.	Ceruletide	116-125	mitogen-activated protein kinase 8	Rattus norvegicus	91-94
18755806-10	2008	The above results imply that downregulation of MAP kinase signaling by MKP induction is a key mechanism involved in the protective effects of PAR2 activation on caerulein-induced intrapancreatic damage.	Ceruletide	161-170	F2R like trypsin receptor 1	Rattus norvegicus	142-146
18755806-6	2008	Caerulein treatment activated extracellular signal-regulated kinase (ERK) and c-Jun NH(2)-terminal kinase (JNK) within 15 min and maintained phosphorylation of ERK and JNK for 2 h in the rat pancreas.	Ceruletide	0-9	Eph receptor B1	Rattus norvegicus	160-163
18755806-6	2008	Caerulein treatment activated extracellular signal-regulated kinase (ERK) and c-Jun NH(2)-terminal kinase (JNK) within 15 min and maintained phosphorylation of ERK and JNK for 2 h in the rat pancreas.	Ceruletide	0-9	mitogen-activated protein kinase 8	Rattus norvegicus	168-171
18985809-5	2008	Three hours later, the mice were given an intraperitoneal injection of cerulein (50 microg/kg), a stable cholecystokinin (CCK) analogue, every hour for a total of 6 h as described previously.	Ceruletide	71-79	cholecystokinin	Mus musculus	105-120
18695645-7	2008	KEY RESULTS: Haemorrhagic lesions induced by icatibant in caerulein-induced pancreatitis were associated with a reduction in alpha(1)-AT and alpha(2)-M in the pancreas and a concomitant augmentation of tissue kallikrein (TK) activity.	Ceruletide	58-67	alpha-2-macroglobulin	Rattus norvegicus	141-151
18985809-5	2008	Three hours later, the mice were given an intraperitoneal injection of cerulein (50 microg/kg), a stable cholecystokinin (CCK) analogue, every hour for a total of 6 h as described previously.	Ceruletide	71-79	cholecystokinin	Mus musculus	122-125
18408139-0	2008	Chondroitin-4-sulphate reduced oxidative injury in caerulein-induced pancreatitis in mice: the involvement of NF-kappaB translocation and apoptosis activation.	Ceruletide	51-60	carbohydrate sulfotransferase 11	Mus musculus	0-13
18511423-7	2008	In vitro studies using freshly prepared pancreatic acini show that genetic deletion of PAR2 reduces bile salt-induced pathological calcium transients, acinar cell injury, and activation of c-Jun N-terminal kinase, whereas genetic deletion of PAR2 has the opposite or no effect on these pancreatitis-related events when they are elicited, in vitro, by caerulein stimulation.	Ceruletide	351-360	F2R like trypsin receptor 1	Homo sapiens	87-91
18498355-8	2008	In addition, the expansion of Eppk1-positive cells occurs in a caerulein-induced acute pancreatitis, an acinar cell regeneration model.	Ceruletide	63-72	epiplakin 1	Mus musculus	30-35
18408139-2	2008	Since reactive oxygen species (ROS) are involved in acute pancreatitis, we studied whether the administration of chondroitin-4-sulphate (C4S), in addition to its antioxidant activity, was able to modulate NF-kappaB and caspase activation in an experimental model of caerulein-induced acute pancreatitis in mice.	Ceruletide	266-275	carbohydrate sulfotransferase 11	Mus musculus	113-126
18408139-2	2008	Since reactive oxygen species (ROS) are involved in acute pancreatitis, we studied whether the administration of chondroitin-4-sulphate (C4S), in addition to its antioxidant activity, was able to modulate NF-kappaB and caspase activation in an experimental model of caerulein-induced acute pancreatitis in mice.	Ceruletide	266-275	carbohydrate sulfotransferase 11	Mus musculus	137-140
18419599-0	2008	Pro-inflammatory effects of hydrogen sulphide on substance P in caerulein-induced acute pancreatitis.	Ceruletide	64-73	tachykinin 1	Mus musculus	49-60
18477679-5	2008	However, Smad6 transgenic mice reacted to hyperstimulation by caerulein injection or a diet containing 0.5% ethionine.	Ceruletide	62-71	SMAD family member 6	Mus musculus	9-14
18477679-10	2008	Pancreatic SNAP25 protein levels in transgenic mice were decreased after caerulein-induced pancreatitis.	Ceruletide	73-82	synaptosomal-associated protein 25	Mus musculus	11-17
18035585-3	2008	We previously showed that cerulein induced IL-1beta expression through the Janus kinase (JAK) 2/signal transducer and activator of transcription (STAT) 3 pathway in pancreatic acinar cells.	Ceruletide	26-34	interleukin 1 beta	Rattus norvegicus	43-51
18035585-3	2008	We previously showed that cerulein induced IL-1beta expression through the Janus kinase (JAK) 2/signal transducer and activator of transcription (STAT) 3 pathway in pancreatic acinar cells.	Ceruletide	26-34	Janus kinase 2	Rattus norvegicus	75-95
18035585-3	2008	We previously showed that cerulein induced IL-1beta expression through the Janus kinase (JAK) 2/signal transducer and activator of transcription (STAT) 3 pathway in pancreatic acinar cells.	Ceruletide	26-34	signal transducer and activator of transcription 3	Rattus norvegicus	146-150
17901594-2	2007	In spite of this observations the effects of LPS and caerulein on pro-apoptotic HSP60 and Bax protein expression in the pancreatic acinar cells has not been examined yet.	Ceruletide	53-62	heat shock protein family D (Hsp60) member 1	Rattus norvegicus	80-85
18378183-8	2008	In the cells treated with cerulein as a physiological stimulus to activate NF-kappaB p65, nuclear translocation of Ku70 increased through NF-kappaB p65-mediated decrease of Hsc70 level.	Ceruletide	26-34	synaptotagmin 1	Rattus norvegicus	85-88
18378183-8	2008	In the cells treated with cerulein as a physiological stimulus to activate NF-kappaB p65, nuclear translocation of Ku70 increased through NF-kappaB p65-mediated decrease of Hsc70 level.	Ceruletide	26-34	X-ray repair cross complementing 6	Rattus norvegicus	115-119
18378183-8	2008	In the cells treated with cerulein as a physiological stimulus to activate NF-kappaB p65, nuclear translocation of Ku70 increased through NF-kappaB p65-mediated decrease of Hsc70 level.	Ceruletide	26-34	synaptotagmin 1	Rattus norvegicus	148-151
18378183-8	2008	In the cells treated with cerulein as a physiological stimulus to activate NF-kappaB p65, nuclear translocation of Ku70 increased through NF-kappaB p65-mediated decrease of Hsc70 level.	Ceruletide	26-34	heat shock protein family A (Hsp70) member 8	Rattus norvegicus	173-178
17901594-2	2007	In spite of this observations the effects of LPS and caerulein on pro-apoptotic HSP60 and Bax protein expression in the pancreatic acinar cells has not been examined yet.	Ceruletide	53-62	BCL2 associated X, apoptosis regulator	Rattus norvegicus	90-93
17901594-11	2007	Pretreatment of suckling rats with LPS (at the total doses of 25, 50 or 75 mg/kg) reversed above caerulein-induced suppression of pro-apoptotic nuclear HSP60 and mitochondrial Bax protein levels in the pancreatic acini obtained from adult rats.	Ceruletide	97-106	heat shock protein family D (Hsp60) member 1	Rattus norvegicus	152-157
17901594-11	2007	Pretreatment of suckling rats with LPS (at the total doses of 25, 50 or 75 mg/kg) reversed above caerulein-induced suppression of pro-apoptotic nuclear HSP60 and mitochondrial Bax protein levels in the pancreatic acini obtained from adult rats.	Ceruletide	97-106	BCL2 associated X, apoptosis regulator	Rattus norvegicus	176-179
17463185-0	2007	PPAR-gamma knockout in pancreatic epithelial cells abolishes the inhibitory effect of rosiglitazone on caerulein-induced acute pancreatitis.	Ceruletide	103-112	peroxisome proliferator activated receptor gamma	Mus musculus	0-10
17537724-6	2007	Mechanisms responsible for the effects of Tpl2 ablation on caerulein-induced proinflammatory events were evaluated under in vivo and in vitro conditions using the techniques of electrophoretic mobility shift assay, immunoblot analysis, and quantitative reverse transcription-PCR.	Ceruletide	59-68	mitogen-activated protein kinase kinase kinase 8	Mus musculus	42-46
17537724-8	2007	The reduction in caerulein-induced pancreatic inflammation is dependent upon Tpl2 ablation in non-myeloid cells and is associated with both in vivo and in vitro inhibition of MEK, JNK, and AP-1 activation and the expression of MCP-1, MIP-2, and interleukin-6.	Ceruletide	17-26	mitogen-activated protein kinase kinase kinase 8	Mus musculus	77-81
17537724-8	2007	The reduction in caerulein-induced pancreatic inflammation is dependent upon Tpl2 ablation in non-myeloid cells and is associated with both in vivo and in vitro inhibition of MEK, JNK, and AP-1 activation and the expression of MCP-1, MIP-2, and interleukin-6.	Ceruletide	17-26	midkine	Mus musculus	175-178
17537724-8	2007	The reduction in caerulein-induced pancreatic inflammation is dependent upon Tpl2 ablation in non-myeloid cells and is associated with both in vivo and in vitro inhibition of MEK, JNK, and AP-1 activation and the expression of MCP-1, MIP-2, and interleukin-6.	Ceruletide	17-26	mitogen-activated protein kinase 8	Mus musculus	180-183
17537724-8	2007	The reduction in caerulein-induced pancreatic inflammation is dependent upon Tpl2 ablation in non-myeloid cells and is associated with both in vivo and in vitro inhibition of MEK, JNK, and AP-1 activation and the expression of MCP-1, MIP-2, and interleukin-6.	Ceruletide	17-26	mast cell protease 1	Mus musculus	227-232
17537724-8	2007	The reduction in caerulein-induced pancreatic inflammation is dependent upon Tpl2 ablation in non-myeloid cells and is associated with both in vivo and in vitro inhibition of MEK, JNK, and AP-1 activation and the expression of MCP-1, MIP-2, and interleukin-6.	Ceruletide	17-26	chemokine (C-X-C motif) ligand 2	Mus musculus	234-239
17537724-8	2007	The reduction in caerulein-induced pancreatic inflammation is dependent upon Tpl2 ablation in non-myeloid cells and is associated with both in vivo and in vitro inhibition of MEK, JNK, and AP-1 activation and the expression of MCP-1, MIP-2, and interleukin-6.	Ceruletide	17-26	interleukin 6	Mus musculus	245-258
17513789-3	2007	Concomitantly, cerulein treatment augmented intrapancreatic gene expression of TNF-alpha, KC/CXCL1, MIP-2/CXCL2, cyclooxygenase-2 (COX-2), and IFN-gamma in WT mice.	Ceruletide	15-23	tumor necrosis factor	Mus musculus	79-88
17114298-7	2007	During pancreatitis, PAR-2 mRNA levels were upregulated in wild-type mice in response to supramaximal caerulein administration.	Ceruletide	102-111	coagulation factor II (thrombin) receptor-like 1	Mus musculus	21-26
17114298-9	2007	PAR-2 activation also reversed the inhibition of secretion observed in both the caerulein and arginine models.	Ceruletide	80-89	coagulation factor II (thrombin) receptor-like 1	Mus musculus	0-5
17513789-3	2007	Concomitantly, cerulein treatment augmented intrapancreatic gene expression of TNF-alpha, KC/CXCL1, MIP-2/CXCL2, cyclooxygenase-2 (COX-2), and IFN-gamma in WT mice.	Ceruletide	15-23	chemokine (C-X-C motif) ligand 1	Mus musculus	93-98
17513789-3	2007	Concomitantly, cerulein treatment augmented intrapancreatic gene expression of TNF-alpha, KC/CXCL1, MIP-2/CXCL2, cyclooxygenase-2 (COX-2), and IFN-gamma in WT mice.	Ceruletide	15-23	chemokine (C-X-C motif) ligand 2	Mus musculus	100-105
17513789-3	2007	Concomitantly, cerulein treatment augmented intrapancreatic gene expression of TNF-alpha, KC/CXCL1, MIP-2/CXCL2, cyclooxygenase-2 (COX-2), and IFN-gamma in WT mice.	Ceruletide	15-23	chemokine (C-X-C motif) ligand 2	Mus musculus	106-111
17513789-3	2007	Concomitantly, cerulein treatment augmented intrapancreatic gene expression of TNF-alpha, KC/CXCL1, MIP-2/CXCL2, cyclooxygenase-2 (COX-2), and IFN-gamma in WT mice.	Ceruletide	15-23	prostaglandin-endoperoxide synthase 2	Mus musculus	113-129
17513789-3	2007	Concomitantly, cerulein treatment augmented intrapancreatic gene expression of TNF-alpha, KC/CXCL1, MIP-2/CXCL2, cyclooxygenase-2 (COX-2), and IFN-gamma in WT mice.	Ceruletide	15-23	prostaglandin-endoperoxide synthase 2	Mus musculus	131-136
17513789-3	2007	Concomitantly, cerulein treatment augmented intrapancreatic gene expression of TNF-alpha, KC/CXCL1, MIP-2/CXCL2, cyclooxygenase-2 (COX-2), and IFN-gamma in WT mice.	Ceruletide	15-23	interferon gamma	Mus musculus	143-152
16934228-8	2006	As a result, cerulein induced the activation of Jak2 and Stat3 as well as IL-1beta expression, which was inhibited by the treatment of AG490 in AR42J cells.	Ceruletide	13-21	Janus kinase 2	Rattus norvegicus	48-52
17170023-0	2007	Mice lacking the transcription factor Mist1 exhibit an altered stress response and increased sensitivity to caerulein-induced pancreatitis.	Ceruletide	108-117	basic helix-loop-helix family, member a15	Mus musculus	38-43
17170023-5	2007	Following the induction of pancreatitis with caerulein, a CCK analog, we observed elevated serum amylase levels, necrosis, and tissue damage in Mist1 KO mice, indicating increased pancreatic damage.	Ceruletide	45-54	cholecystokinin	Mus musculus	58-61
17170023-5	2007	Following the induction of pancreatitis with caerulein, a CCK analog, we observed elevated serum amylase levels, necrosis, and tissue damage in Mist1 KO mice, indicating increased pancreatic damage.	Ceruletide	45-54	basic helix-loop-helix family, member a15	Mus musculus	144-149
16873893-8	2007	Either prophylactic or therapeutic treatment with a potent selective NK-1R antagonist CP-96,345 significantly suppressed caerulein-induced increase in MCP-1, MIP-1alpha, and MIP-2 expression but had no apparent effect on RANTES expression.	Ceruletide	121-130	tachykinin receptor 1	Mus musculus	69-74
16873893-8	2007	Either prophylactic or therapeutic treatment with a potent selective NK-1R antagonist CP-96,345 significantly suppressed caerulein-induced increase in MCP-1, MIP-1alpha, and MIP-2 expression but had no apparent effect on RANTES expression.	Ceruletide	121-130	chemokine (C-C motif) ligand 2	Mus musculus	151-156
16873893-8	2007	Either prophylactic or therapeutic treatment with a potent selective NK-1R antagonist CP-96,345 significantly suppressed caerulein-induced increase in MCP-1, MIP-1alpha, and MIP-2 expression but had no apparent effect on RANTES expression.	Ceruletide	121-130	chemokine (C-C motif) ligand 3	Mus musculus	158-168
16873893-8	2007	Either prophylactic or therapeutic treatment with a potent selective NK-1R antagonist CP-96,345 significantly suppressed caerulein-induced increase in MCP-1, MIP-1alpha, and MIP-2 expression but had no apparent effect on RANTES expression.	Ceruletide	121-130	chemokine (C-X-C motif) ligand 2	Mus musculus	174-179
17625947-8	2007	As a result, cerulein induced the activation of NADPH, increased production of reactive oxygen species, and apoptotic indices determined by the expression of apoptosis-inducing factor, caspase-3 activation, TUNEL staining, DNA fragmentation, and cell viability.	Ceruletide	13-21	caspase 3	Rattus norvegicus	185-194
17109890-9	2007	As compared to wild-type, STAT6-deficient mice had increased lung injury from 1 to 6 h, with full recovery by 12 h. An opposite pattern was observed in STAT4-deficient mice with mild injury seen at 1 and 6 h, and maximal injury at 12 h. MPO activity was significantly increased at 6 h in caerulein-treated wild-type mice compared to saline-treated controls.	Ceruletide	288-297	signal transducer and activator of transcription 6	Mus musculus	26-31
17109890-10	2007	Caerulein-treated STAT6 and STAT4 mice had markedly increased MPO activity as compared with their saline controls during the first 6 h. Both caerulein-treated STAT4- and STAT6-deficient mice had significantly increased MPO activity in comparison with wild-type mice with pancreatitis at 6 h. CONCLUSION: We found the maximal lung injury after caerulein-induced pancreatitis occurred at different time-points in STAT4 and STAT6-deficient mice.	Ceruletide	141-150	signal transducer and activator of transcription 6	Mus musculus	18-23
17109890-10	2007	Caerulein-treated STAT6 and STAT4 mice had markedly increased MPO activity as compared with their saline controls during the first 6 h. Both caerulein-treated STAT4- and STAT6-deficient mice had significantly increased MPO activity in comparison with wild-type mice with pancreatitis at 6 h. CONCLUSION: We found the maximal lung injury after caerulein-induced pancreatitis occurred at different time-points in STAT4 and STAT6-deficient mice.	Ceruletide	141-150	signal transducer and activator of transcription 4	Mus musculus	28-33
17109890-10	2007	Caerulein-treated STAT6 and STAT4 mice had markedly increased MPO activity as compared with their saline controls during the first 6 h. Both caerulein-treated STAT4- and STAT6-deficient mice had significantly increased MPO activity in comparison with wild-type mice with pancreatitis at 6 h. CONCLUSION: We found the maximal lung injury after caerulein-induced pancreatitis occurred at different time-points in STAT4 and STAT6-deficient mice.	Ceruletide	141-150	myeloperoxidase	Mus musculus	62-65
17109890-10	2007	Caerulein-treated STAT6 and STAT4 mice had markedly increased MPO activity as compared with their saline controls during the first 6 h. Both caerulein-treated STAT4- and STAT6-deficient mice had significantly increased MPO activity in comparison with wild-type mice with pancreatitis at 6 h. CONCLUSION: We found the maximal lung injury after caerulein-induced pancreatitis occurred at different time-points in STAT4 and STAT6-deficient mice.	Ceruletide	141-150	signal transducer and activator of transcription 4	Mus musculus	159-164
17109890-10	2007	Caerulein-treated STAT6 and STAT4 mice had markedly increased MPO activity as compared with their saline controls during the first 6 h. Both caerulein-treated STAT4- and STAT6-deficient mice had significantly increased MPO activity in comparison with wild-type mice with pancreatitis at 6 h. CONCLUSION: We found the maximal lung injury after caerulein-induced pancreatitis occurred at different time-points in STAT4 and STAT6-deficient mice.	Ceruletide	141-150	signal transducer and activator of transcription 6	Mus musculus	170-175
17109890-10	2007	Caerulein-treated STAT6 and STAT4 mice had markedly increased MPO activity as compared with their saline controls during the first 6 h. Both caerulein-treated STAT4- and STAT6-deficient mice had significantly increased MPO activity in comparison with wild-type mice with pancreatitis at 6 h. CONCLUSION: We found the maximal lung injury after caerulein-induced pancreatitis occurred at different time-points in STAT4 and STAT6-deficient mice.	Ceruletide	141-150	myeloperoxidase	Mus musculus	219-222
17109890-10	2007	Caerulein-treated STAT6 and STAT4 mice had markedly increased MPO activity as compared with their saline controls during the first 6 h. Both caerulein-treated STAT4- and STAT6-deficient mice had significantly increased MPO activity in comparison with wild-type mice with pancreatitis at 6 h. CONCLUSION: We found the maximal lung injury after caerulein-induced pancreatitis occurred at different time-points in STAT4 and STAT6-deficient mice.	Ceruletide	141-150	signal transducer and activator of transcription 4	Mus musculus	159-164
17109890-10	2007	Caerulein-treated STAT6 and STAT4 mice had markedly increased MPO activity as compared with their saline controls during the first 6 h. Both caerulein-treated STAT4- and STAT6-deficient mice had significantly increased MPO activity in comparison with wild-type mice with pancreatitis at 6 h. CONCLUSION: We found the maximal lung injury after caerulein-induced pancreatitis occurred at different time-points in STAT4 and STAT6-deficient mice.	Ceruletide	141-150	signal transducer and activator of transcription 6	Mus musculus	170-175
16873895-3	2006	It has been shown that pancreatic acinar cells produce the chemokine monocyte chemoattractant protein-1 (MCP-1) in response to caerulein hyperstimulation, demonstrating that acinar-derived MCP-1 is an early mediator of inflammation in acute pancreatitis.	Ceruletide	127-136	chemokine (C-C motif) ligand 2	Mus musculus	69-103
16873895-3	2006	It has been shown that pancreatic acinar cells produce the chemokine monocyte chemoattractant protein-1 (MCP-1) in response to caerulein hyperstimulation, demonstrating that acinar-derived MCP-1 is an early mediator of inflammation in acute pancreatitis.	Ceruletide	127-136	chemokine (C-C motif) ligand 2	Mus musculus	105-110
16873895-3	2006	It has been shown that pancreatic acinar cells produce the chemokine monocyte chemoattractant protein-1 (MCP-1) in response to caerulein hyperstimulation, demonstrating that acinar-derived MCP-1 is an early mediator of inflammation in acute pancreatitis.	Ceruletide	127-136	chemokine (C-C motif) ligand 2	Mus musculus	189-194
17175457-5	2006	Pancreatic fragments stimulated with caerulein showed activation of ERK, p38, and JNK and increased cytokine concentrations (ANOVA, P<0.05).	Ceruletide	37-46	Eph receptor B1	Rattus norvegicus	68-71
17175457-5	2006	Pancreatic fragments stimulated with caerulein showed activation of ERK, p38, and JNK and increased cytokine concentrations (ANOVA, P<0.05).	Ceruletide	37-46	mitogen activated protein kinase 14	Rattus norvegicus	73-76
17175457-5	2006	Pancreatic fragments stimulated with caerulein showed activation of ERK, p38, and JNK and increased cytokine concentrations (ANOVA, P<0.05).	Ceruletide	37-46	mitogen-activated protein kinase 8	Rattus norvegicus	82-85
17175457-6	2006	Specific stress kinase inhibitors significantly attenuated caerulein-induced activation of the corresponding stress kinase and cytokine production; however, the effect of the JNK inhibitor was comparatively less convincing.	Ceruletide	59-68	mitogen-activated protein kinase 8	Rattus norvegicus	175-178
17135311-6	2007	Caerulein injection in wild-type mice resulted in 6- and 36-fold increases in serum amylase and lipase levels, respectively, increased serum trypsinogen activation peptide (TAP) levels, gross oedema and a marked inflammatory response in the pancreas that consisted mainly of neutrophils and macrophages.	Ceruletide	0-9	lipase, endothelial	Mus musculus	96-102
17488480-7	2007	In addition, cells pre-treated with DL-propargylglycine (PAG, 3 mM), a CSE inhibitor, reduced the formation of H(2)S in caerulein treated cells, suggesting that CSE may be the main enzyme involved in H(2)S formation in mouse acinar cells.	Ceruletide	120-129	cystathionase (cystathionine gamma-lyase)	Mus musculus	71-74
17488480-7	2007	In addition, cells pre-treated with DL-propargylglycine (PAG, 3 mM), a CSE inhibitor, reduced the formation of H(2)S in caerulein treated cells, suggesting that CSE may be the main enzyme involved in H(2)S formation in mouse acinar cells.	Ceruletide	120-129	cystathionase (cystathionine gamma-lyase)	Mus musculus	161-164
17488480-8	2007	Furthermore, substance P (SP) concentration in the acini and expression of SP gene (preprotachykinin-A, PPT-A) and neurokinin-1 receptor (NK-1R), the primary receptor for SP, are increased in secretagogue caerulein-treated acinar cells.	Ceruletide	205-214	tachykinin 1	Mus musculus	13-24
17488480-8	2007	Furthermore, substance P (SP) concentration in the acini and expression of SP gene (preprotachykinin-A, PPT-A) and neurokinin-1 receptor (NK-1R), the primary receptor for SP, are increased in secretagogue caerulein-treated acinar cells.	Ceruletide	205-214	tachykinin 1	Mus musculus	26-28
17488480-8	2007	Furthermore, substance P (SP) concentration in the acini and expression of SP gene (preprotachykinin-A, PPT-A) and neurokinin-1 receptor (NK-1R), the primary receptor for SP, are increased in secretagogue caerulein-treated acinar cells.	Ceruletide	205-214	tachykinin 1	Mus musculus	84-102
17488480-8	2007	Furthermore, substance P (SP) concentration in the acini and expression of SP gene (preprotachykinin-A, PPT-A) and neurokinin-1 receptor (NK-1R), the primary receptor for SP, are increased in secretagogue caerulein-treated acinar cells.	Ceruletide	205-214	tachykinin receptor 1	Mus musculus	115-136
17488480-8	2007	Furthermore, substance P (SP) concentration in the acini and expression of SP gene (preprotachykinin-A, PPT-A) and neurokinin-1 receptor (NK-1R), the primary receptor for SP, are increased in secretagogue caerulein-treated acinar cells.	Ceruletide	205-214	tachykinin receptor 1	Mus musculus	138-143
17488480-8	2007	Furthermore, substance P (SP) concentration in the acini and expression of SP gene (preprotachykinin-A, PPT-A) and neurokinin-1 receptor (NK-1R), the primary receptor for SP, are increased in secretagogue caerulein-treated acinar cells.	Ceruletide	205-214	tachykinin 1	Mus musculus	75-77
16870717-14	2007	A combination of supramaximal caerulein stimulation with induction of IKK2(CA) caused increased tissue damage compared with either IKK2(CA) or caerulein alone.	Ceruletide	30-39	inhibitor of kappaB kinase beta	Mus musculus	131-135
17198196-0	2007	Substance P mediates cerulein-induced pancreatic microcirculatory dysfunction in mice.	Ceruletide	21-29	tachykinin 1	Mus musculus	0-11
17384281-4	2006	As a result, cerulein induced IL-expression, which was inhibited in the cells transfected with TAM-67 or MAD-3 or treated inhibitors of MAPK.	Ceruletide	13-21	NFKB inhibitor alpha	Homo sapiens	105-110
16934228-8	2006	As a result, cerulein induced the activation of Jak2 and Stat3 as well as IL-1beta expression, which was inhibited by the treatment of AG490 in AR42J cells.	Ceruletide	13-21	signal transducer and activator of transcription 3	Rattus norvegicus	57-62
16934228-8	2006	As a result, cerulein induced the activation of Jak2 and Stat3 as well as IL-1beta expression, which was inhibited by the treatment of AG490 in AR42J cells.	Ceruletide	13-21	interleukin 1 beta	Rattus norvegicus	74-82
16764691-3	2006	Intraperitoneal injection of cerulein into PPAR-alpha wild-type (WT) mice resulted in severe, acute pancreatitis characterized by oedema, neutrophil infiltration and necrosis and by elevated serum levels of amylase and lipase.	Ceruletide	29-37	lipase, endothelial	Mus musculus	219-225
17228101-13	2006	Caerulein stimulation reduced mRNA signal for HSP60.	Ceruletide	0-9	heat shock protein family D (Hsp60) member 1	Rattus norvegicus	46-51
16838115-6	2006	Cerulein given repeatedly twice produced acute pancreatitis, with concomitant increases in the serum amylase level, pancreas weight, myeloperoxidase activity, lipid peroxidation and microvascular permeability.	Ceruletide	0-8	myeloperoxidase	Rattus norvegicus	133-148
16764691-3	2006	Intraperitoneal injection of cerulein into PPAR-alpha wild-type (WT) mice resulted in severe, acute pancreatitis characterized by oedema, neutrophil infiltration and necrosis and by elevated serum levels of amylase and lipase.	Ceruletide	29-37	peroxisome proliferator activated receptor alpha	Mus musculus	43-53
16764691-6	2006	Acute pancreatitis in PPAR-alphaWT mice was also associated with a significant mortality (20% survival at 5 days after cerulein administration).	Ceruletide	119-127	peroxisome proliferator activated receptor alpha	Mus musculus	22-26
16767690-7	2006	Conversely, cerulein-induced acute pancreatitis was more severe in transgenic mice overexpressing JAM-C on endothelial cells under the control of the Tie2 promoter.	Ceruletide	12-20	junction adhesion molecule 3	Mus musculus	98-103
16767690-7	2006	Conversely, cerulein-induced acute pancreatitis was more severe in transgenic mice overexpressing JAM-C on endothelial cells under the control of the Tie2 promoter.	Ceruletide	12-20	TEK receptor tyrosine kinase	Mus musculus	150-154
16392107-5	2006	RESULTS: Administration of caerulein and LPS induced an increase in serum amylase and IL-6 levels, severe acute pancreatitis, pancreatitis-associated lung injury, and phosphorylation of signal transducer and activator of transcription (STAT) 3 in the pancreas.	Ceruletide	27-36	interleukin 6	Mus musculus	86-90
16769810-10	2006	Caerulein administration caused significant increases in pancreatic edema, serum amylase, MPO activity, and NK-1R internalization.	Ceruletide	0-9	myeloperoxidase	Rattus norvegicus	90-93
16769810-10	2006	Caerulein administration caused significant increases in pancreatic edema, serum amylase, MPO activity, and NK-1R internalization.	Ceruletide	0-9	tachykinin receptor 1	Rattus norvegicus	108-113
16700916-5	2006	RESULTS: In both wild type and CF mice caerulein induced similar elevations in serum amylase (maximal at 12 h), pancreatic edema (maximal at 7 h), and pancreatic myeloperoxidase activity (MPO, a marker of neutrophil infiltration; maximal at 7 h).	Ceruletide	39-48	myeloperoxidase	Mus musculus	162-177
16520745-5	2006	3 Caerulein, given hourly six times in total, caused more profound abdominal hyperalgesia/allodynia in PAR2-KO mice, as compared with WT mice, although no significant differences were detected in the severity of pancreatitis between the KO and WT animals.	Ceruletide	2-11	pulmonary adenoma resistance 2	Mus musculus	103-107
16520745-6	2006	4 The PAR2-activating peptide, 2-furoyl-LIGRL-NH(2), coadministered repeatedly with caerulein six times in total, abolished the caerulein-evoked abdominal hyperalgesia/allodynia in WT, but not PAR2-KO, mice.	Ceruletide	84-93	pulmonary adenoma resistance 2	Mus musculus	6-10
16520745-6	2006	4 The PAR2-activating peptide, 2-furoyl-LIGRL-NH(2), coadministered repeatedly with caerulein six times in total, abolished the caerulein-evoked abdominal hyperalgesia/allodynia in WT, but not PAR2-KO, mice.	Ceruletide	128-137	pulmonary adenoma resistance 2	Mus musculus	6-10
16520745-6	2006	4 The PAR2-activating peptide, 2-furoyl-LIGRL-NH(2), coadministered repeatedly with caerulein six times in total, abolished the caerulein-evoked abdominal hyperalgesia/allodynia in WT, but not PAR2-KO, mice.	Ceruletide	128-137	pulmonary adenoma resistance 2	Mus musculus	193-197
16525355-7	2006	In contrast, the degree of (a) pancreatic inflammation and tissue injury (histological score), (b) expression of ICAM-1, (c) the staining for nitrotyrosine and PAR, and (d) myeloperoxidase activity was markedly reduced in pancreatic tissue sections obtained from cerulein-treated mice administered Hypericum perforatum extract (30 mg/kg, suspended in 0.2 mL of saline solution, o.s.).	Ceruletide	263-271	myeloperoxidase	Mus musculus	173-188
16369913-4	2006	Treatment with the NK1R antagonist, CP96,345, results in protection against caerulein-induced acute pancreatitis in mice.	Ceruletide	76-85	tachykinin receptor 1	Mus musculus	19-23
16482627-14	2006	Caerulein-induced pancreatic and liver damage was accompanied with a significant increase in tissue MDA levels (P = 0.01, P = 0.003, respectively) whereas a significant decrease in CAT (P = 0.002, P = 0.003, respectively) and GPx activities (P = 0.002, P = 0.03, respectively).	Ceruletide	0-9	catalase	Rattus norvegicus	181-184
15629143-5	2005	Substance P levels in plasma, pancreas, and lungs were found to be elevated in a caerulein dose-dependent manner.	Ceruletide	81-90	tachykinin 1	Mus musculus	0-11
16239966-8	2005	Similarly, hemin pretreatment in caerulein-induced pancreatitis reduces serum amylase and lipase, decreases pancreatic trypsin generation, and protects from lung injury.	Ceruletide	33-42	lipase, endothelial	Mus musculus	90-96
15920015-1	2005	Supramaximal stimulation of the rat pancreas with CCK, or its analog caerulein, triggers acute pancreatitis and a number of pancreatitis-associated acinar cell changes including intracellular activation of digestive enzyme zymogens and acinar cell injury.	Ceruletide	69-78	cholecystokinin	Rattus norvegicus	50-53
16204768-2	2005	However the effects of caerulein, melatonin or hyperthermia preconditioning on mRNA signal for HSP60 in the pancreatic acinar cells has not been examined yet.	Ceruletide	23-32	heat shock protein family D (Hsp60) member 1	Rattus norvegicus	95-100
16204768-4	2005	To investigate the gene expression for HSP60 in the pancreatic AR42J cells stimulated by melatonin, caerulein or combination of both these substances.	Ceruletide	100-109	heat shock protein family D (Hsp60) member 1	Rattus norvegicus	39-44
16204768-12	2005	Caerulein stimulation reduced mRNA signal for HSP60.	Ceruletide	0-9	heat shock protein family D (Hsp60) member 1	Rattus norvegicus	46-51
16204768-21	2005	The strongest gene expression for HSP60 has been found in the cells subjected to the combination of hyperthermia preconditioning, caerulein and melatonin.	Ceruletide	130-139	heat shock protein family D (Hsp60) member 1	Rattus norvegicus	34-39
15976386-7	2005	Both the oscillatory and the peak plateau [Ca(2+)](i) changes that follow PAR2 stimulation are prevented by the phospholipase C (PLC) inhibitor U73122, but U73122 prevents only the oscillatory [Ca(2+)](i) changes triggered by caerulein.	Ceruletide	226-235	F2R like trypsin receptor 1	Homo sapiens	74-78
15976386-7	2005	Both the oscillatory and the peak plateau [Ca(2+)](i) changes that follow PAR2 stimulation are prevented by the phospholipase C (PLC) inhibitor U73122, but U73122 prevents only the oscillatory [Ca(2+)](i) changes triggered by caerulein.	Ceruletide	226-235	heparan sulfate proteoglycan 2	Homo sapiens	129-132
15870229-12	2005	Necrosis, Sirius red staining, OH-proline content, and expression of alpha-1 collagen I, alpha-smooth muscle actin, transforming growth factor beta1, and tissue inhibitor of metalloproteinase 1 were all increased in mice fed the alcohol containing diet and given caerulein compared with those fed the control diet and given caerulein.	Ceruletide	263-272	tissue inhibitor of metalloproteinase 1	Mus musculus	154-193
15782092-6	2005	RESULTS: Repeated administration of cerulein induced significant pancreatic fibrosis, but of which fibrosis was remarkably attenuated in pS2-dnR II mice compared with wild-type littermates (P < 0.01).	Ceruletide	36-44	trefoil factor 1	Mus musculus	137-140
15782105-9	2005	Capsazepine also reduced cerulein-induced Evans blue, MPO, and histologic severity of inflammation in the pancreas but had no effect on serum amylase.	Ceruletide	25-33	myeloperoxidase	Rattus norvegicus	54-57
15582989-6	2005	Caerulein stimulation caused a time- and concentration-dependent translocation of soluble V-ATPase V(1) subunits to a membrane fraction, a marker of V-ATPase activation.	Ceruletide	0-9	dynein axonemal heavy chain 8	Homo sapiens	92-98
15582989-6	2005	Caerulein stimulation caused a time- and concentration-dependent translocation of soluble V-ATPase V(1) subunits to a membrane fraction, a marker of V-ATPase activation.	Ceruletide	0-9	dynein axonemal heavy chain 8	Homo sapiens	90-98
15567768-0	2004	[Expressions of early growth response 1 and tissue factor in caerulein-induced acute pancreatitis tissues in rats].	Ceruletide	61-70	early growth response 1	Rattus norvegicus	16-39
16259748-5	2005	Caerulein caused moderate or severe pancreatitis, depending on the times of injections, resulting in different degrees of increase in serum amylase levels and pancreas weight, and the marked elevation of MPO activity was observed only after injections of caerulein given 4 times per hour.	Ceruletide	255-264	myeloperoxidase	Rattus norvegicus	204-207
15641142-8	2005	RESULTS: PACAP augmented caerulein-induced pancreatitis and failed to ameliorate sodium taurocholate-induced pancreatitis.	Ceruletide	25-34	adenylate cyclase activating polypeptide 1	Rattus norvegicus	9-14
15641142-9	2005	ELISA revealed that relative concentrations of PACAP in pancreas and duodenum were significantly increased in both sodium taurocholate- and caerulein-induced pancreatitis compared with those in normal controls.	Ceruletide	140-149	adenylate cyclase activating polypeptide 1	Rattus norvegicus	47-52
15567768-0	2004	[Expressions of early growth response 1 and tissue factor in caerulein-induced acute pancreatitis tissues in rats].	Ceruletide	61-70	coagulation factor III, tissue factor	Rattus norvegicus	44-57
14962849-0	2004	Endothelial nitric oxide synthase is protective in the initiation of caerulein-induced acute pancreatitis in mice.	Ceruletide	69-78	nitric oxide synthase 3, endothelial cell	Mus musculus	0-33
15286555-10	2004	Injections of cerulein induced an edematous pancreatitis that was of similar severity in wild-type and TLR4-deficient mice.	Ceruletide	14-22	toll-like receptor 4	Mus musculus	103-107
15359896-5	2004	MT-I/II null mice were found to be much more sensitive than wild-type mice to the toxicity caused by free radical-inducing factors, which include paraquat, acetaminophen, ethanol, X-ray, ultraviolet B, carbon tetrachloride, cisplatin, doxorubicin, cerulein and streptozotocin.	Ceruletide	248-256	metallothionein 1	Mus musculus	0-7
15016612-8	2004	Six intraperitoneal injections of cerulein induced acute pancreatitis in both AT(1a)(-/-) and WT mice.	Ceruletide	34-42	angiotensin II receptor, type 1a	Mus musculus	78-83
15033703-7	2003	As a result, cerulein induced IL-6 expression time-dependently at 10(-8) M, and apoptosis dose-dependently at 24 h in the wild-type cells.	Ceruletide	13-21	interleukin 6	Rattus norvegicus	30-34
15178901-8	2004	RESULTS: Supramaximal cerulein stimulation induced an increase in serum pancreatic enzymes, interleukin (IL)-6, pancreatic edema, and produced histologic evidence of AP.	Ceruletide	22-30	interleukin 6	Rattus norvegicus	92-110
15140659-1	2004	OBJECTIVE: To investigate the role of inducible cyclooxygenase (COX-2) mRNA expression in local microvessels in rats with acute interstitial pancreatitis (AIP) induced by caerulein injection.	Ceruletide	171-180	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	64-69
15028960-3	2004	Cerulein administration produced pancreatic edema and a marked increase in serum lipase and amylase activity; induced a severe depletion of reduced glutathione, catalase, and superoxide dismutase levels; primed lipid peroxidation; and promoted neutrophil intervention.	Ceruletide	0-8	lipase G, endothelial type	Rattus norvegicus	81-87
15028960-3	2004	Cerulein administration produced pancreatic edema and a marked increase in serum lipase and amylase activity; induced a severe depletion of reduced glutathione, catalase, and superoxide dismutase levels; primed lipid peroxidation; and promoted neutrophil intervention.	Ceruletide	0-8	catalase	Rattus norvegicus	161-169
14751415-3	2004	The aim of our studies was to determine the role of cyclooxygenase-1 and cyclooxygenase-2 in the protective effect of HGF administration against caerulein-induced pancreatitis.	Ceruletide	145-154	prostaglandin-endoperoxide synthase 1	Rattus norvegicus	52-68
14751415-3	2004	The aim of our studies was to determine the role of cyclooxygenase-1 and cyclooxygenase-2 in the protective effect of HGF administration against caerulein-induced pancreatitis.	Ceruletide	145-154	hepatocyte growth factor	Rattus norvegicus	118-121
14751415-12	2004	The maximal increase in cyclooxygenase-2 mRNA expression was observed when HGF administration was combined with caerulein infusion.	Ceruletide	112-121	prostaglandin-endoperoxide synthase 2	Rattus norvegicus	24-40
14747941-3	2004	Galectin-3, which occurs only in duct cells under physiological conditions, is expressed in a subset of acinar cells after the end of a 12-h caerulein infusion, giving rise to a "patchy" staining pattern.	Ceruletide	141-150	galectin 3	Rattus norvegicus	0-10
15033703-8	2003	Cerulein-induced IL-6 expression (at 10(-8) M) and apoptosis (at 10(-7) M) were inhibited in the transfected cells with mutant gene (IkappaB mt, Ras N17, TAM-67) as compared to pcDNA cells and the wild-type cells.	Ceruletide	0-8	interleukin 6	Rattus norvegicus	17-21
14726611-7	2003	Ghrelin was administrated twice (30 min prior to the first caerulein or saline injection and 3 h later) at the doses: 2, 10 or 20 nmol/kg.	Ceruletide	59-68	ghrelin and obestatin prepropeptide	Rattus norvegicus	0-7
14726611-22	2003	Ghrelin was administrated twice (30 min prior to the first caerulein or saline injection and 3 h later) at the doses: 2, 10 or 20 nmol/kg.	Ceruletide	59-68	ghrelin and obestatin prepropeptide	Rattus norvegicus	0-7
14726612-0	2003	IGF-1 stimulates production of interleukin-10 and inhibits development of caerulein-induced pancreatitis.	Ceruletide	74-83	insulin like growth factor 1	Homo sapiens	0-5
14726612-3	2003	The aim of our studies was to determine the effect of IGF-1 administration on the development of caerulein-induced pancreatitis.	Ceruletide	97-106	insulin like growth factor 1	Homo sapiens	54-59
14726613-10	2003	Leptin (10(-10)-10(-7) M) also dose-dependently attenuated caerulein-induced amylase release from isolated pancreatic acini, whereas basal enzyme secretion was unaffected.	Ceruletide	59-68	leptin	Rattus norvegicus	0-6
12808617-3	2003	The aim of this study was to evaluate the effect of Met-RANTES, a CC chemokine receptor antagonist, on pancreatic inflammation and lung injury in caerulein-induced acute pancreatitis in mice.	Ceruletide	146-155	chemokine (C-C motif) ligand 5	Mus musculus	56-62
14646970-1	2003	BACKGROUND: Previous studies have shown that sensory nerves and calcitonin gene-related peptide (CGRP) affect caerulein-induced pancreatitis.	Ceruletide	110-119	calcitonin-related polypeptide alpha	Rattus norvegicus	64-95
14646970-1	2003	BACKGROUND: Previous studies have shown that sensory nerves and calcitonin gene-related peptide (CGRP) affect caerulein-induced pancreatitis.	Ceruletide	110-119	calcitonin-related polypeptide alpha	Rattus norvegicus	97-101
12773302-0	2003	Caerulein-induced acute pancreatitis inhibits protein synthesis through effects on eIF2B and eIF4F.	Ceruletide	0-9	eukaryotic translation initiation factor 2B, subunit 4 delta	Mus musculus	83-88
12773302-6	2003	Caerulein inhibited the two major regulatory points of translation initiation: the activity of the guanine nucleotide exchange factor eIF2B (with an increase of eIF2alpha phosphorylation) and the formation of the eIF4F complex due, in part, to degradation of eIF4G.	Ceruletide	0-9	eukaryotic translation initiation factor 2B, subunit 4 delta	Mus musculus	134-139
12773302-6	2003	Caerulein inhibited the two major regulatory points of translation initiation: the activity of the guanine nucleotide exchange factor eIF2B (with an increase of eIF2alpha phosphorylation) and the formation of the eIF4F complex due, in part, to degradation of eIF4G.	Ceruletide	0-9	eukaryotic translation initiation factor 2A	Mus musculus	161-170
12709512-6	2003	EGR-1 expression occurred within acinar cells and correlated with the development of caerulein-induced acute pancreatitis in rats.	Ceruletide	85-94	early growth response 1	Rattus norvegicus	0-5
12709512-7	2003	Furthermore, the levels of the inflammation-related genes MCP-1, PAI, TF, IL-6, and ICAM-1 and the extent of lung inflammation were reduced during the initiation of caerulein-induced acute pancreatitis in EGR-1-deficient mice.	Ceruletide	165-174	mast cell protease 1	Mus musculus	58-63
12709512-7	2003	Furthermore, the levels of the inflammation-related genes MCP-1, PAI, TF, IL-6, and ICAM-1 and the extent of lung inflammation were reduced during the initiation of caerulein-induced acute pancreatitis in EGR-1-deficient mice.	Ceruletide	165-174	serine (or cysteine) peptidase inhibitor, clade E, member 1	Mus musculus	65-68
12709512-7	2003	Furthermore, the levels of the inflammation-related genes MCP-1, PAI, TF, IL-6, and ICAM-1 and the extent of lung inflammation were reduced during the initiation of caerulein-induced acute pancreatitis in EGR-1-deficient mice.	Ceruletide	165-174	interleukin 6	Mus musculus	74-78
12709512-7	2003	Furthermore, the levels of the inflammation-related genes MCP-1, PAI, TF, IL-6, and ICAM-1 and the extent of lung inflammation were reduced during the initiation of caerulein-induced acute pancreatitis in EGR-1-deficient mice.	Ceruletide	165-174	intercellular adhesion molecule 1	Mus musculus	84-90
12709512-7	2003	Furthermore, the levels of the inflammation-related genes MCP-1, PAI, TF, IL-6, and ICAM-1 and the extent of lung inflammation were reduced during the initiation of caerulein-induced acute pancreatitis in EGR-1-deficient mice.	Ceruletide	165-174	early growth response 1	Mus musculus	205-210
12808617-0	2003	Treatment with Met-RANTES reduces lung injury in caerulein-induced pancreatitis.	Ceruletide	49-58	chemokine (C-C motif) ligand 5	Mus musculus	19-25
12808617-11	2003	CONCLUSION: Treatment with Met-RANTES reduces lung damage associated with caerulein-induced pancreatitis in mice.	Ceruletide	74-83	chemokine (C-C motif) ligand 5	Mus musculus	31-37
12745080-5	2003	These results suggest that RhoA and ROCK-II assemble normal CCK-stimulated pancreatic enzyme secretion and prevent caerulein-induced acute pancreatitis.	Ceruletide	115-124	ras homolog family member A	Rattus norvegicus	27-31
12745080-5	2003	These results suggest that RhoA and ROCK-II assemble normal CCK-stimulated pancreatic enzyme secretion and prevent caerulein-induced acute pancreatitis.	Ceruletide	115-124	Rho-associated coiled-coil containing protein kinase 2	Rattus norvegicus	36-43
12772861-5	2003	An effect of caerulein to increase alpha-amylase release (P < 0.10) was only observed with prior exposure to abomasal casein infusion in vivo or with simultaneous incubation with amino acids in vitro.	Ceruletide	13-22	alpha amylase	Bos taurus	35-48
12385773-2	2002	Expression of P23 is stimulated strongly by caerulein, an analogue of cholecystokinin (CCK).	Ceruletide	44-53	RAS related	Rattus norvegicus	14-17
12510864-0	2002	Role of endogenous melatonin and its MT2 receptor in the modulation of caerulein-induced pancreatitis in the rat.	Ceruletide	71-80	metallothionein 2A	Rattus norvegicus	37-40
12510864-8	2002	These results suggest that endogenous melatonin through its receptor MT2 plays an important role in the attenuation of pancreatic damage produced by overstimulation with caerulein.	Ceruletide	170-179	metallothionein 2A	Rattus norvegicus	69-72
12411162-1	2002	OBJECTIVE: To explore the changes in hemorheology and expression of neutrophil adhesion molecules CD18 and CD62L in pancreatic microcirculation of Caerulein induced experimental acute pancreatitis (AP).	Ceruletide	147-156	integrin subunit beta 2	Rattus norvegicus	98-102
12385773-2	2002	Expression of P23 is stimulated strongly by caerulein, an analogue of cholecystokinin (CCK).	Ceruletide	44-53	cholecystokinin	Rattus norvegicus	70-85
12385773-2	2002	Expression of P23 is stimulated strongly by caerulein, an analogue of cholecystokinin (CCK).	Ceruletide	44-53	cholecystokinin	Rattus norvegicus	87-90
12385773-11	2002	Taken together with a previous observation that P23 is specifically upregulated 14-fold by 24-h caerulein infusion, these results suggest that elevated levels of P23 should be taken into consideration in the mechanism of trypsinogens within the pancreas in pathological conditions.	Ceruletide	96-105	RAS related	Rattus norvegicus	48-51
12385773-11	2002	Taken together with a previous observation that P23 is specifically upregulated 14-fold by 24-h caerulein infusion, these results suggest that elevated levels of P23 should be taken into consideration in the mechanism of trypsinogens within the pancreas in pathological conditions.	Ceruletide	96-105	RAS related	Rattus norvegicus	162-165
12223354-6	2002	Caerulein significantly increased MPO activity and wet-to-dry weight ratio, produced histological evidence of edematous pancreatitis, induced plasma extravasation, and caused hyperamylasemia.	Ceruletide	0-9	myeloperoxidase	Rattus norvegicus	34-37
12379770-3	2002	This study aimed to investigate whether cerulein induced ROS generation, lipid peroxide and hydrogen peroxide production, NF-kappaB activation, and expression of cytokines (IL-1beta, IL-6) in pancreatic acinar cells.	Ceruletide	40-48	interleukin 1 beta	Homo sapiens	173-181
12370536-0	2002	Cerulein-induced acute pancreatitis in the rat is significantly ameliorated by treatment with MEK1/2 inhibitors U0126 and PD98059.	Ceruletide	0-8	mitogen activated protein kinase kinase 1	Rattus norvegicus	94-100
12370536-2	2002	AIMS AND METHODOLOGY: ERK1/2 in pancreas homogenates was activated in rats rendered pancreatitic by subcutaneous injections of cerulein (5 microg/kg per hour).	Ceruletide	127-135	mitogen activated protein kinase 3	Rattus norvegicus	22-28
12379770-3	2002	This study aimed to investigate whether cerulein induced ROS generation, lipid peroxide and hydrogen peroxide production, NF-kappaB activation, and expression of cytokines (IL-1beta, IL-6) in pancreatic acinar cells.	Ceruletide	40-48	interleukin 6	Homo sapiens	183-187
11787767-0	2001	Effect of sensory nerves and CGRP on the development of caerulein-induced pancreatitis and pancreatic recovery.	Ceruletide	56-65	calcitonin-related polypeptide alpha	Rattus norvegicus	29-33
11951059-14	2002	prevents the development of caerulein-induced pancreatitis through the activation of SN and though the release of leptin.	Ceruletide	28-37	leptin	Rattus norvegicus	114-120
11751160-6	2002	Cerulein-induced increase in MCP-1 synthesis was accompanied by increase in nuclear factor (NF)-kappaB activation shown by EMSA.	Ceruletide	0-8	C-C motif chemokine ligand 2	Rattus norvegicus	29-34
12121873-4	2002	Cerulein induces NF-kappaB/Rel via activation of IkappaB kinase (IKK), which causes degradation of IkappaBalpha but not IkappaBbeta.	Ceruletide	0-8	nuclear factor kappa B subunit 1	Homo sapiens	17-26
12121873-4	2002	Cerulein induces NF-kappaB/Rel via activation of IkappaB kinase (IKK), which causes degradation of IkappaBalpha but not IkappaBbeta.	Ceruletide	0-8	NFKB inhibitor alpha	Homo sapiens	99-111
12121700-13	2002	CONCLUSION: PSP/reg and PAP levels are increased through similar mechanisms by physiological and supramaximal doses of caerulein.	Ceruletide	119-128	regenerating family member 1 alpha	Rattus norvegicus	12-15
12121700-13	2002	CONCLUSION: PSP/reg and PAP levels are increased through similar mechanisms by physiological and supramaximal doses of caerulein.	Ceruletide	119-128	regenerating family member 1 alpha	Rattus norvegicus	16-19
12121700-13	2002	CONCLUSION: PSP/reg and PAP levels are increased through similar mechanisms by physiological and supramaximal doses of caerulein.	Ceruletide	119-128	regenerating family member 3 beta	Rattus norvegicus	24-27
12203079-6	2002	After the induction of acute pancreatitis by caerulein, the Cx 32 mRNA expression levels were increased on day 1, day 4, day 7, and day 14 compared with levels in the normal pancreas (1.63-fold, 1.61-fold, 1.49-fold, and 1.35-fold, respectively).	Ceruletide	45-54	gap junction protein, beta 1	Rattus norvegicus	60-65
11787767-17	2001	Stimulation of sensory nerves or the administration of CGRP during development of AP exhibits protective effects against pancreatic damage induced by caerulein overstimulation.	Ceruletide	150-159	calcitonin-related polypeptide alpha	Rattus norvegicus	55-59
11753807-9	2001	During a perfusion with the cholecystokinin analogue ceruletid (10(-8) M) we found an increase of lipase (p < 0.05) after 30 minutes and an increase of amylase (p < 0.05) after 50 minutes perfusion.	Ceruletide	53-62	lipase G, endothelial type	Rattus norvegicus	98-104
11668042-6	2001	Caerulein administration caused significant elevations in serum amylase and pancreatic MPO activity, produced histological evidence of pancreatitis, and caused a dramatic increase in NK1R endocytosis.	Ceruletide	0-9	myeloperoxidase	Mus musculus	87-90
11668042-6	2001	Caerulein administration caused significant elevations in serum amylase and pancreatic MPO activity, produced histological evidence of pancreatitis, and caused a dramatic increase in NK1R endocytosis.	Ceruletide	0-9	tachykinin receptor 1	Mus musculus	183-187
11698071-0	2001	Hepatocyte growth factor attenuates pancreatic damage in caerulein-induced pancreatitis in rats.	Ceruletide	57-66	hepatocyte growth factor	Rattus norvegicus	0-24
11698071-2	2001	These observations prompted us to determine the effect of HGF administration on the development of caerulein-induced pancreatitis in rats.	Ceruletide	99-108	hepatocyte growth factor	Rattus norvegicus	58-61
11698071-5	2001	Caerulein administration induced acute edematous pancreatitis manifested by 41% decrease in DNA synthesis, 53% inhibition of pancreatic blood flow, a significant increase in plasma amylase and lipase activity, plasma interleukin-1beta and interleukin-6 concentration, as well as, the development of the histological signs of pancreatic damage (edema, leukocyte infiltration, and vacuolization).	Ceruletide	0-9	lipase G, endothelial type	Rattus norvegicus	193-199
11698071-5	2001	Caerulein administration induced acute edematous pancreatitis manifested by 41% decrease in DNA synthesis, 53% inhibition of pancreatic blood flow, a significant increase in plasma amylase and lipase activity, plasma interleukin-1beta and interleukin-6 concentration, as well as, the development of the histological signs of pancreatic damage (edema, leukocyte infiltration, and vacuolization).	Ceruletide	0-9	interleukin 1 beta	Rattus norvegicus	217-234
11698071-5	2001	Caerulein administration induced acute edematous pancreatitis manifested by 41% decrease in DNA synthesis, 53% inhibition of pancreatic blood flow, a significant increase in plasma amylase and lipase activity, plasma interleukin-1beta and interleukin-6 concentration, as well as, the development of the histological signs of pancreatic damage (edema, leukocyte infiltration, and vacuolization).	Ceruletide	0-9	interleukin 6	Rattus norvegicus	239-252
11451153-7	2001	Cerulein administration dose-dependently increased pancreatic wet weight, myeloperoxidase activity, and levels of nitrite and amylase in C57B1/6 mice.	Ceruletide	0-8	myeloperoxidase	Mus musculus	74-89
11478495-4	2001	Cerulein caused a concentration-dependent activation of p70 S6 kinase, with the maximal effect at 1-10 microg/kg.	Ceruletide	0-8	ribosomal protein S6 kinase B1	Rattus norvegicus	60-69
10856460-0	2000	Epidermal growth factor accelerates pancreatic recovery after caerulein-induced pancreatitis.	Ceruletide	62-71	epidermal growth factor like 1	Rattus norvegicus	0-23
10987993-7	2000	These observations in the rat are different from those in the dog where desulfation of tyrosine renders the CCK analog, caerulein, ineffective in its ability to stimulate acid secretion.	Ceruletide	120-129	cholecystokinin	Canis lupus familiaris	108-111
10856460-2	2000	Caerulein-induced pancreatitis was evoked in rats with intact or removed salivary glands and EGF (10 microg/kg) was administered starting 24 h after cessation of caerulein infusion.	Ceruletide	0-9	epidermal growth factor like 1	Rattus norvegicus	93-96
10856460-9	2000	We conclude that EGF reduces the severity of pancreatic damage evoked by caerulein-induced pancreatitis-related pancreatic damage and accelerates tissue repair.	Ceruletide	73-82	epidermal growth factor like 1	Rattus norvegicus	17-20
10541353-12	1999	All members of the CCK or gastrin family were stable in serum (with t(1/2)s of several hours at 37 degrees C); nevertheless, the stability of those peptides was highest that bore the NH2-terminal pGlu residues (e.g., big gastrin, gastrin-I, caerulein, and others) or D-amino acids.	Ceruletide	241-250	cholecystokinin	Homo sapiens	19-22
10644575-0	2000	CEP-1347 inhibits caerulein-induced rat pancreatic JNK activation and ameliorates caerulein pancreatitis.	Ceruletide	18-27	mitogen-activated protein kinase 8	Rattus norvegicus	51-54
10644575-1	2000	Pancreatic caerulein-induced activation of c-Jun NH(2)-terminal kinase (JNK) has been reported, and JNK has been proposed as a mediator during induction of hyperstimulated pancreatitis.	Ceruletide	11-20	mitogen-activated protein kinase 8	Rattus norvegicus	43-70
10644575-1	2000	Pancreatic caerulein-induced activation of c-Jun NH(2)-terminal kinase (JNK) has been reported, and JNK has been proposed as a mediator during induction of hyperstimulated pancreatitis.	Ceruletide	11-20	mitogen-activated protein kinase 8	Rattus norvegicus	72-75
10644575-3	2000	We tested whether CEP-1347 inhibits caerulein-induced pancreatic JNK activation in isolated acini and in vivo.	Ceruletide	36-45	mitogen-activated protein kinase 8	Rattus norvegicus	65-68
10644575-4	2000	CEP-1347 dose dependently inhibited acinar caerulein-induced JNK activation with nearly complete inhibition at 2 microM but had no effect on digestive enzyme release.	Ceruletide	43-52	mitogen-activated protein kinase 8	Rattus norvegicus	61-64
10644575-8	2000	Caerulein hyperstimulation strongly activated JNK, p38, and ERK.	Ceruletide	0-9	mitogen-activated protein kinase 8	Rattus norvegicus	46-49
10644575-8	2000	Caerulein hyperstimulation strongly activated JNK, p38, and ERK.	Ceruletide	0-9	mitogen activated protein kinase 14	Rattus norvegicus	51-54
10644575-8	2000	Caerulein hyperstimulation strongly activated JNK, p38, and ERK.	Ceruletide	0-9	Eph receptor B1	Rattus norvegicus	60-63
10644575-9	2000	CEP-1347 pretreatment dose dependently reduced caerulein-induced pancreatic JNK activation without p38 or ERK inhibition.	Ceruletide	47-56	mitogen-activated protein kinase 8	Rattus norvegicus	76-79
10824691-7	2000	Cerulein administration increased serum amylase, lipase level, and wet weight of pancreatic tissue.	Ceruletide	0-8	lipase G, endothelial type	Rattus norvegicus	49-55
10721682-1	2000	OBJECTIVE: To examine the influence of pre-experimental stress on the anxiogenic-like action of caerulein, an agonist of cholecystokinin (CCK) receptors.	Ceruletide	96-105	cholecystokinin	Rattus norvegicus	121-136
10721682-1	2000	OBJECTIVE: To examine the influence of pre-experimental stress on the anxiogenic-like action of caerulein, an agonist of cholecystokinin (CCK) receptors.	Ceruletide	96-105	cholecystokinin	Rattus norvegicus	138-141
10721682-8	2000	The anti-exploratory action of caerulein in stressed rats was reversed by the CCK antagonist L-365,260 (100 micrograms/kg, intraperitoneal injection), demonstrating the involvement of the CCKB receptor subtype.	Ceruletide	31-40	cholecystokinin	Rattus norvegicus	78-81
10541353-12	1999	All members of the CCK or gastrin family were stable in serum (with t(1/2)s of several hours at 37 degrees C); nevertheless, the stability of those peptides was highest that bore the NH2-terminal pGlu residues (e.g., big gastrin, gastrin-I, caerulein, and others) or D-amino acids.	Ceruletide	241-250	gastrin	Homo sapiens	26-33
10484394-9	1999	Cyclosporin A, a Ca2+/calmodulin-dependent protein phosphatase (PP2B) inhibitor, decreased caerulein-induced NF-kappaB/Rel activation and IkappaBalpha degradation.	Ceruletide	91-100	nuclear factor kappa B subunit 1	Homo sapiens	109-118
10484394-9	1999	Cyclosporin A, a Ca2+/calmodulin-dependent protein phosphatase (PP2B) inhibitor, decreased caerulein-induced NF-kappaB/Rel activation and IkappaBalpha degradation.	Ceruletide	91-100	NFKB inhibitor alpha	Homo sapiens	138-150
10484394-0	1999	Caerulein-induced NF-kappaB/Rel activation requires both Ca2+ and protein kinase C as messengers.	Ceruletide	0-9	nuclear factor kappa B subunit 1	Homo sapiens	18-27
10484394-3	1999	Here, we show that activation of NF-kappaB/Rel by caerulein, a CCK analog, requires increasing intracellular Ca2+ levels and protein kinase C activation.	Ceruletide	50-59	nuclear factor kappa B subunit 1	Homo sapiens	33-42
10484394-10	1999	The inhibitory effect of bisindolylmaleimide suggests that protein kinase C activity is also required for caerulein-induced NF-kappaB/Rel activation.	Ceruletide	106-115	nuclear factor kappa B subunit 1	Homo sapiens	124-133
10484394-3	1999	Here, we show that activation of NF-kappaB/Rel by caerulein, a CCK analog, requires increasing intracellular Ca2+ levels and protein kinase C activation.	Ceruletide	50-59	cholecystokinin	Homo sapiens	63-66
10484394-4	1999	Caerulein induces a dose-dependent increase of nuclear NF-kappaB/Rel binding activity in pancreatic lobules, which is paralleled by degradation of IkappaBalpha.	Ceruletide	0-9	nuclear factor kappa B subunit 1	Homo sapiens	55-64
10484394-11	1999	These data suggest that Ca2+- as well as protein kinase C-dependent mechanisms are required for caerulein-induced NF-kappaB/Rel activation.	Ceruletide	96-105	nuclear factor kappa B subunit 1	Homo sapiens	114-123
10484394-4	1999	Caerulein induces a dose-dependent increase of nuclear NF-kappaB/Rel binding activity in pancreatic lobules, which is paralleled by degradation of IkappaBalpha.	Ceruletide	0-9	NFKB inhibitor alpha	Homo sapiens	147-159
10467964-4	1999	Rats infused with caerulein plus ethanol showed increased plasma amylase and lipase activities, and aggravated pancreatic interstitial oedema when compared with rats given caerulein alone.	Ceruletide	18-27	lipase G, endothelial type	Rattus norvegicus	77-83
10484394-7	1999	The intracellular Ca2+ chelator TMB-8 prevented IkappaBalpha degradation and subsequent nuclear translocation of NF-kappaB/Rel induced by caerulein.	Ceruletide	138-147	NFKB inhibitor alpha	Homo sapiens	48-60
10484394-7	1999	The intracellular Ca2+ chelator TMB-8 prevented IkappaBalpha degradation and subsequent nuclear translocation of NF-kappaB/Rel induced by caerulein.	Ceruletide	138-147	nuclear factor kappa B subunit 1	Homo sapiens	113-122
10467964-5	1999	Sepimostat at 10 and 30 mg kg(-1) prevented the increase in plasma amylase and lipase activities caused by caerulein plus ethanol infusion.	Ceruletide	107-116	lipase G, endothelial type	Rattus norvegicus	79-85
10208291-4	1999	The hypothermic response induced by caerulein, a CCK-related decapeptide but not morphine was decreased by selective CCK(A) receptor antagonist MK-329.	Ceruletide	36-45	cholecystokinin	Mus musculus	49-52
10210154-1	1999	UNLABELLED: We have recently shown that treatment with calcitonin gene-related peptide (CGRP) before and during induction of acute pancreatitis exhibits a protective effect against pancreatic damage evoked by overdose of caerulein.	Ceruletide	221-230	calcitonin-related polypeptide alpha	Rattus norvegicus	55-86
10210154-1	1999	UNLABELLED: We have recently shown that treatment with calcitonin gene-related peptide (CGRP) before and during induction of acute pancreatitis exhibits a protective effect against pancreatic damage evoked by overdose of caerulein.	Ceruletide	221-230	calcitonin-related polypeptide alpha	Rattus norvegicus	88-92
10210154-7	1999	RESULTS: Caerulein-induced pancreatitis (CIP) led to 42% decrease in DNA synthesis, 30% inhibition of PBF, as well as, a significant increase in pancreatic weight, plasma amylase activity, plasma interleukin-1beta concentration, and development of the histological signs of pancreatic damage (edema, leukocyte infiltration and vacuolization).	Ceruletide	9-18	interleukin 1 beta	Rattus norvegicus	196-213
10208291-4	1999	The hypothermic response induced by caerulein, a CCK-related decapeptide but not morphine was decreased by selective CCK(A) receptor antagonist MK-329.	Ceruletide	36-45	cholecystokinin A receptor	Mus musculus	117-132
9647465-9	1998	The amphibian peptide caerulein (1 microg kg(-1) intraperitoneally three times daily) was used as a CCK agonist, while camostate (200 mg kg(-1) intragastrically once daily), a synthetic protease inhibitor, was used to release endogenous CCK.	Ceruletide	22-31	cholecystokinin	Rattus norvegicus	100-103
9885794-7	1999	Subcutaneous (s.c.) injections of caerulein (10 micrograms/kg) a mixed CCKA/B agonist, partially reversed amphetamine-induced reduction of PPI; whereas, s.c. haloperidol (0.5 mg/kg) totally reversed amphetamine-induced disruption of PPI.	Ceruletide	34-43	cholecystokinin A receptor	Homo sapiens	71-75
9885794-8	1999	Caerulein"s effect on PPI was blocked by pretreatment with a CCKA antagonist (devazepide) but not a CCKB antagonist (L-365,260).	Ceruletide	0-9	cholecystokinin A receptor	Homo sapiens	61-65
9885794-12	1999	In a separate experiment, s.c. caerulein produced to a more potent neuroleptic-like profile on amphetamine-induced hyperlocomotion, suggesting that selection of preclinical paradigms may be important in evaluating the antipsychotic potential of CCK-based treatments.	Ceruletide	31-40	cholecystokinin	Homo sapiens	245-248
9863488-3	1998	AIMS: To examine the systemic release of IL-10 and its messenger RNA production in the pancrease, liver, and lungs and analyse the effects of IL-10 neutralisation in caerulein induced acute pancreatitis in mice.	Ceruletide	166-175	interleukin 10	Mus musculus	142-147
9688663-1	1998	Supramaximal stimulation of the pancreas with the CCK analog caerulein causes acute edematous pancreatitis.	Ceruletide	61-70	cholecystokinin	Rattus norvegicus	50-53
9660181-7	1998	Clusterin mRNA was expressed with similar intensity in oedematous caerulein-induced pancreatitis and in response to various degrees of necrohaemorrhagic taurocholate-induced pancreatitis, indicating a maximal gene activity in all types of pancreatitis; in situ hybridization showed that the acinar cells and some ducts expressed clusterin mRNA.	Ceruletide	66-75	clusterin	Rattus norvegicus	0-9
10082226-2	1999	Treatment with caerulein (0.01-1 microg/kg), a nonselective agonist of CCK receptors, induced a large reduction of jumping frequency without parallel suppression of locomotor activity.	Ceruletide	15-24	cholecystokinin	Mus musculus	71-74
10082226-5	1999	Devazepide (1 microg/kg), a preferential CCK(A) receptor antagonist, completely reversed the action of caerulein (0.1 gmg/kg) and CCK-4 (2 mg/kg).	Ceruletide	103-112	cholecystokinin A receptor	Mus musculus	41-56
10082226-5	1999	Devazepide (1 microg/kg), a preferential CCK(A) receptor antagonist, completely reversed the action of caerulein (0.1 gmg/kg) and CCK-4 (2 mg/kg).	Ceruletide	103-112	cholecystokinin	Mus musculus	41-44
11341608-0	1999	Thromboxane A2 receptor antagonist prevents pancreatic microvascular leakage in rats with caerulein-induced acute pancreatitis.	Ceruletide	90-99	thromboxane A2 receptor	Rattus norvegicus	0-23
9802838-3	1998	The cholecystokinin (CCK)-related decapeptide ceruletide (120 and 400 microg/kg, i.p.	Ceruletide	46-56	cholecystokinin	Rattus norvegicus	4-19
9802838-3	1998	The cholecystokinin (CCK)-related decapeptide ceruletide (120 and 400 microg/kg, i.p.	Ceruletide	46-56	cholecystokinin	Rattus norvegicus	21-24
10189057-2	1998	The acute administration of non-selective CCK agonist caerulein (1 and 5 microg/kg) and a selective CCK(B) receptor agonist BOC-CCK-4 (1, 10 and 50 microg/kg) induced a dose-dependent anxiogenic-like action in the plus-maze model of anxiety.	Ceruletide	54-63	cholecystokinin	Rattus norvegicus	42-45
10189057-3	1998	BOC-CCK-4 displayed a similar efficacy with caerulein, indicating that the described effect was mediated via CCK(B) receptor subtype.	Ceruletide	44-53	cholecystokinin	Rattus norvegicus	4-7
9444624-5	1997	Treatment with CGRP (2 x 10 micrograms/kg s.c.) attenuated the pancreatic tissue damage in caerulein-induced pancreatitis and completely reversed the deleterious effect of the ablation of sensory nerves on caerulein-induced pancreatitis.	Ceruletide	91-100	calcitonin-related polypeptide alpha	Rattus norvegicus	15-19
9586822-2	1998	The aim of this study was to compare the gene and immunohistochemical expression of EGF and TGF-beta1, cell proliferation, and biochemical parameters in AP induced by infusion of a supramaximal dose of caerulein in rats.	Ceruletide	202-211	epidermal growth factor like 1	Rattus norvegicus	84-87
9586822-2	1998	The aim of this study was to compare the gene and immunohistochemical expression of EGF and TGF-beta1, cell proliferation, and biochemical parameters in AP induced by infusion of a supramaximal dose of caerulein in rats.	Ceruletide	202-211	transforming growth factor, beta 1	Rattus norvegicus	92-101
9444624-5	1997	Treatment with CGRP (2 x 10 micrograms/kg s.c.) attenuated the pancreatic tissue damage in caerulein-induced pancreatitis and completely reversed the deleterious effect of the ablation of sensory nerves on caerulein-induced pancreatitis.	Ceruletide	206-215	calcitonin-related polypeptide alpha	Rattus norvegicus	15-19
9444624-6	1997	We conclude that CGRP exerts protective effect against caerulein-induced pancreatitis and is able to reverse the damage caused by deactivation of sensory nerves.	Ceruletide	55-64	calcitonin-related polypeptide alpha	Rattus norvegicus	17-21
9260201-2	1997	Hyperstimulation with cerulein (a CCK analogue) induces acute edematous pancreatitis.	Ceruletide	22-30	cholecystokinin	Rattus norvegicus	34-37
9098826-7	1997	Caerulein infused caused a time-dependent decrease in DNA synthesis accompanied by gradual decrease of PBF and significant increase in pancreatic weight.	Ceruletide	0-9	PTTG1 interacting protein	Rattus norvegicus	103-106
9207291-0	1997	Cerulein-induced in vitro activation of trypsinogen in rat pancreatic acini is mediated by cathepsin B.	Ceruletide	0-8	cathepsin B	Rattus norvegicus	91-102
9272621-3	1997	Subcutaneous injection of the CCK agonist caerulein dose-dependently decreased food intake in Zucker obese and lean rats whereas the CCK-B agonist gastrin-17 did not.	Ceruletide	42-51	cholecystokinin	Rattus norvegicus	30-33
9272621-4	1997	Caerulein at 4 microg/kg, which resulted in CCK plasma bioactivity slightly above postprandial levels, decreased food intake in lean rats but not in obese rats.	Ceruletide	0-9	cholecystokinin	Rattus norvegicus	44-47
9135530-4	1997	RESULTS: Cerulein infusion caused a significant increase in type I PLA2 activity (p < 0.01) and IR-PLA2 protein concentration (p < 0.01) in serum and pancreas, whereas type II PLA2 activity remained unchanged during the 12 hour observation period.	Ceruletide	9-17	phospholipase A2 group IB	Rattus norvegicus	67-71
9135530-4	1997	RESULTS: Cerulein infusion caused a significant increase in type I PLA2 activity (p < 0.01) and IR-PLA2 protein concentration (p < 0.01) in serum and pancreas, whereas type II PLA2 activity remained unchanged during the 12 hour observation period.	Ceruletide	9-17	phospholipase A2 group IB	Rattus norvegicus	99-106
9135530-4	1997	RESULTS: Cerulein infusion caused a significant increase in type I PLA2 activity (p < 0.01) and IR-PLA2 protein concentration (p < 0.01) in serum and pancreas, whereas type II PLA2 activity remained unchanged during the 12 hour observation period.	Ceruletide	9-17	phospholipase A2 group IB	Rattus norvegicus	102-106
9013214-0	1997	Caerulein may potentiate morphine-induced antinociception by cholecystokinin-A and/or cholecystokinin-B receptor mechanisms.	Ceruletide	0-9	cholecystokinin B receptor	Mus musculus	86-112
23338219-12	1997	The administration of CCK agonists [ceruletide (caerulein), CCK-4, pentagastrin] has an anxiogenic action in various animal models and in different animal species.	Ceruletide	36-46	cholecystokinin	Homo sapiens	22-25
23338219-12	1997	The administration of CCK agonists [ceruletide (caerulein), CCK-4, pentagastrin] has an anxiogenic action in various animal models and in different animal species.	Ceruletide	48-57	cholecystokinin	Homo sapiens	22-25
9098826-12	1997	We conclude that 1) the development of caerulein-induced pancreatitis results in the inhibition of pancreatic growth and the reduction in PBF accompanied by enhanced expression of TGF-beta 1; 2) The expression of EGF that was observed at the end of the induction of pancreatitis may indicate the initiation of pancreatic repair; 3) TGF-beta 1 seems to lead to subsequent induction of EGF that may stimulate the regeneration of injured pancreas.	Ceruletide	39-48	PTTG1 interacting protein	Rattus norvegicus	138-141
9098826-12	1997	We conclude that 1) the development of caerulein-induced pancreatitis results in the inhibition of pancreatic growth and the reduction in PBF accompanied by enhanced expression of TGF-beta 1; 2) The expression of EGF that was observed at the end of the induction of pancreatitis may indicate the initiation of pancreatic repair; 3) TGF-beta 1 seems to lead to subsequent induction of EGF that may stimulate the regeneration of injured pancreas.	Ceruletide	39-48	transforming growth factor, beta 1	Rattus norvegicus	180-190
9098826-12	1997	We conclude that 1) the development of caerulein-induced pancreatitis results in the inhibition of pancreatic growth and the reduction in PBF accompanied by enhanced expression of TGF-beta 1; 2) The expression of EGF that was observed at the end of the induction of pancreatitis may indicate the initiation of pancreatic repair; 3) TGF-beta 1 seems to lead to subsequent induction of EGF that may stimulate the regeneration of injured pancreas.	Ceruletide	39-48	epidermal growth factor	Rattus norvegicus	213-216
9098826-12	1997	We conclude that 1) the development of caerulein-induced pancreatitis results in the inhibition of pancreatic growth and the reduction in PBF accompanied by enhanced expression of TGF-beta 1; 2) The expression of EGF that was observed at the end of the induction of pancreatitis may indicate the initiation of pancreatic repair; 3) TGF-beta 1 seems to lead to subsequent induction of EGF that may stimulate the regeneration of injured pancreas.	Ceruletide	39-48	transforming growth factor, beta 1	Rattus norvegicus	332-342
9098826-12	1997	We conclude that 1) the development of caerulein-induced pancreatitis results in the inhibition of pancreatic growth and the reduction in PBF accompanied by enhanced expression of TGF-beta 1; 2) The expression of EGF that was observed at the end of the induction of pancreatitis may indicate the initiation of pancreatic repair; 3) TGF-beta 1 seems to lead to subsequent induction of EGF that may stimulate the regeneration of injured pancreas.	Ceruletide	39-48	epidermal growth factor	Rattus norvegicus	384-387
8959469-1	1996	The effect of intravenously administered ceruletide, a cholecystokinin (CCK) analogue, on neurophysiologic signs of stimulus processing was tested in 16 young (19-28 years) and 16 aged (70-86 years) healthy subjects.	Ceruletide	41-51	cholecystokinin	Homo sapiens	72-75
9267858-1	1997	Cholecystokinin (CCK)-like peptides, such as ceruletide, have been found to improve selective attention as indicated by the processing negativity (PN) of the event-related brain potential.	Ceruletide	45-55	cholecystokinin	Homo sapiens	0-15
9267858-1	1997	Cholecystokinin (CCK)-like peptides, such as ceruletide, have been found to improve selective attention as indicated by the processing negativity (PN) of the event-related brain potential.	Ceruletide	45-55	cholecystokinin	Homo sapiens	17-20
8944658-8	1996	Our data indicate that caerulein-induced AA release results from the combined action of PLC and DAG lipase without PLA2 or PLD activation.	Ceruletide	23-32	lipase G, endothelial type	Rattus norvegicus	100-106
8944658-0	1996	Caerulein-stimulated arachidonic acid release in rat pancreatic acini: a diacylglycerol lipase affair.	Ceruletide	0-9	lipase G, endothelial type	Rattus norvegicus	88-94
8913708-0	1996	Increases in Ki-ras and ornithine decarboxylase gene expression in rat pancreas after caerulein-induced pancreatitis.	Ceruletide	86-95	KRAS proto-oncogene, GTPase	Rattus norvegicus	13-19
8913708-0	1996	Increases in Ki-ras and ornithine decarboxylase gene expression in rat pancreas after caerulein-induced pancreatitis.	Ceruletide	86-95	ornithine decarboxylase 1	Rattus norvegicus	24-47
8913708-9	1996	During that period, maximal increases in ODC activity and Ki-ras mRNA expression occurred after 1 day of caerulein treatment; ODC mRNA expression was also significantly increased after 3 and 5 days in the pancreatitis animals with no effect of caerulein treatment.	Ceruletide	105-114	ornithine decarboxylase 1	Rattus norvegicus	41-44
8913708-9	1996	During that period, maximal increases in ODC activity and Ki-ras mRNA expression occurred after 1 day of caerulein treatment; ODC mRNA expression was also significantly increased after 3 and 5 days in the pancreatitis animals with no effect of caerulein treatment.	Ceruletide	105-114	KRAS proto-oncogene, GTPase	Rattus norvegicus	58-64
8831604-11	1996	The measurement of PAF in pancreatic tissue showed a ninefold increase with cerulein treatment alone and a 14-fold increase in cerulein-infused, neutrophil-depleted animals.	Ceruletide	76-84	PCNA clamp associated factor	Rattus norvegicus	19-22
8831604-11	1996	The measurement of PAF in pancreatic tissue showed a ninefold increase with cerulein treatment alone and a 14-fold increase in cerulein-infused, neutrophil-depleted animals.	Ceruletide	127-135	PCNA clamp associated factor	Rattus norvegicus	19-22
8877029-5	1996	In groups of healthy subjects (n = 6 each) stimulation of pancreatic polypeptide was assessed in five different tests: (i) insulin-hypoglycaemia; (ii) modified sham feeding; (iii) intravenous infusion of the cholecystokinin analogue ceruletide; (iv) injection of corticotropin releasing hormone; (v) infusion of the muscarinic acetylcholine agonist bethanechol.	Ceruletide	233-243	pancreatic polypeptide	Homo sapiens	58-80
8944697-6	1996	Contractile and secretory responses to low-dose caerulein (CCK analogue) were inhibited by 60-80% under telezepine, whereas high-dose (supraphysiological) stimulation overrode this effect.	Ceruletide	48-57	cholecystokinin	Homo sapiens	59-62
8726834-1	1996	The role of endogenous platelet-activating factor (PAF) in the control of pancreatic blood flow during caerulein stimulation was investigated.	Ceruletide	103-112	PCNA clamp associated factor	Rattus norvegicus	51-54
8930982-2	1996	Caerulein (10(-10)-10(-7) M), a CCK receptor agonist, increased formation of inositol phosphates in primary cultured bovine adrenal medullary (BAM) chromaffin cells in a concentration-dependent manner.	Ceruletide	0-9	cholecystokinin	Bos taurus	32-35
8930982-5	1996	Stimulation of these receptors with caerulein activates a signal transduction pathway via phospholipase C. CCK may regulate catecholamine release in BAM cells.	Ceruletide	36-45	cholecystokinin	Bos taurus	107-110
8726834-4	1996	Changes in pancreatic blood flow induced by caerulein were completely inhibited by a cholecystokinin (CCK) antagonist (loxiglumide, 5 mg/ kg per h, i.v.)	Ceruletide	44-53	cholecystokinin	Rattus norvegicus	102-105
8690301-3	1996	The histological changes due to caerulein-induced acute pancreatitis were also decreased by KSG-504 when KSG-504 (25, 50 and 100 mg/kg) was administered after the induction of acute pancreatitis; the increases in plasma amylase, lipase and pancreatic wet weight were reduced, but the histological changes of the pancreas were not decreased significantly.	Ceruletide	32-41	lipase G, endothelial type	Rattus norvegicus	229-235
8723555-15	1996	Cerulein-treated rats also had increased lung myeloperoxidase (0.069 to 0.097 U/g) and lung permeability, as assessed by a alveolar lavage to serum ratio of labeled albumen (0.041:0.121) both p < 0.05).	Ceruletide	0-8	myeloperoxidase	Rattus norvegicus	46-61
8886577-5	1996	Furthermore, mouse pancreatic PAP-I mRNA levels are rapidly and dramatically down-regulated (3 h) after the initiation of caerulein injections, but slowly return to high levels by 72 h. Interestingly, we found that pancreatic PAP-I mRNA levels are also transiently and dramatically down-regulated after L-buthionine-[S,R]-sulfoximine administration.	Ceruletide	122-131	annexin A5	Mus musculus	30-35
8886577-5	1996	Furthermore, mouse pancreatic PAP-I mRNA levels are rapidly and dramatically down-regulated (3 h) after the initiation of caerulein injections, but slowly return to high levels by 72 h. Interestingly, we found that pancreatic PAP-I mRNA levels are also transiently and dramatically down-regulated after L-buthionine-[S,R]-sulfoximine administration.	Ceruletide	122-131	annexin A5	Mus musculus	226-231